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     Novel, rationally-designed acrylate analogs of various known dipeptide substrates 
were found to be mechanism-based inactivators of the enzyme peptidylglycine α-
amidating monoxygenase (PAM, EC 1.14.17.3).  This enzyme is responsible for the rate-
limiting and final bioactivation step, a C-terminal amidation of glycine-extended 
peptides, of a variety of peptide hormones including the potent pro-inflammatory 
compound Substance P.  Protein-ligand docking studies, in tandem with in vitro kinetic 
analysis of these inactivators, indicated that the rational design of this class of compounds 
was successful in creating potent competitive inactivators of this enzyme.  
Pharmacological evaluation, via both acute and chronic models of inflammation in 
Sprague-Dawley rats, of these compounds indicates that they are highly potent anti-
inflammatory agents which ameliorate both acute carrageenan-induced edema and the 
deleterious effects of chronic adjuvant-induced polyarthritis.  Furthermore, these 
compounds were also able to induce a return toward a more normal phenotype in 
cancerous WB-Ras epithelial cells, via the interruption of the growth factor-stimulated 
pathway precipitated by Substance P.  Finally, our modeling studies provide a structural 
basis for both the reaction and subsite stereospecificity of PAM toward its substrates, 



































     Neuropeptides, also known as peptide hormones, were first discovered by von Euler 
and Gaddum in 1931 (von Euler, 1931) with the identification of Substance P (SP).  
Unlike a wide variety of non-peptide hormones or messengers which are either inherently 
unstable (such as prostaglandins) or quickly degraded by various enzymes (such as 
acetylcholine) and as such act only in an autocrine or paracrine fashion, the amino acid 
chain of a neuropeptide is remarkably robust and may persist long enough in the 
circulation to act at targets far removed from the site of production in a truly endocrine 
manner.   In 1953, Tuppy and Michl found, surprisingly, that the active form of the 
peptide hormone oxytocin contains a C-terminal amide functionality, rather than a free 
carboxylic acid group. (Tuppy, 1953)  Although Substance P had been known since its 
discovery in 1931, many years passed before Susan Leeman and colleagues demonstrated 
that SP possesses an amide moiety at its C-terminus (Leeman, 1980).  Since then, many 
neuropeptides have been isolated and characterized.  Nearly 50% of these peptides 
require C-terminal amidation for full biological activity. 
     Although the existence of amidated neuropeptides was well-known by the time that 
Leeman et al. proved that Substance P (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-
Met-NH2) fell into this category, the amidation mechanism remained unknown.  The list 
of known amidated peptides included sequences which terminated in every natural amino 




penultimate position or those located further toward the N-terminus of the C-terminal 
amide.  This seemed to rule out the possibility that the amidation reaction proceeded via 
any type of process in which either the C-terminal residue or sequence of residues of a 
given amidated peptide participated in or directed the mechanism of peptide amidation.  
Indeed, SP terminates in Gly-Leu-Met-NH2 while oxytocin terminates in Pro-Leu-Gly-
NH2 and vasoactive intestinal peptide (VIP) in Ile-Leu-Asn-NH2, illustrating the lack of 
consensus of the residues which precede the C-terminal amidated residue.  Since 
approximately half of known neuropeptides are not amidated at the C-terminus, any type 
of transamidase activity (which would proceed regardless of the sequence of the peptide 
substrate, since there seemed to be few, if any, restrictions engendered by the nature of 
the residues to the N-terminal side of the amide) would have to be extensively 
colocalized only with those particular peptides for which amidation is absolutely 
required, and to the exclusion of all non-amidated neuropeptides.  A priori, this would 
completely obviate the possibility that amidation could occur extracellularly, and would 
indicate a complex process of sequestration of both enzyme and peptide substrates within 
subcellular compartments.  Alternatively, if the product peptide amide were generated 
from a larger precursor, any extra residues to the C-terminal side of the ultimately 
amidated amino acid would be able to lend specificity to the amidation reaction and 
restrict any peptide without such a sequence (or residue) from being subject to amidation. 
     In 1977, Suchanek and Kreil (Suchanek, 1977) expressed melittin (terminating in Arg-
Gln-Gln-NH2) mRNA from queen bee venom glands in a cell-free wheat germ system 
and found that while, unsurprisingly, no peptide amide product was detected, a 




COOH.  The authors suggested that, if the residue Gly could be shown to be present 
immediately to the C-terminal side of the ultimately amidated residue of other potential 
amidation substrates, then perhaps the extra glycine residue is both necessary and 
sufficient to target a peptide sequence for amidation.  Moreover, this glycine would also 
suggest a possibility for the mechanism of amidation, which they reasoned could 
plausibly proceed via the involvement of some currently unknown (but C-terminal 
glycine-specific) aminotransferase activity.  Their hypothesis was strengthened by the 
fact that the sequence of corticotropin (Scott, 1973), an α-melanotropin precursor (α-
melanotropin itself terminates in Val-NH2 (Harris, 1957)), contains two potential protease 
cleavage sites (for trypsin- and carboxypeptidase-B-like activities) which, following 
proteolysis, would yield a C-terminus of Val-Gly-COOH and be subject to that putative 
activity which amidates peptides terminating in X-Gly-COOH (where X = any amino 
acid residue). 
     Several years later, Bradbury et al. succeeded in isolating a peptide amidating activity 
from gel-filtration fractions (corresponding to MW of approximately 60,000 daltons) of 
porcine pituitary homogenate. (Bradbury, 1982)  The synthetic peptide D-YVG was 
chosen as the substrate in the amidation assays based on the perception that the C-
terminal sequence Val-Gly likely contained “the minimal structural elements of 
corticotropin necessary for the formation of the valine amide group present at the C-
terminus of α-melanotropin.”  The N-terminal D-tyrosine was chosen for two reasons:  
first, a D-amino acid residue at the N-terminus of peptides was known to inhibit 
degradation from aminopeptidases likely to be present in the pituitary homogenate 




phenolic hydroxyl group, which obviously vastly increases the sensitivity of any 
subsequent chromatographic analysis of both the substrate and product (D-YV-NH2).  
Additionally, when D-YVG synthesized with 15N-glycine was incubated with the 
fractionated pituitary homogenate, the product amide D-YV-NH2 invariably terminated 
with 15N-labeled amide.  This proved that the C-terminal glycine is the source of the 
nitrogen atom found in the amidated product.  Inclusion of the ammonium ion or the 
aminotransferase donors glutamine or asparagine failed to increase the efficiency of the 
amidation reaction, effectively ruling out any type of aminotransferase activity as the 
amidating enzyme.  Further investigations served to demonstrate that the amidating 
activity was eliminated when the C-terminal glycine was replaced by (L)-Sar, (L)-Ala, 
(L)-Leu, (L)-Lys or (L)-Glu.  The reaction proceeded when (L)-Val (the penultimate 
residue) was replaced with (L)-Phe or Gly, but not when replaced by (D)-Ala, (L)-Lys, or 
(L)-Asp.  This was consistent with the knowledge (at the time) that no peptides were 
known to terminate in (D)-Ala, (L)-Lys, or (L)-Asp amides.  Finally, based on the fact 
that glyoxylate was identified as the second product of the amidation of glycine-extended 
tripeptides, the mechanistic conjecture was refined to include the oxidative formation of 
an imine intermediate followed by aqueous hydrolysis. 
     At this point, the door was opened to a full investigation of the properties of this 
amidating activity.  If this enzyme were responsible for the bioactivation of all amidated 
neuropeptides, it was evident that the development of amidation inhibitors would provide 
a new tool for the amelioration of a potentially immense variety of pathophysiological 
conditions arising from excessive production of these hormones.  Indeed, Substance P, 




transmission of chronic pain signals and is also a potent pro-inflammatory mediator that 
serves to “prime” a great many cells of the immune system.  Reduction of SP levels in 
patients with chronic pain, inflammation, or autoimmune disorders could prove an 
invaluable tool in the amelioration of these conditions.  Most of the thrust of this thesis is 
based on the design, development, and analysis of inhibitors of the α-amidating enzyme 
(now called peptidylglycine α-amidating monooxygenase, or PAM; EC 1.14.17.3), more 
specifically toward the goal of reducing in vivo levels of Substance P and mitigating its 
deleterious effects as a pro-inflammatory agent run amok in, for example, the devastating 
condition of rheumatoid arthritis. 
     The rest of this portion of the Introduction will investigate many aspects and 
properties of this fascinating enzyme.  Initially, we will explore the expression and 
localization of PAM in various tissues and at various levels of subcellular organization 
and sequestration, and any different isozymes which may be present from one tissue to 
another.  We will discuss substrate specificity and cofactor requirements of the various 
isozymes of this enzyme known to be expressed in various tissues.  The processing, 
routing, trafficking, storage, and secretion of PAM will be explored.  We will discuss a 
wide variety of competitive inhibitors (and briefly touch upon several uncompetitive 
inhibitors) in relation to the structure of the PAM active site.  Finally, the mechanism of 
PAM will be extensively explored, especially in the context of the mechanism-based 
inactivators developed in this laboratory.  The second portion of the introduction will 
concentrate more upon Substance P and its physiological effects, especially as they relate 




autocrine growth loops evident in many neoplastic pathologies which are thought to be 
governed and reinforced by a variety of amidated neuropeptides. 
 
PAM Localization and Expression 
 
      In 1986, Mizuno, et al., developed a sensitive radioassay for monitoring PAM activity 
in vitro using  (125I)-Ac-D-YFG and were the first group to purify the enzyme to 
homogeneity, using frog skin (X. Laevis) as the enzyme source. (Mizuno, 1986) After 
several purification steps, a hydroxylapatite column resolved the amidating activity into 
two different fractions, AE-I (amidating enzyme-I) and AE-II (amidating enzyme-II), 
with AE-1 being the major, and later-eluting, fraction.  After further purification (c. 
8300-fold), AE-1 was found to be homogeneous with a molecular weight of 
approximately 39,000 Daltons.  Further purification of AE-II failed to yield a 
homogeneous product and instead was composed of two active fractions, with molecular 
weights of 39,000 (AE-IIa) and 34,000 (AE-IIb).  Sequence analysis by Edman 
degradation revealed that all three proteins were possessed of the same N-terminal 
sequence (Ser-Leu-Ser), which indicated that the three isozymes were related and most 
likely expressed from the same gene.  Indeed, in the same year, experiments by Murthy, 
et al. (Murthy, 1986) to purify PAM from bovine pituitary also revealed the presence of 
multiple forms of PAM.  AE-I was then incubated with a variety of glycine-extended 
peptides (YFG, N-Ac-YFG, (D)-YVG, and (D)-YGG), yielding the following activity 
profile:  YFG > N-Ac-YFG > (D)-YVG > (D)-YGG.  Two peptides which do not contain 




incubation with purified AE-I.  The optimal pH range was between 6.0 and 7.0.  Activity 
was abolished upon addition of 0.1 mM EDTA, and subsequently rescued by the addition 
of excess copper sulfate (0.12 mM).  Addition of 1 mM dithiothreitol, likely via copper 
ligation, also greatly inhibited the amidation activity, which could again be rescued by 
the addition of excess copper sulfate, or by 5 mM N-ethylmaleimide, a sulfhydryl 
alkylating reagent.  Activity was found to be much lower in the absence of exogenously-
applied ascorbic acid, or when the enzyme ascorbate oxidase was included in the assay 
solution. 
     The same year, Sakata et al. performed ammonium sulfate precipitations on a wide 
variety of tissues from adult male Wister rats (Sakata, 1986) and assayed the precipitates 
for amidating activity.  Surprisingly, the activity was found in nearly every tissue 
assayed, with the notable exceptions of the thymus and liver.  The highest activities were 
found in the pituitary, heart atrium, submaxillary gland, parotid gland, and thyroid gland, 
respectively (c. 45/18/11/8/6).  The lowest detected levels were found in the kidney, 
spleen, cerebellum, and esophagus, respectively (c. 0.034/0.054/0.132/0.220).  These 
findings indicated that the amidation activity responsible for the bioactivation of 
neuropeptides was to be found throughout the entire body of the rat, and suggested that 
the systemic importance of neuropeptides in controlling or influencing various metabolic 
functions was much greater than had been previously anticipated. 
     Interestingly, the same year Mollay et al. also attempted to isolate homogeneous 
amidating enzyme from the skin of X. Laevis.  Although they failed to achieve the degree 
of purity of Mizuno et al. (150-fold vs. 8,300-fold), they nevertheless discovered several 




5.5 and 8.4, rather than the 6.0-7.0 optimum range found with Mizuno’s enzyme.  This 
was actually the hint of a two-step mechanism in the formation of C-terminal amides 
from glycine-extended precursors, one with an acidic optimum and one with an alkaline 
optimum.  Conceivably, then, it was possible that two distinct enzymes (or a single 
bifunctional enzyme) were responsible for the production of amidated peptides.  In the 
absence of added cofactors, the rates of amide formation at the two pHs were nearly 
identical (540/460 @ pH 5.5/8.4).  Addition of exogenous copper and ascorbate (2 μM 
and 2 mM, respectively) selectively increased the rate of amide formation at pH 8.4 vs. 
pH 5.5 (4.2 fold to 1.5 fold, respectively).  Also, at pH 5.5 this enzyme, in contrast to 
findings from the mammalian amidating enzyme which was stimulated only by the 
addition of Cu+2, was greatly increased by addition of Cu+2 or Fe+3, Mn+2, Zn+2, or Fe+2. 
     Subsequently, work by von Zastrow et al. (von Zastrow,1986) demonstrated that the 
amidating enzymes were also to be found in the pancreas, and the submaxillary, 
lachrymal, and parotid glands.  This was the first time that PAM was found to be actively 
expressed in exocrine tissues, which secrete their products into ducts (endocrine glands 
secrete products directly into the bloodstream).  Indeed, as with prior work with pituitary 
PAM, it was found that the majority of the activity was found to coelute with α-amylase 
in the secretory granule fraction.  About 15% of the total amidating activity was 
associated with the endoplasmic reticulum and Golgi fractions.  In vivo, administration of 
the β-adrenergic agonist isoproterenol allowed the collection of exocytosed secretory 
granules via cannula.  The contents of the secretion were found to be nearly identical in 
content to the purified secretory granules.  With regard to kinetic parameters, while this 




weight), the pH optimum with respect to the substrate D-YVG was found to be between 
6.5 and 7.0.  The amidating activity was, again, stimulated by exogenous copper and 
ascorbate.  Addition of 2 mM ascorbate increased both the Vmax and, to a lesser degree, 
the KM values. 
     Concurrently, Murthy et al. (Murthy, 1986) analyzed the anterior, neural, and 
intermediate lobes of the bovine pituitary for amidating enzyme activity.  In all cases, the 
PAM activity was highly localized to the secretory granule fractions.  The ratio of 
activity for the anterior, neural, and intermediate lobes was found to be approximately 
10:10:1, respectively.  Further purification of the PAM activity yielded two forms of 
PAM, PAM-A and PAM-B (M.W. = 54K and 38K, respectively); tryptic digests 
indicated that the two forms of the enzyme were related, with PAM-B likely a further 
modified form of PAM-A.  Crude PAM, PAM-A, and PAM-B all behaved identically 
with regard to pH optima (alkaline) and exogenously added Cu+2 and ascorbate (all 
stimulated above baseline).  Interestingly, initial attempts to purify PAM directly from 
secretory granules resulted in very low yields of enzyme.  The authors estimate that there 
are, at most, several molecules of PAM per secretory granule. 
    In 1987, Mizuno et al. (Mizuno, 1987) were able to clone the amidating enzyme from 
frog skin (X. Laevis).  All introns were removed from the mRNA and a cDNA construct 
was synthesized and expressed in stably transfected E. Coli.  The molecular weight of 
this purified, cloned enzyme was approximately 38,500 Daltons.  Naturally, this was to 
be a very important step in the later mechanistic analysis of the amidating enzyme, 





     Since the evidence that the amidating enzyme was actually a bifunctional enzyme with 
both monooxygenase and lyase activities (or two soluble monofunctional enzymes acting 
sequentially) was not known until 1990 when PGL was discovered in this laboratory, 
assays performed on various substrates, and their reported pH optima, KM and Vmax 
values acquired prior to this date must be very carefully parsed in order to gain 
meaningful insight into the nature of the enzymatic reaction.  Four tripeptides of the 
sequence D-Tyr-Xxx-Gly, where the middle residue was either Val, Trp, Glu, or Pro, 
were tested as substrates in the presence of purified PAM-B (M.W. = 38,000 Daltons) 
from bovine neurointermediate pituitary (Murthy, 1987).  As an important aside, later 
studies (Katopodis, 1990) demonstrated that purified monofunctional PAM has a 
molecular weight of approximately 39,000 Daltons, and that PGL activity elutes from an 
analytical gel filtration column with an apparent molecular weight of 45,000 Daltons.  
Therefore, in hindsight, the 38,000 Dalton bovine neurointermediate pituitary PAM can 
only be the monofunctional monooxygenase enzyme.  Furthermore, it is now known that 
the monooxygenase reaction yields an α-hydroxyglycine intermediate which is stable at 
acidic pH and requires the action of the lyase (PGL) to yield the amidated peptide 
product under acidic conditions (as in the secretory granule).  However, at alkaline pH 
the hydroxylated peptide intermediate is spontaneously dealkylated via a base-catalyzed 
reaction.  So, the authors in this case are measuring the rate of formation of the amidated 
product and thus are really measuring the product of two rates:  first, that of PAM; 
second, that of the spontaneous dealkylation.  Whether the former or the latter 
mechanistic step is rate-limiting is impossible to determine (in the absence of direct 




assumptions can be made about the relative efficacy of the enzyme with regard to one 
tetrapeptide substrate vis-a-vis the next. 
     Nevertheless, the results of the amino acid substitutions at the P2 position proved 
interesting.  Valine and tryptophan are hydrophobic residues, although the latter is of 
much greater size.  With proline at the P2 position, owing to the rotational restriction 
imposed by the nature of its side chain, the peptide substrate cannot adopt as wide a range 
of conformers as those tripeptides with Trp, Val, or Glu at the P2 position.  This 
restriction, if it locks the molecule in a conformation amenable to the residues of the 
enzyme’s active site, can allow for an extremely favorable substrate.  On the other hand, 
this same conformational restriction may result in a very poor substrate, relative to one 
containing any of the other 19 naturally-occurring amino acids.  Glutamic acid, with a 
side chain pKa of approximately 4.0, is expected to exist almost entirely as the anionic 
form (90% at pH = 5.0; 99% at pH =6.0, etc.) over the range of pH values used in the 
assays (5.0-9.0).  Again, this ionization may be either highly favorable as regards 
substrate binding to the active site or highly unfavorable depending on the nature of the 
microenvironment in which the side chain must bind.  Obviously, the rate of reaction may 
be affected by the nature of the P2 residue as well. 
     Basically, it was found that the Val and Trp-containing peptides were about equipotent 
substrates with regard to kcat/KM at 0.25 mM ascorbate, with the larger Trp possessed of a 
slightly lower substrate binding constant (1.1 μM vs. 1.9 μM for Val) and also a slightly 
higher value for kcat (8.4 nmol/μg*h vs. 7.5 nmol/μg*h for Val).  When the concentration 
of ascorbate in the assay mixture was raised to 1.25 mM, KM values tripled for both 




Pro-containing peptide was found to have a significantly higher KM value (30.6 μM) but a 
kcat value approximately equal to the Trp- and Val-containing peptides (9.7 nmol/μg*h).  
At the higher ascorbate concentration, the trend was the same as for Trp and Val; KM and 
kcat each increasing 3- or 4-fold.  However, the Glu-containing tripeptide, at the lower 
ascorbate concentration, has KM and kcat values of 129 μM and 45.9 nmol/μg*h, 
respectively.  Interestingly, at the higher concentration of ascorbate, the KM value jumped 
(in line with the other tripeptides) approximately 3-fold while the kcat value increased to 
1970 nmol/μg*h, approximately a 50-fold increase.  The pH optima for Val, Trp, and Pro 
were approximately 8.5, while that for the Glu-containing tripeptide was about 5.5.  The 
only explanation for these phenomena appears to be the following:  it is now known that 
monofunctional PAM generally has a pH optimum of approximately 5.5 and is the rate-
limiting step in the overall amidation reaction.  PGL is also functional at this pH and 
serves to catalyze the dealkylation of the α-hydroxy intermediate to the des-Gly amide 
product, which can also occur non-enzymatically by general base catalysis at alkaline pH.  
For Trp, Val, and Pro, the alkaline pH optima likely reflects a much kinetically-subdued 
PAM reaction, but allows for an accelerated rate of non-enzymatic dealkylation to yield 
the product amide (recall that only the final amide product is being assayed here, and not 
the PAM-catalyzed hydroxyglycine intermediate).  At the pH optimum for the Glu-
containing tripeptide, the acidic conditions allow for amide formation from the 
hydroxyglycine intermediate at a very slow rate (possibly the rate-limiting step) for Trp, 
Val, and Pro.  However, because Glu contains a second ionizable carboxylate 
functionality in close proximity to the PAM-added hydroxyl group the Glu-containing 




catalysis at a rate commensurate with the incredibly elevated kcat values of this molecule.  
So the acidic pH optimum for the Glu-containing peptide allows for a much higher rate of 
formation of the α-hydroxyglycine (since the PAM pH optimum is about 5.5), while the 
side chain carboxylate group is able to catalyze the dealkylation of the intermediate to the 
detectable amide product.  These types of data and their subsequent analysis illustrate the 
difficulty in describing an enzymatic system in the absence of all relevant facts, 
especially as relates to a bifunctional enzymatic system such as PAM/PGL proved to be 
in later experiments. 
     PAM was also later discovered to be expressed at an appreciable rate and quantity by 
rat and bovine atrial cardiocytes.  (Eipper, 1988)  It had recently come to be known that 
the heart also functioned as an endocrine organ, insofar as it secretes the peptide 
hormones atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP).  Neither 
peptide is amidated at the C-terminus in its active, fully-processed form (deBold, 1985).  
Eipper et al. found that PAM is localized in the secretory granule fractions of atrial 
myocytes, initially both in a membrane-associated form (70% in the rat) and a soluble 
form (30% in the rat).  Moreover, the specific activity of the PAM collected from the rat 
atrial myocytes was between 5- and 20-fold higher than in the anterior pituitary.  The 
distribution of PAM was found to be colocalized with ANP in the crude granule and 
microsomal fractions.  As later work by this laboratory indicates (presented in Results 
section and Discussion section), there is an appreciable amount of soluble PAM found in 
the bloodstream (serum PAM) which is inactivated in vivo by our acrylate inhibitors (and 
PBA), and the amount of inactivation is proportional to a large degree to the anti-




source of PAM found in rat serum.  With the amidating enzyme present in the 
bloodstream, it is possible that glycine-extended peptides, requiring amidation for full 
biological activity, may be secreted in an inactive form (by various cells of the innate or 
humoral immune system, for instance) and activated by serum PAM (bloodstream pH is 
alkaline, pH 7.4, and the intermediate is readily dealkylated non-enzymatically and does 
not necessarily require PGL activity).  In this way, various cell types could express 
initially inactive peptide hormones which could be activated in the bloodstream or 
extracellular space without also expressing active PAM themselves. 
     In 1988, Fenger et al. (Fenger, 1988) demonstrated that dietary ascorbate was a major 
influence on the levels of peptide amidation in guinea pig pituitary.  Animals from the 
experimental group were fed an ascorbate-depleted diet (resulting in 6-fold less ascorbate 
than control animals; 1.2 μmol/g tissue) while control animals consumed a normal diet 
with respect to ascorbate.  Following ascorbate depletion, the pituitary glands were 
assayed for variously processed derivatives of adrenocorticotrophic hormone (ACTH): 
ACTH (1-39), the amidated peptide α-MSH (ACTH (1-13-NH2), and ACTH (1-14), 
which has a C-terminal glycine.  In the depleted animals, α-MSH levels dropped to 
approximately 50% of controls, while ACTH (1-14) accumulated to approximately 300% 
of controls.  Interestingly, although the ascorbate-depleted animals’ average body weight 
was only about 60% of control animals, the difference in mass of the pituitary glands of 
both groups was statistically insignificant.  The authors did not investigate whether levels 
of ascorbate in the bloodstream or in other bodily tissues of the experimental animals 




be able to maintain higher levels of ascorbate in general during a systemic depletion in 
order to maintain its function, relative to other tissues). 
     Various regions of sheep brain were assayed for amidating enzyme by Gale, et al. 
(Gale 1988).  As expected from previous results, high levels of PAM activity were found 
in the anterior pituitary and the hypothalamus (specifically the medial basal 
hypothalamus).  The highest levels were found in the median eminence of the 
hypothalamus, the region which, via the hypophyseal portal system, connects the anterior 
pituitary and hypothalamus.  Both the synaptosomal fractions (synaptosomes are artifacts 
of the homogenization process, formed from cell-membrane phospholipids and including 
many proteins, peptides, and receptors originally localized at the synapse) and the 
neurosecretory granule fractions were especially enriched with PAM activity.  Also in 
line with previous work, the enzyme was stimulated by the addition of exogenous 
ascorbate and copper and was found to have an alkaline pH optimum with D-Tyr-Pro-
Gly-Gly, the C-terminal sequence of gonadotropin-releasing hormone, as the substrate.  
This is an interesting substrate for several reasons.  First, Gly and Pro are found at the P2 
and P3 positions of the peptide substrate, respectively, and both are known to adopt 
peculiar φ and ψ values as a function of the rigid conformational restriction of dihedral 
angle values available to Pro and the relatively rich availability of conformational 
freedom with regard to Gly.  Moreover, after D-Tyr-Pro-Gly-Gly undergoes amidation by 
PAM, the peptide terminates in a glycyl amide.  Since no D-Tyr-Pro-NH2 was evident in 
the PAM assay, it seemed safe to assume that C-terminal glycine amides are not PAM 
substrates, indicating that the free carboxylate is obligatory for PAM catalysis.  The KM 




reported for D-YVG.  Addition of ascorbate, catalase (to degrade any hydrogen peroxide 
formed by non-enzymatic reduction of water/oxygen by ascorbate), and copper (as 
copper (II) sulfate) stimulated activity, increasing both the KM and Vmax in parallel, as 
was previously described for a variety of other peptide substrates.  Production of D-Tyr-
Pro-Gly-NH2 was inhibited by concurrent incubation with D-Tyr-Val-Gly, and 
production of D-Tyr-Val-NH2 was inhibited by the addition of D-Tyr-Pro-Gly-Gly.  This 
implies a competitive inhibition of one peptide by the other.  Lastly, very little activity 
with respect to D-Tyr-Pro-Gly-Gly was found in either the cerebral cortex or the pineal 
gland, areas of the brain known to synthesize amidated peptides other than gonadotropin-
releasing hormone, which could, perhaps, imply some varying substrate specificity in 
PAM from different tissues. 
     Further investigations by May et al. (May, 1988) into PAM distribution in rat anterior 
and neurointermediate pituitary reinforced the idea that both membrane-associated and 
soluble PAM have basically identical properties with regard to copper and ascorbate 
requirements, pH optima, and KM values with respect to various glycine-extended peptide 
substrates.  Interestingly, at least half of the amidating activity in the anterior pituitary 
was membrane-associated, while only about 10% of the activity in the neurointermediate 
pituitary was membrane-associated.  Typically, approximately 5-fold more PAM was 
found in secretory granules relative to rough endoplasmic reticulum/Golgi fractions.  
Moreover, as the PAM is packaged in early granules and transported from the Golgi 
apparatus, the enzyme is increasingly processed to a soluble form which is released upon 




was affected by the location in the transport chain from rough ER to mature secretory 
granules. 
     PAM was next found to be expressed to a remarkably high degree in rat medullary 
thyroid carcinoma cells.  Since many cellular growth factors are amidated peptides, it was 
not surprising that a cancerous cell-line was thusly enriched with amidating enzyme.  
Mehta, et al., (Mehta 1988), described four gel-filtration chromatography peaks with 
amidating activity, or which Peak III (M.W. = 75,000) was purified to homogeneity.  In 
contrast to PAM from other sources (porcine and bovine pituitary and frog skin), this 
enzyme had an acidic pH optimum (5.0-5.5).  In hindsight, the larger size of this enzyme 
indicates that PGL is also present in a bifunctional enzyme (PAM and PGL).  Since the 
authors are still assaying for the amide product (rather than the then unknown 
hydroxyglycine intermediate), results for this enzyme are likely more reflective of the 
overall kinetic parameters of the amidation reaction than those investigations where only 
monofunctional PAM was used and the pH optima were found to be more alkaline than 
in this particular case.  During these years, prior to the discovery of PGL, it is very 
difficult to compare the kinetic parameters of PAM from tissue to tissue or species to 
species because of the multiple substrates used by various research groups and, more 
importantly, the varying concentrations of exogenously added copper and ascorbate used 
in the various assays.  Finally, the specific activity of the PAM from the carcinoma cells 
was found to be higher than that described for bovine/porcine pituitary and frog skin.  
The amount of PAM relative to total protein was two orders of magnitude greater in the 
thyroid carcinoma cells than these other cell types.  Clearly, these carcinoma cells are 




indication that PAM might in fact be a desirable target for inhibition in the treatment of 
various neoplastic pathologies. 
     Subsequently, significant amidating enzyme activity was found in both mouse atrial 
myocytes (previously investigated in rats) and in AtT-20 cells, a mouse corticotropic 
tumor cell line (corticotropes are cells in the anterior pituitary which express and secrete 
adrenocorticotropic hormone, as well as α-MSH, and which are sensitive to the 
polypeptide corticotropin-releasing factor (CRF, also known as corticotropin-releasing 
hormone, or CRH).  Thiele, et al., (Thiele, 1989) investigated the degree to which the 
expression of PAM in both of these cell types varied in the presence of either the 
synthetic glucocorticoid dexamethasone or the cyclic-AMP analog (Bu)2cAMP.  
Dexamethasone is a potent immunosuppressant and anti-inflammatory agent which exerts 
its effects through the HPA axis (hypothalamus/pituitary/adrenal axis).  (Bu)2cAMP 
activates protein kinase A (PKA), which in turn activates a variety of intracellular 
enzymes via phosphorylation, and can ultimately result in the activation of specific 
promoter regions in the DNA of the cell nucleus which causes the activation and 
expression of genes stimulating the production of growth hormones and a variety of pro-
inflammatory mediators. 
     Treatment of the AtT-20 (pituitary-derived) cell with dexamethasone, unsurprisingly, 
resulted in an appreciable decrease in PAM mRNA (to 55% controls) while treatment 
with (Bu)2cAMP resulted in an increase in the transcription of PAM mRNA (to 132% 
controls).  The specific activity of the extracted, cell-associated PAM enzyme (M.W. = 
100,000 and likely bifunctional PAM/PGL) decreased in both cases to approximately 




stimulation of secretion of PAM into the cultural medium.  Interestingly, the heart atrial 
cultures responded in a similar manner to both compounds, with PAM mRNA increasing 
in both cases to approximately 220% of the controls.  Secretion also increased by the 
same proportion.  The effects of the coadministration of both compounds resulted in an 
additive effect, where secretion increased to nearly 350% of controls.  AtT-20 cells were 
unable to maintain baseline levels of PAM in the face of higher secretion levels, whereas 
the cellular PAM levels of atrial cardiocytes were unaffected, even as secretion increased 
dramatically.  This provides further evidence that atrial myocytes might be the major 
source of amidating enzyme in the bloodstream.  Naturally, only soluble amidating 
enzyme is secreted.  The authors do not describe the molecular weight of the soluble, 
secreted enzyme, but it is extremely likely that it is the monofunctional PAM 
monooxygenase. 
     Later that year, PAM was also discovered in chromaffin granules of bovine adrenal 
medulla (as well as other ganglia of the sympathetic nervous system) (Bastiaensen, 
1989).  This is interesting for an additional reason, namely that these neuroendocrine 
cells are known for the secretion of the catecholamines epinephrine and norepinephrine, 
the latter of which is a β-hydroxylated product that is formed from dopamine by the 
action of the enzyme dopamine β-monooxygenase (DBM), an enzyme with considerable 
sequence homology to PAM and also requiring the cofactors copper and ascorbate.  The 
amidated peptides Neuropeptide Y (NPY), metorphamide, and amidorphin were also 
known to be present in chromaffin granules.  These cells are innervated by the splanchic 
nerve and are readily stained by chromium salts (hence the name “chromaffin”).  While 




in the soluble fraction of the secretory granules.  The molecular weight of the enzyme 
was found to be 40,000 Daltons and had a pH optimum of approximately 8.0.  This 
alkaline pH optimum and lower molecular weight indicates, again, that the soluble form 
of the enzyme investigated here is monofunctional PAM. 
     In 1990, Rhodes et al. (Rhodes, 1990) further investigated the distribution of PAM 
throughout the nervous system of the rat, finding PAM in a wide variety of both neuronal 
and non-neuronal cell types.  Immunostaining of PAM was effected via an antiserum 
raised against seventeen amino acid residues of the N-terminus of the enzyme.  
Unsurprisingly, a great deal of immunoreactivity was detected in the perikarya (neuronal 
cell bodies) of various neuronal cells, including pituitary, the hypothalamic 
periventricular and supraoptic nuclei, the neocortex, and sensory ganglia.  
Immunoreactivity was highest in regions known to receive amidated peptidergic 
afferents, as well as some neurons not known to produce amidated peptides (such as the 
pyrimidal cells of the hippocampus, a structure known to be involved in long-term 
memory and spatial navigation).  Moreover, some of the most intensely-stained areas of 
the brain involved a variety of non-neuronal cell types, especially in the ependyma 
(neuroglia in the epithelial lining of the ventricular system of the brain) and choroid 
plexus (modified ependymal cells in the ventricular system which are involved in the 
production of cerebrospinal fluid).  The following glial cells (glial cells are a wide variety 
of cells which support neurons in a number of different fashions) also exhibited a 
considerable amount of PAM immunoreactivity:  oligodendroglia, cells involved in the 
insulation of axons of neurons in the central nervous system, each capable of supporting 




as well as basic biochemical support of the endothelial cells which form the blood-brain 
barrier; and Schwann cells, glia which insulate the axons of the peripheral nervous 
system, and which are associated with, in contrast to oligodendroglia, only one neuronal 
axon.  Finally, a comparatively huge degree of PAM immunoreactivity was found in the 
sciatic nerve, the largest nerve in the body, which runs from the lower back through the 
lower limb.  Braas et al. (Braas, 1992) also found PAM immunoreactivity in the heart, 
salivary glands, thyroid, adrenal glands, the α-islet cells of the pancreas, the kidneys, and 
the testis. 
     By 1992, the bifunctional nature of the amidating enzyme had been demonstrated by 
this laboratory (Katopodis, 1990) with the discovery of PGL (Peptidoamidoglycolate 
Lyase, E.C. 3.2.1.15), the enzyme which catalyzes the dealkylation of the α-
hydroxyglycine product of the PAM (monooxygenase) reaction.  Our laboratory 
(Oldham, 1992) investigated whether PAM and/or PGL was expressed in endothelial 
cells, and found both the monooxygenase and lyase activities to be present therein.  
Endothelial cells release a variety of vasoconstrictors (endothelin and angiontensin II) 
and vasorelaxants (endothelium-derived relaxing factor and the eicosanoid prostaglandin 
prostacyclin) and also express a variety of cell-surface attachment proteins (intracellular 
adhesion molecule, or ICAM, and vascular cell-adhesion molecule, or VCAM, e.g.) 
involved in the recruitment, diapedesis, rolling, and extravasation of leukocytes into areas 
of inflammation, infection, or cellular damage in the extravascular space.  The 
monooxygenase and lyase reactions were measured simultaneously by monitoring the 
conversion of trinitrophenyl-D-YVG (TNP-YVG) to both TNP-YV(OH)G and TNP-YV-




hydroxybenzoylglycine to benzamide.  The full amidation reaction (requiring both PAM 
and PGL) was ascorbate dependent, whereas the isolated PGL reaction showed no such 
dependency.  Preincubation of the cell extracts with 4-phenyl-3-butenoic acid (PBA), a 
known inactivator of PAM, abolished all activity in the PAM assay, while the PGL 
reaction was unaffected by this preincubation. 
     Eipper et al. (Eipper 1992) demonstrated that, although PAM/PGL is encoded by a 
single gene in the rat, alternative splicing in various tissues results in as many as seven 
different forms of amidating-enzyme mRNA.  Five encode the full bifunctional enzyme.  
Of these five, three are translated into the membrane-bound form while two encode 
soluble proteins.  One mRNA encodes a soluble, monofunctional PAM.  The final 
mRNA, strangely, encodes only part of the PAM domain (it does not include the region 
of sequence homology to DBM), which is completely inactive toward common PAM 
substrates.  Of the five bifunctional enzymes, only one, rPAM-1, contains the dibasic 
cleavage site (Lys-Lys, in Exon A) which allows for the proteolytic cleavage of a soluble 
PAM from PGL, leaving the PGL membrane-bound.  The different enzyme forms may 
lead to targeting of the newly formed enzymes along different trafficking pathways to 
various subcellular locations, or allow for different N-glycosylation sites, or may allow 
for endocytosis and recycling of certain forms of PAM to the exclusion of others.  There 
do not appear to exist any monofunctional PAM derivatives which could conceivably 
remain associated with the cellular membrane.  Interestingly, concurrent work by Kato et 
al. (Kato, 1992) detected significant PAM/PGL in the saliva and submaxillary gland 
(exocrine) of the rat.  The salivary PAM had a molecular weight of 75,000 Daltons, 




Daltons.  A trypsin digest (a protease which cleaves peptides to the carboxy side of Lys 
and Arg residues) of the salivary PAM resulted in PAM with a molecular weight of 
25,000, identical to that found originally in the submaxillary gland. 
     Saldise et al. (Saldise, 1996) found an abundance of amidating enzyme in both normal 
human lung and a variety of lung cancer resections, including adenocarcinomas, small-
cell lung carcinomas, large-cell carcinomas, and well-differentiated neuroendocrine 
carcinomas.     Interestingly, PAM activity was found to some degree in all tumor types, 
but PGL was absent in many resections, or present only to a much smaller degree than 
PAM.  Not surprisingly, the neuroendocrine tumors were richest in PAM and PGL 
activity.  In normal human lung, PAM immunoreactivity was found in airway epithelium, 
endothelium, some chondrocytes, alveolar macrophages, smooth muscle cells, and both 
myelinated nerves and neurons of the intrinsic ganglia.   
      Guembe, et al. (Guembe, 1999) followed the expression of PAM and PGL in adult 
mouse lung, finding significant immunoreactivity in epithelial cells, smooth muscle cells, 
and pulmonary parenchymal cells (the authors assume these to be macrophages).   More 
interestingly, the authors found that some cells were immunoreactive to either PAM or 
PGL, but not both.  Since both enzymes are encoded by the same gene, the fact that some 
cells express one but not the other implies that a preferential secretion or degradation of 
one enzyme or the other may occur in a given cell type.  This may imply a heretofore 
unknown function for either glycine-extended PAM substrates in their own right (by 
virtue of cells lacking PAM immunoreactivity) or for α-hydroxyglycine intermediates of 
various peptides (no PGL activity).  Indeed, CGRP-positive (a known amidated peptide) 




1993; Steel, 1994).  Such a functional role for either of these types of species would 
greatly increase the known complexity and flexibility of the neuroendocrine system.  
Indeed, it was later shown that SP-Gly is equipotent with SP in the stimulation of NO 
release from cultured bovine cardiac endothelial cells (Abou-Mohammed, 2000).  
However, it is possible that this effect is derived from the N-terminus of SP/SP-Gly, 
rather than from the C-terminus, associating with the appropriate receptor.  Differential, 
rather than similar, effects of a given glycine-extended peptide relative to its des-Gly 
amide would serve to increase the complexity of a given system. 
 
Substrates and Inhibitors 
 
    For reference, the overall amidation reaction is shown in Figure 1.  Among the earliest 
investigations into the substrates of Peptidylglycine α-Amidating Monooxygenase were 
those begun in the early 1980’s by Bradbury and coworkers.  The first known synthetic 
PAM substrate was the tripeptide D-YVG, utilized in these early experiments (Bradbury, 
1983).  This same tripeptide, albeit modified with a trinitrophenyl adduct to increase UV 
activity,  has been utilized exhaustively as a PAM substrate in inhibition experiments by 
this laboratory for many years (Katopodis 1988).  Other laboratories have utilized 
dansylated or N-acetylated derivatives of this tripeptide as their standard PAM substrate.  
As mentioned previously, the sequence is based on the R-Val-NH2 carboxy terminus of 
α-MSH (melanocyte-stimulating hormone) and the fact that corticotropin (the α-MSH 
precursor) contains the MSH sequence followed by a glycine residue.  D-Tyrosine, easily 





























Figure 1.  Reaction scheme for PAM and PGL, including appropriate 
stereochemistry and cofactors.  The monooxygenase incorporates one 
atom of molecular oxygen into the peptide substrate, the other is reduced 
to water.  Ascorbate reduces both active-site copper ions to Cu(I), and is 
oxidized to semidehydroascorbate.  PGL catalyzes the oxidative 




included as the residue at the P3 position of the substrate.  The incorporation of a (D)-
residue may also serve to decrease the rate of substrate hydrolysis by any proteases 
present in biologically-derived samples.  D-YVG was converted to D-YV-NH2 by 
purified amidating enzyme.  Replacement of Gly by either negatively charged Glu, 
positively charged Lys, or the small hydrophobic Ala, resulted in no amide formation.  
This was the first demonstration that only glycine-extended peptides are accepted as 
PAM substrates.  Further studies revealed that all (L)-amino acids are tolerated at the P2 
position, but that neutral hydrophobic residues are preferred.  The tripeptide D-Tyr-D-
Ala-Gly was found not to be a PAM substrate, demonstrating stereospecificity at the P2 
position as well.  Obviously, (D)-amino acids are tolerated at the P3 position.  It was 
hypothesized that peptide amidation was the final step of a three-step process whereby 
ACTH is initially cleaved to the carboxy-side of a pair of dibasic residues by a 
prohormone convertase, followed by cleavage to the N-terminal side of the dibasic pair of 
residues by a Carboxypeptidase B-like activity, followed by amidation of the glycine-
extended peptide by PAM. 
     With the knowledge that glyoxylic acid was a product of the amidation reaction 
(Bradbury 1987) and that amidation does not occur under anaerobic conditions, Bradbury 
et al. hypothesized that the amidation reaction involved the incorporation of a hydroxyl 
group into the glycine-extended precursor followed by a dealkylation to yield, in addition 
to free glyoxylate, the amidated peptide product.  To that end, a series of glyoxylate 
phenylhydrazones, thiosemicarbazones, and semicarbazones were synthesized as 
potential substrates for the amidating enzyme.  The interesting feature common to these 




sp3 methylene carbon present in peptide substrates possessed of a C-terminal glycine 
residue.  Assuming an enzyme mechanism involving substrate hydroxylation, the product 
of the reaction of glyoxylate phenylhydrazone and purified PAM was expected to be 
oxalate phenylhydrazide, and indeed this was the sole product of the reaction.  This 
involved oxidation of the putative alcohol intermediate concomitant with reduction of the 
imine.   Glyoxylate phenylhydrazone was found to inhibit the formation of D-YV-NH2 
with a KI value of 15 μM (approximately equal in value to the KM of the substrate used).  
At 0.1 mM, this compound was found to exhibit about 96% inhibition.  Interestingly, the 
pyruvate phenylhydrazone derivative not only was not a substrate for PAM, but was also 
unable to inhibit the enzyme to any degree in the presence of known substrates.  They 
also showed that [14C]-glyoxylic acid was formed from D-Tyr-Val-[14C]-Gly. 
     At about the same time, Tamburini et al. were conducting experiments regarding 
structural requirements for amidation substrates along the same lines as Bradbury 
(Tamburini 1990).  They also found the C-terminal glycine residue was obligatory for 
activity, with all substitutions/additions for glycine at the C-terminus resulting in no 
product formation, amide or otherwise.  Neither peptide amides corresponding to 
formerly glycine-extended peptides, nor C-terminal glycine methyl esters were PAM 
substrates, although they were weakly competitive inhibitors (15-30 fold decrease in 
binding affinity relative to C-terminal glycine substrates).  Any additional C-terminal 
residues beyond Gly also abolished binding.  Furthermore, P2 and P3 amino acid residues 
also heavily influenced the binding affinity of various glycine-terminal peptides.  At the 
P2 position, the effect on binding affinity was found to correspond to:  sulfur-containing 




terminal sequence as a variety of prohormones exhibited very nearly the same binding 
affinity as the prohormones themselves.  This indicated that the secondary and/or tertiary 
structure of larger prohormones does not influence substrate binding, for better or for 
worse.  Replacement of the amide nitrogen with a methylene group (i.e. C-terminal β-
alanine) abolished binding affinity, as does C-terminal sarcosine (i.e. C-terminal glycine 
with a pendant methyl group on the amide nitrogen).  One final interesting finding in this 
study was the fact that although the PAM used was derived from AtT-20 thyroid 
carcinoma cells, the prohormones with the greatest binding affinity were Substance P-Gly 
and Neuropeptide Y-Gly, both peptides associated with the central nervous system rather 
than the thyroid gland.  This indicated that PAM from different tissues have very similar 
affinities for a given substrate. 
     In 1988, this laboratory (Katopodis, 1988) developed a highly UV-active tripeptide 
PAM substrate (TNP-(D)-YVG) which greatly improved the ease of detection of the 
hydroxyglycine intermediate and amidated product by HPLC.  Previously, radioiodinated 
tyrosyl substrates and fluorescent (dansyl) peptides were used to quantify PAM products, 
as the working substrate concentrations (c. 2-20 μM) without these modifications 
provided a UV response too low to detect by UV-Vis HPLC.  Unlike D-YVG, the 
trinitrophenylated TNP-YVG substrate has no charge at the N-terminus.  This lack of 
charge, and the inclusion of another large aromatic residue, resulted in a substrate with 
increased binding affinity (3 μM). 
     The most involved and detailed study of PAM (the bifunctional enzyme) substrates 
and inhibitors to date was undertaken by this laboratory in 1990 (Katopodis and May, 




including O-glycolate esters, S-glycolate ethers, N-glycolate amines, O-glycolate ethers, 
and benyoylacrylate (Figure 2).  This was the first elucidation of a series of non-peptide 
substrates for the amidating enzyme and represented a conceptual breakthrough in the 
evaluation of its substrates and inhibitors.  First, the kinetic parameters of hippuric acid, 
4-nitrohippuric acid, and 4-methoxyhippuric acid were found to depend on the 
substitution (or lack thereof) at the para position.  The best substrate was 4-nitrohippuric 
acid, with a KM value of 1.0 mM and a Vmax of 1370 nmol/mg/h.  The nitrophenyl group 
is strongly electron-withdrawing.  Hippuric acid itself had a slightly higher KM (1.6 mM) 
and a greatly reduced Vmax (493 nmol/mg/h).  Inclusion of the electron-donating methoxy 
group resulted in a further decline in Vmax (109 nmol/mg/h) while the KM slightly 
increased to 1.7 mM.  All were converted to the corresponding amide product.  The 4-
nitro ether (uncharged) analog was an especially good substrate, converted to the 
corresponding alcohol with KM and Vmax values of 0.16 mM and 1360 nmol/mg/h, 
respectively.  The positively-charged 4-nitro secondary amine analog displayed a much 
poorer binding affinity (KM = 1.7 mM) but a higher Vmax value (2930 nmol/mg/h) and 
was converted to the dealkylated primary amine.  Since we are dealing with the 
bifunctional enzyme, it is likely that the positive charge of the amino moiety impairs 
binding to PAM, but allows for more efficient dealkylation by PGL relative to the 
uncharged ether analog.  When the corresponding 4-methoxy O-glycolate ester was 
incubated with the bifunctional enzyme, no dealkylation product (i.e. 4-methoxybenzoic 
acid) was detected.  However, this compound was a weak competitive inhibitor (KI = 
0.48 mM).  The 4-nitro S-glycylthioether was also a very good substrate (KM = 0.34 mM, 












Figure 2.  Structures of hippuric acid analogs.  All are PAM substrates, 
except for the ester which is a competitive inhibitor.  The thioether 




expected sulfhydryl dealkylation product.  This is likely exclusively a rearrangement 
product of the PAM reaction (presumably forming the α-hydroxy product initially), 
without any subsequent PGL catalysis. 
     Trans-benzoylacrylic acid was found, like 4-phenyl-3-butenoic acid (PBA), to be a 
mechanism-based inactivator of the amidation reaction (KI = 0.16 mM, kinact = 3.6 min-1).  
It is certainly interesting that both 2- and 3-alkenyl carboxylic acids are able to serve as 
mechanism-based inactivators of the amidation reaction, since the former lacks the 
requisite sp3-hybridized methylene group adjacent to the carboxylic acid requisite for 
substrate hydroxylation.  Noteworthy was the lack or any epoxide or diol product 
following the incubation of trans-benzoylacrylate with PAM.  Moreover, incubation with 
the corresponding epoxide failed to inactivate the enzyme, suggesting another pathway of 
inactivation.  Monoethyl fumarate was also found to weakly inactivate the enzyme, 
indicating that the phenyl ring of trans-benzoylacrylate is not obligatory for inactivation.  
Also notable for failure to inactivate PAM was CBZ-dehydroalanine, which contains a 
terminal alkene functionality at the α-carbon, rather than an internal alkene.  The 
consequences of these findings will be developed more exhaustively in the Discussion 
section of this thesis when comparisons to the second-generation peptidyl-acrylates (e.g. 
N-Ac-(L)-Phe-acrylate, N-Ac-(D)-Phe-acrylate, and N-Ac-(L)-Met-acrylate) are 
investigated. 
     In 1992 and 1993, this laboratory fully elucidated the stereochemistry (reaction and 
subsite) of the PAM and PGL reactions (Ping, 1992; Ping, 1995).  Incubation of TNP-
(D)-Tyr-(L)-Val-NH2 with glyoxylic acid monohydrate under reflux resulted in the 




with PAM resulted in the formation of a single hydroxyglycine intermediate which 
coeluted with the later-eluting synthetic hydroxyglycine, indicating that the PAM 
reaction is stereospecific.  Incubation of both synthetic hydroxyglycine diastereomers 
with PGL resulted in the decrease of only the later-eluting peak.  This proved that PAM 
catalyzes the production of only one of the two possible hydroxyglycine diastereomers of 
TNP-YV(OH)G, and that PGL stereospecifically catalyzes the N-dealkylation of the 
PAM product only.  Further experiments with PGL and Acylase I (i.e. N-acyl-(L)-amino 
acid amidohydrolase, E.C.3.5.1.14) using racemic N-cinnamoyl-α-hydroxy-Gly showed 
that both enzymes reacted with the same enantiomer (reaction with PGL yields 
cinnamide, reaction with Acylase I yields cinnamic acid).  Since it is known that (S)-
cinnamoyl-α-hydroxy-Gly is stereotopically equivalent to an N-acyl-(L)-amino acid, it 
was concluded that PGL reacts only with (S)-α-hydroxyglycines.  Therefore the PAM 
reaction itself yields (S)-α-hydroxyglycines exclusively. 
     Although peptides and peptide analogs with (D)-amino acids in the P2 position had 
previously been shown to be poor PAM substrates in the past (Bradbury 1982, Bradbury 
1983), these studies were carried out without the knowledge that the process of peptide 
amidation actually was the product of two separate and distinct catalytic functionalities.  
As mentioned previously, this discovery obviously cast a new light upon many of the 
kinetic parameters and binding constants for various substrates and inhibitors which had 
been evaluated (unknowingly) in the presence of both enzymes.  When assaying a 
potential inhibitor, for instance, for its efficacy in impeding the amidation process when 
both PAM and PGL are present, it is impossible to determine to what degree a given 




is assayed, and not both the amide and hydroxyglycine intermediate.  Thus, although it 
was known that certain molecular functionalities and spatial orientations did indeed 
inhibit overall amidation, it remained to be seen exactly which of these properties was 
effective in inhibiting PAM vs. PGL.  Thus, this laboratory set out to determine to what 
extent the stereochemical properties of various substrates and inhibitors affected PAM 
and PGL catalysis on an individual basis. 
      To this end, a variety of derivatives with varying stereochemistry at the P2 position 
were evaluated.  Incubation of purified PAM with N-Ac-(L)-Phe-Gly and N-Ac-(D)-Phe-
Gly resulted in stark differences in product formation.  The former was about as effective 
a substrate, with respect to kinetic parameters, as TNP-YVG, and underwent 100% 
conversion to the hydroxyglycine intermediate.  The (D)-enantiomer, on the other hand, 
evinced only about an initial 0.5% conversion which did not increase after extended 
incubation times.  This product coeluted with the (L)-Phe-(S)-hydroxy-Gly seen from the 
(L)-Phe-Gly incubation (recall that diastereomeric hydroxyglycines were resolved 
previously by RP-HPLC) and was therefore either, firstly, (L)-Phe-(S)-hydroxy-Gly 
resulting from a slight enantiomeric impurity in the (D)-Phe-Gly preparation, or 
secondly, (D)-Phe-(R)-hydroxy-Gly (which, as an enantiomer of (L)-Phe-(S)-hydroxy-
Gly would indeed coelute with that compound).  The failure of extended incubations to 
increase the size of the product peak after the initial 0.5% conversion argues for the 
presence of a very slight enantiomeric impurity in the (D)-Phe-Gly preparation.  
Interestingly, not only was the (D)-Phe-Gly not a PAM substrate but was also an 
exceedingly poor competitive inhibitor (KI = 1.3 mM) of PAM, indicating that its spatial 




comparison, the apparent KI of N-Ac-(L)-Phe-Gly in the presence of TNP-YVG substrate 
was found to be 2.0 μM, nearly 3 orders of magnitude less than the (D)-enantiomer.  
Similar trends were seen with the enantiomeric pair (S)-O-Ac-mandelyl-Gly and (R)-O-
Ac-mandelyl-Gly (O-acetylated-α-hydroxybenzeneacetic acids) and the diastereomeric 
pair N-Ac-(L)-Phe-(L)-Phe-Gly and N-Ac-(L)-Phe-(D)-Phe-Gly.  These results plainly 
indicated the stringent subsite stereospecificity of PAM with respect to its substrates.  
The same subsite specificity was evident with N-Ac-Phe-O-glycolate enantiomers, and 
although neither underwent PAM catalysis the (L)-enantiomer was found to be a potent 
competitive inhibitor (KI = 45.2 μM) whereas the (D)-enantiomer was very ineffective 
(KI = 2.25 mM).  PGL was found to exhibit very low subsite specificity, converting (S)-
hydroxyglycines to the amide in a nondiscriminant manner regardless of the 
stereochemistry at the P2 position. 
     Another important advance in the study of peptide amidation were the crystal 
structures of oxidized PAM, ascorbate-soaked reduced PAM, and oxidized PAM with 
bound substrate in the active site (Prigge, 1997).  Obviously, the solving of the crystal 
structures is an extremely important step in the ability to design, tailor, and refine 
effective enzyme inhibitors.  PAM (Figure 3) was found to be a prolate ellipsoid, with 
dimensions of approximately 55 X 45 X 25 Å.  Two domains are associated through an 
extensive hydrophobic interface in an overall horseshoe-shaped structure, with the rest of 
the interface separated by a broad solvent accessible cleft approximately 8 Å in width.  
Two copper ions (CuA and CuB, also CuH and CuM, respectively), separated across the 
solvent-accessible cleft by approximately 11 Å, are each ligated by three amino acid 












Figure 3.  Cartoon of the X-ray crystal structure 
of oxidized PAM (PDB ID: 1OPM).  Bound copper ions 
represented as green spheres, one on each side of the 
solvent-accessible cleft.  Substrate binds above CuB. 
The copper ions are 11 Å distant from each other. 




substrate (diiodo-Tyr-Gly) binds at the top of the cleft, offset to one side so as to place 
the reactive pro-(S) glycyl hydrogen in close proximity to CuB.  The carboxylate of the 
substrate is anchored by a bidentate salt-bridge to the guanidinium group of R240, also 
forming a hydrogen bond with the phenolic hydrogen of Y318.  The main chain amide of 
the peptide bond forms another hydrogen bond with the amide side chain of N316.  The 
aromatic ring projects upwards into a large hydrophobic pocket bordered by a variety of 
Ile, Phe, Tyr, and Met residues.  Other van der Waals’ contacts are formed with M314, 
which is ligated to CuB.  Neither the oxidation state of the copper ions or the binding of 
substrate appears to significantly influence the structure of the active site of the enzyme 
(R.M.S. of 0.3 Å for the protein α-carbons).  The only noticeable change upon substrate 
binding is the loss of a hydrogen bond between Y318 and N316, with the latter instead 
forming a hydrogen bond with the substrate as mentioned previously.  The formation of 
the salt-bridge between the substrate carboxylate and the guanidinium of R240 helps to 
explain the poor binding of C-terminal amide and ester-derivatives of known substrates.  
The formation of the α-hydroxyglycine intermediate requires an overall two-electron 
reduction of molecular oxygen, one electron each donated from CuA and CuB, so the most 
obvious question which arises from the crystal structure is the mechanism by which an 
electron is transferred from CuA (11 Å distant) to the ROS at CuB.  The mechanism of the 
PAM reaction will be discussed in far more detail below. 
     Subsequently, Prigge et al. (Prigge, 2004) were able to crystallize reduced PAM with 
both substrate and molecular oxygen bound to the active site of the enzyme.  In this case, 
since the enzyme is catalytically competent in the presence of reduced copper and 




hydrogen (to illustrate the proximity of said hydrogen to molecular oxygen) which either 
failed to undergo catalytic turnover or was an exceedingly slow substrate on the time-
scale of the crystallization experiments.  To this end, the “substrate” diiodo-Tyr-(D)-Thr 
was cocrystallized with reduced PAM under aerobic conditions, and again with oxidized 
PAM.  In both cases the substrate docked in essentially the same position relative to the 
active site residues, but molecular oxygen bound only in an “end-on” manner to CuB in 
the case of reduced, catalytically competent PAM.  All other interactions of the substrate 
and enzyme were the same as described for the case of diiodo-Tyr-Gly above, with the 
sole exception that an additional hydrogen bond was formed between the hydroxyl group 
of the threonine side chain and Y318.  The CuB-O-O bond angle was found to be 
approximately 110°, and the O-O bond length 1.23 Å.  This bond length is indicative of 
dioxygen either in the dioxygen or superoxo (reduced by one electron) form, but not in 
the peroxo (reduced by two electrons) form.  The latter would also present a CuB-O-O 
bond angle closer to 90°.  It is likely, however, based on mechanistic evidence to be 
presented later, that the O2 is found in the unreduced dioxygen form in the case of this 
poor substrate.  The two oxygens are within 4.13 and 4.73 Å of the glycyl Cα, and 
predicted to be within 3.16 Å of the pro-(S) glycyl hydrogen (which cannot be explicitly 
seen in the crystal structure), an appropriate distance for abstraction of this hydrogen 
atom from the substrate.  The authors propose that, ultimately, an electron is transferred 
from CuA to CuB-O2 via H108 (a CuA ligand), a solvent water, and the substrate 
carboxylate moiety.  This is the “substrate-mediated electron-transfer pathway” 
mechanistic hypothesis.  Again, oxygen only binds under aerobic conditions in the 




    In recent years, a spate of research has shown that PAM is capable of hydroxylating 
(and PGL dealkylating) many physiological non-peptide substrates which are either 
possessed of a CH2-COOH moiety, or glycine-extended in their own right.  These include 
various N-acylglycines such as N-myristoylglycine (Merkler, 1996) and N-lauroylglycine 
(Wilcox, 1999).  Indeed, physiologically, a variety of carboxylic acids are conjugated to 
glycine via the enzyme Acyl-CoA: Glycine N-Acyltransferase (E.C.2.3.1.13), including 
nicotinic acid.  The glycine-extended conjugate is a PAM substrate which is converted to 
nicotinamide (vitamin B3) by the tandem activities of PAM and PGL (Merkler, 1999).   
Aspirin (acetylsalicylic acid) is perhaps the most widely used pharmaceutical product in 
existence.  In vivo, aspirin is initially hydrolyzed to salicylic acid and then further 
metabolized by glycine conjugation in the liver to salicyluric acid (which is then 
maintained at nearly constant concentrations in the bloodstream for extended periods of 
time.  DeBlassio et al. found that salicyluric acid and gentisuric acid (ring-hydroxylated 
salicyluric acid) are converted to the corresponding amides by PAM and PGL activities 
(DeBlassio, 2000).  Whether or not these amides have any significant biological activity 
remains to be determined, but it is possible that concentrations of these compounds in the 
bloodstream is high enough to inhibit serum PAM (with respect to other substrates) 
following common aspirin dosages.  Also, glycine-conjugated bile acids, which are 
released into the bloodstream under pathological conditions in the liver, have been found 
to be PAM substrates. (Merkler, 1988) 
     Further work by Merkler et al. (Merkler, 2003) found that glutathione, S-substituted 
glutathiones, and leukotriene C4 (a pro-inflammatory mediator conjugated to glutathione) 




values.  All were found to proceed via the corresponding α-hydroxyglycine intermediate, 
with glyoxylate production lagging until the amide is formed (ultimately 1:1 ratio 
amide/glyoxylate).  Interestingly, amidated glutathione is an exceedingly poor substrate 
for the enzyme glutathione-S-transferase (E.C.2.5.1.18), an enzyme involved in the 
detoxification of peroxidized lipids and various xenobiotics via conjugation with reduced 
glutathione.  Amidated glutathione, being a poor substrate for glutathione-S-transferase, 
is effectively rendered physiologically useless in this regard, although it may have 
various potentially unknown physiological functions.  Glutathione and PAM are known 
to be colocalized in a variety of tissues, such as the anterior pituitary, hypothalamus, 
choroid plexus, heart atrium, secretory vesicles of small-cell lung carcinoma cells, 
cerebrospinal fluid, and the bloodstream.  The C-class leukotrienes, conjugated to 
glutathione, are the so-called “slow-reacting substance of anaphylaxis”.  It is unknown 
whether amidation of the attached glutathione either inhibits or exacerbates these adverse 
effects.  Finally, the protein ubiquitin, when conjugated to peptides/proteins, targets them 
for destruction by the proteasome.  Ubiquitin terminates in the sequence Gly-Gly and is 
therefore a candidate for amidation by PAM.  Chew et al. (Chew 2005) found that 
ubiquitin is indeed a PAM substrate (KM = 600 μM vs. 220 μM for D-YVG in their 
hands) and that amidation of ubiquitin (i.e. to ubiquitin 1-75-NH2) eliminates its ability to 
label peptides and proteins for subsequent proteasome degradation. 
    As the recent work with various substrates has shown, although PAM has a strict 
requirement for a carboxylate functionality and an α-methylene (or methine, if the 
hydrogen is pro-(S) and the other hydrogen has been replaced with a small group such as 




indiscriminant beyond these minimal requirements.  Of course, molecules with 
inappropriate stereochemistry in a position analogous to the P2 residue in peptidyl 
substrates are exceedingly poor substrates, but a wide variety of fatty acids and N-
acylglycines have been shown to be substrates for amidation.  A variety of competitive 
inhibitors have been identified, including O-glycolate esters (Ping 1995), C-terminal 
homocysteines, and the glycine-terminal dipeptide analogs thiorphan and tiopronin.  The 
sulfur-containing compounds appear to interact strongly with CuB, with the 
homocysteines possessed of a sulfhydrylethyl group which is stereotopically equivalent 
to the reactive pro-(S) hydrogen of glycine-extended peptides.  Other copper-chelating 
compounds, such as disulfiram and diethylthiocarbonate, have been shown to inhibit the 
amidation reaction in cultured cells, but these presumably do not affect the enzyme 
directly as exogenous copper is able to overcome these inhibitory effects.  Also, dietary 
copper deficiency, like dietary ascorbate deficiency, results in a net decrease in 
amidation, with the PAM in the brain less affected than PAM in the periphery, possibly 
due to some sort of “copper-hoarding” mechanism by the applicable brain cells.  (Mains, 
1986; Mueller, 1993; Mueller, 1995)  N-Ac-(L)-Phe-Pyruvate and other pyruvate-
extended amino acids, developed by this laboratory, are the only known noncompetitive 
inhibitors of PAM, competing instead with ascorbate at the site of copper reduction.  The 
most interesting compounds, from both a chemical and pharmacological viewpoint, are 
the competitive mechanism based inactivators.  These include two classes of compounds:  
first, the commercially available 4-phenyl-3-butenoic acid (PBA) and any related 3-enoic 
acids; and secondly, the 2-enoic peptide acrylate class of compounds developed by this 




Acrylate).  Finally, unsaturated thioacetic acid derivatives, such as trans-styrylthioacetic 
acid (KI = 0.1 mM, kinact = 0.2 min-1), were found to be reasonably effective with regards 
to PAM inactivation (Casara, 1996).  These compounds, although they contain a main-
chain sulfur atom, are structurally and electronically equivalent to 4-alkenyl carboxylic 
acids.  Only the trans isomer was found to be capable of enzyme inactivation. 
     The 3-enoic acid PBA (4-phenyl-3-butenoic acid), along with its potent PAM 
inactivation properties, satisfies the basic structural requirements (R-CH2-COOH) for a 
PAM substrate and has a pro-(S) methylene hydrogen available for extraction by the ROS 
generated at CuB.  Although PBA has been studied and utilized as a PAM inactivator in 
vivo, in vitro, and ex vivo for many years as described previously, its powerful 
inactivation properties, coupled with a rather meager UV-Vis activity, made it difficult to 
generate enough products from PBA (in the absence of huge quantities of purified PAM) 
to be readily analyzed by HPLC.  To this end, Driscoll et al. utilized PBA radiolabeled by 
tritium exchange as a PAM substrate/inactivator and found that two hydroxylated 
products were formed: 2-hydroxy-4-phenyl-3-butenoic acid and 4-hydroxy-4-phenyl-2-
butenoic acid (Driscoll, 2000).  Pulse-chase experiments indicated that both were direct 
products of PAM catalysis, and not formed one from the other in solution.  Additionally, 
product formation was stereoselective rather than stereospecific (strictly stereospecific 
with regard to peptide substrates) with the (R)-stereoisomer formed preferentially at a 
ratio of 70:30 for the 2-hydroxy product and spatially the same as (S)-hydroxyglycines 
derived exclusively from peptide substrates.  For the 4-hydroxy product, no absolute 
configuration was derived, but one stereoisomer was formed over the other at a ratio of 




which was unexpected owing to the structural similarity of both to known inactivators, 
the 4-hydroxy product to 2-enoic inactivating compounds, and the 2-hydroxy product to 
PBA itself.  Clearly, since both (R) and (S)-stereoisomers of the 2-hydroxy are formed, 
and because peptides terminating in (D)-alanine are, albeit very poor, PAM substrates, 
one of the isomeric products would necessarily possess a pro-(S) hydrogen and therefore 
inactivate the enzyme.  The fact that they do not suggests, therefore, a mechanistic or 
electronic, rather than structural, impediment to inactivation by this species (especially 
the 4-hydroxy product).  The partition ratio was found to be approximately ninety (90 
pmol product produced/pmol PAM inactivated).  The high partition ratio, coupled with 
the knowledge that both 2-hydroxy and 4-hydroxy products are formed rather than 
exclusively, as would be expected, the 2-hydroxy product, indicates that PBA, following 
hydrogen atom abstraction, binds less tightly to the active site than does PBA itself.  
Therefore, it is possible that a PBA radical may, one time out of ninety, escape the active 
site and leave an activated ROS bound to CuB which may lead to a reaction with an active 
site residue (possibly Y318) which permanently inactivates the enzyme.  The fact that 
PBA lacks a hydrogen-bond donor (no amide functionality) obviates the possibility of a 
hydrogen bond forming with N316 (as it does with peptide substrates) and may 
contribute to a “loose” binding in the active site, explaining the existence of both 2-
hydroxy and 4-hydroxy products, as well as enzyme inactivation.  Finally, no 3H 
radioactivity was seen to coelute with inactive PAM.  Therefore, no covalent adduct is 
formed during the inactivation of PAM by PBA.  This finding contradicts the results of 
Bradbury’s work with 14C-labeled PBA which showed by HPLC that radioactivity 




     The peptidylacrylate class of compounds developed by this laboratory in the 1990s 
(Feng, 2000) remain the most potent mechanism-based PAM inactivators known today.  
Based on the idea that a transient cationic radical intermediate may form during the 
course of PAM catalysis, it was posited that a 2-alkenyl group would stabilize and trap 
the nascent radical such that further chemistry may occur with active site residues 
resulting in the irreversible inactivation of the enzyme.  Moreover, structural similarity to 
peptide substrates with relatively higher binding affinities was expected to yield more 
potent inactivation properties.  NMR analysis of the acrylates indicates that they exist 
entirely in the trans configuration when synthesized by our protocol.  The molecule N-
Ac-Phe-acrylate is essentially a rational modification of N-Ac-(L)-Phe-Gly, one of the 
most efficient dipeptide PAM substrates, where the main-chain -N-Cα- group of the 
glycine residue is replaced by a –C=C- functionality.  Essentially, this change creates an 
α-β-unsaturated ketoacid.  Feng et al. found that N-Ac-(L)-Phe-acrylate was a cofactor-
dependent, time-based irreversible competitive inhibitor of PAM (KI = 95 ± 12 μM, kinact 
= 1.1 ± 0.2 min-1, kinact/KI = 12, 000 M-1 min-1). 
     Also, with a view to optimizing active-site binding via ligation with the active-site 
CuB ion, N-Ac-Phe-acrylate was further modified by the replacement of the phenyl group 
with a 2’-thienyl group to yield N-Ac-2’-thienyl-acrylate (4-oxo-5-acetamido-6-(2-
thineyl)-hex-2-enoic acid).  The thienyl ring is a five-membered sulfur-containing 
aromatic ring, similar in size to a phenyl group, and is electron-rich relative to benzene 
by virtue of possessing a complement of 6 e- distributed over a 5-membered, rather than 
6-membered, ring.  Thiophene is a well-known and potent ligator of copper ions.  Indeed, 




corresponding phenylalanine derivative (KI = 31.9 ± 0.2 μM, kinact = 0.56 ± 0.1 min-1, 
kinact/KI = 17,600 M-1 min-1).  Interestingly, however, although the binding of the thienyl 
derivative was approximately 3-fold more potent than the phenylalanyl derivative, its rate 
constant of inactivation dropped by about one-half.  An appeal to Prigge’s crystal 
structure provides some explanation for this divergence of potency relative to the 
individual kinetic parameters of the thienyl derivative.  The tyrosine of IYG bound to 
oxidized PAM in the crystal structure is oriented upwards into the large hydrophobic 
pocket of the PAM active site, whereas CuB (to which the thiophene ring could 
presumably ligate) lies in the opposite direction.  It is not possible for the thiophene ring 
to interact with both CuB and the hydrophobic residues of the active site.  Presumably, 
the difference in binding energy vis-a-vis the hydrophobic pocket between thiophenyl and 
phenyl rings should be negligible, when size and hydrophobicity of the rings are taken 
into account.  This leads to the assumption that the thiophene ring does indeed interact 
directly with CuB, and if this is the case it explains both the increase in binding affinity 
and the decrease in the rate of inactivation.  The latter is decreased because the ligation of 
the inhibitor to the active-site copper would be expected to interfere with the actual 
electron-transfer catalysis by either displacing one of the copper ligands (M318, H108, or 
H109) or by occupying the fourth position which is normally taken by molecular oxygen.  
It would not be surprising that this would result in a less efficient mechanistic 
inactivation than that seen with the phenylalanyl derivative where the active-site copper 
is expected to be unmolested. 
     As this laboratory had illustrated the stereochemical requirements of peptidyl PAM 




same requirements extended to our acrylate inactivators.  Racemic N-Ac-Thienyl-acrylate 
was also synthesized, with both kinetic parameters moving in an unfavorable direction 
with regard to the pure (L)-enantiomer (racemate: KI = 60.5 ± 0.3 μM, kinact = 0.40 ± 0.01 
min-1).  Extrapolation of this result, as regards binding of the (D)-enantiomer, indicates 
that, theoretically, this compound would have a binding constant at least one order of 
magnitude greater than that of the pure (L)-enantiomer.  Since the acrylate inactivators do 
not possess a glycyl sp3 hydrogen (as do C-terminal glycine substrates or the inactivator 
PBA) near the carboxy terminus, but instead an alkenyl sp2-hybridized hydrogen atom, it 
is worth mentioning that the mechanism of inactivation of PAM by these compounds 
likely proceeds through a mechanistic pathway entirely different than the hydroxylation 




     Although the mechanism of the PAM reaction is academically interesting for a variety 
of a reasons, not least of which is the question of the mechanism of long-distance 
electron-transfer from the two copper ions to molecular oxygen and substrate, it remains 
rather tangential to our investigations here and therefore will not be discussed as 
exhaustively as the substrates, inhibitors, and inactivators mentioned above.  
Nevertheless, a brief recapitulation of which mechanistic aspects of the PAM 
monooxygenase reaction are known, and unknown, will be instructive to our discussion.  
Following years of mutagenesis studies, kinetic-isotope investigations, EPR 




evaluation of a vast array of different substrates, inhibitors, and inactivators, there is still 
no absolute consensus on the entirety of the PAM reaction mechanism.  A feasible and 
complete mechanistic evaluation of the PAM reaction is complicated by the multistep 
nature of the catalysis, which includes copper binding, ascorbate binding and reduction of 
the active site coppers, peptide substrate binding, binding of molecular oxygen, two 
distinct electron transfers, reduction of molecular oxygen, hydrogen atom abstraction 
from substrate, hydroxylation of substrate, and product release.  Much is known 
regarding the steps prior to electron-transfer, and there is a fairly established consensus as 
to the order of binding of substrates and cofactors.  The difficulty lies largely in the 
electron-transfer steps, the nature of the activated reduced molecular oxygen species 
present at CuB, and the nature of the species responsible both for hydrogen atom 
abstraction from the substrate and the subsequent hydroxylation.  Molecular oxygen is 
reduced to superoxide, a radical anion, following a one-electron reduction.  Superoxide, a 
relatively weak nucleophile, may either be protonated (acting as a base), or may undergo 
a subsequent one-electron reduction to the peroxy dianion which may exist in the singly 
protonated form (hydroperoxy anion) when ligated to Cu+1.  It is unknown which of these 
species is responsible for hydrogen atom abstraction and the subsequent hydroxylation. 
     Prior to 1992, owing to its extensive sequence homology to the copper- and ascorbate- 
and molecular oxygen-dependent monooxygenase dopamine-β-hydroxylase (DβM 
E.C.1.14.17.1), the PAM mechanism was largely taken for granted to be very similar to 
that of DβM.  Although there are structural differences in the natural substrates (PAM 
hydroxylates the α-carbon of carboxylic acids whereas DβM hydroxylates the β-carbon 




(identical for the residues which ligate the two copper ions in each enzyme) argued 
strongly for both enzymes having very similar, if not necessarily identical, mechanisms.  
The first proof that PAM was itself a monooxygenase (i.e. one oxygen atom is 
incorporated into the substrate and the other is reduced to water) came in 1992 when 
Merkler et al. (Merkler, 1992) investigated the 18O isotopic 13C NMR shift of the product 
of the PAM reaction in the presence of isotopically labeled molecular oxygen or water.  
This isotopic shift in the product was only seen in the presence of 18O2, and not in the 
presence of H218O.  The authors also showed that a 1:1 stoichiometry exists between all 
of the following pairs:  glyoxylate formed/dansyl-YVG consumed, pyruvate 
formed/dansyl-Tyr-Val-(D)-Ala consumed, dansyl-YV-NH2 formed/ascorbate oxidized, 
and dansyl-YV-NH2 formed/O2 consumed.  The authors showed, via the use of the 
enzyme semidehydroascorbate reductase (SDR, E.C.1.14.17.11), that each ascorbate 
which participates in the PAM reaction is oxidized to semidehydroascorbate (which is 
reduced back to ascorbate by SDR).  Any dehydroascorbate present in the final reaction 
mixture results from disproportionation of semidehydroascorbate.  Therefore, each 
molecule of ascorbate reduces only one equivalent of enzyme-bound Cu(II). 
     Once the two copper centers of PAM have been individually reduced by two 
molecules of ascorbate, the enzyme becomes catalytically competent.  At this point, the 
two substrates (O2 and peptidyl substrate) must associate prior to substrate hydroxylation.  
With hippuric acid (KM = 1.6 mM) as the substrate, an equilibrium-ordered mechanism 
predominates, indicating that the dissociation rate of the E-S complex is much faster than 
binding of molecular oxygen to the E-S complex.  For substrates with higher binding 




ordered, where the E-S complex forms rapidly upon addition of substrate and molecular 
oxygen then binds to the E-S complex.  In this case, the dissociation rate of the E-S 
complex is much slower than the association rate of molecular oxygen with the E-S 
complex (Francisco, 1998).  In any event, O2 does not bind to free enzyme to from an E-
O2 complex.  Therefore, no reactive (reduced) oxygen species can be formed in the 
absence of substrate. 
     Further, it was shown that dideuteration of hippuric acid at the α-carbon resulted in 
significant primary and α-secondary deuterium isotope effects.  The primary deuterium 
isotope effect (kH/kD) was found to be 10.9 ± 1.9, an extremely large value that fairly 
proved that C-H bond cleavage is the first irreversible step in the PAM reaction.  The α-
secondary deuterium isotope effect was found to be 1.17 ± 0.03.  This bond (nor this 
deuterium) is directly involved in the PAM reaction.  A value of 1.2 for the α-secondary 
deuterium isotope effect is indicative of an impediment (caused by the heavier D atom) in 
the rearrangement of an sp3 to an sp2 center.  While a nascent sp2 center in this case could 
indicate either the development of a neutral radical or cationic carbon species, it 
necessarily rules out the possibility of a carbanion intermediate (which would retain an 
sp3 configuration).  However, the development of a carbon-centered radical cation would 
involve a hydride migration from the peptidyl substrate to molecular oxygen, which 
would be without precedent as pertains to copper/oxygen chemistry.  Also, if tunneling 
indeed contributes to the C-H bond cleavage step a hydride transfer is all the more 
unlikely as it requires the tunneling of two electrons and one proton, rather than simply 
the one electron and one proton of a hydrogen atom.  All available evidence points the C-




formation of an uncharged carbon-centered glycyl substrate radical.  The bond-
dissociation energy for a glycyl C-H bond is approximately 87 kcal/mol.  This 
mechanism is supported by a wealth of literature which establishes the relative ease of 
formation and stability of carbon-centered glycine radicals. (Barratt 2004)  These results 
do not, of course, establish the nature of the reactive oxygen species which drives H-atom 
abstraction. 
     The question of the mechanism of electron-transfer from CuH to CuM and the nature of 
the ROS which activates the peptide substrate are perhaps the most difficult to answer 
with any degree of confidence.  At which point the electron-transfer occurs will likely be 
instructive as to the nature of the ROS, independent of the mechanism of transfer.  If the 
second electron transfer (CuH to CuM) occurs subsequent to substrate hydroxylation, for 
instance, then the reactive oxygen species at CuM responsible for hydrogen-atom 
abstraction can be only Cu(I)-superoxide.  If, instead, both reducing equivalents are 
present at CuM prior to hydrogen-atom abstraction, then the reactive oxygen species may 
be Cu(I)-superoxide, Cu(II)-hydroperoxide, or Cu(II)-peroxide (depending on 
protonation of the ROS, in the latter two cases). 
     Based upon models of CO reactivity with PAM copper centers (Jaron, 1999), it was 
proposed that the reducing equivalent from CuH is transferred via an “assisted 
superoxide-channeling mechanism.”  Under anaerobic conditions, the stoichiometry of 
CO-binding per copper was found to be 1:2 in wild-type PAM, with CO binding 
exclusively to CuM (based on IR spectroscopy).  Substrate-binding then provided a 
second site for CO binding, presumably at CuH.  Naturally, the PAM mechanism does not 




dioxygen binds if CO binds) at CuH.  The appearance of this second CO binding site upon 
substrate-binding led the authors to propose that a superoxide is formed at both CuM and 
CuH, with the latter then migrating, with the assistance of the active site residue Y79, 
toward the superoxide at CuM, at which point the two superoxides undergo dismutation, 
yielding either a CuM(II)-peroxo or CuM(I)-superoxo species and regenerating one 
dioxygen molecule (fitting with the earlier finding that molecular oxygen and substrate 
are consumed at a 1:1 ratio).   
     Subsequent studies (Francisco, 2003), however, using both 18O2 and substrate 
deuterated at the glycyl pro-(S) hydrogen, showed a dependence of the oxygen isotope 
effects upon the deuteration (or lack thereof) of the substrate, indicating that ALL oxygen 
activation steps are reversible prior to the first irreversible catalytic step of hydrogen-
atom abstraction.  Certainly, the reversibility of a superoxide-channeling mechanism is 
not feasible.  Once the reducing equivalent (superoxide) has been decoupled from CuH 
and transferred across the solvent-accessible cleft of the active site, it is quite unlikely 
that it could then return to CuH, reoxidize Cu(I) to Cu(II) and be released as molecular 
oxygen again.  Even if this reversibility were indeed possible in principle, it does not 
seem possible that the long distance transfer of this ROS (and subsequent return to CuH) 
could possible proceed with 100% efficiency.  In other words, the superoxide assisted-
channeling mechanism would require at least some decoupling of product formation and 
oxygen consumption.  By analogy with DβM, the only other known enzyme to exhibit an 
18O2 KIE dependent on substrate deuteration, there can be no decoupling of oxygen 
consumption from product formation/substrate depletion.  (Evans, 2003)  Using a non-




phenethylamine, but with a non-labile fluorine in place of the hydrogen atom of the 
substrate, and operating at concentrations three times the KI value for the substrate 
analog, there was no evidence that the ratio of dioxygen consumption/product formation 
departed from unity.  Comparison of three other “fast” substrates (dopamine, tyramine, 
and phenethylamine) to the very slow p-trifluorophenethylamine (kcat/KM three orders of 
magnitude smaller than any of the “fast” substrates) also failed to indicate any departure 
of this ratio from unity.  Logically, the poorer a substrate, the more likely that activated 
oxygen species can escape from the active site after they are generated (whether 
reversibly or irreversibly), owing to the correspondingly much decreased rate of the 
irreversible step of hydrogen-atom abstraction.  The fact that this is not the case is 
probably the best argument against the superoxide assisted-channeling mechanism, which 
is ripe with opportunity for the escape of ROS generated at CuH.  Moreover, if any of the 
oxygen activations steps were irreversible, the 18O2 isotope effect would not be dependent 
on substrate deuteration. 
     In light of the above, a long-range electron-transfer step occurring subsequent to the 
hydroxylation of substrate remains possible.  Under this assumption, oxygen activation 
would remain reversible (consistent with the 18O2/2H data) and hydrogen atom abstraction 
from substrate would remain the first irreversible step.  Simply, dioxygen at CuM would 
be initially reduced to superoxide.  Superoxide would abstract a hydrogen atom from the 
substrate, yielding a hydroperoxide anion.  Substrate would then be hydroxylated by the 
hydroperoxide species, leaving a Cu(II)-O1- radical, or its protonated form.  Then, with 
product formation already completed, a second electron would be transferred (although 




oxygen species at CuM, reducing it further to CuM(II)-O2-.  Following protonation, the 
product and one molecule of water would then be released, or, alternatively, hydroxide 
ion could remain ligated to CuM(II), as seen in the crystal structure of oxidized PAM 
(Prigge, 1998).  This mechanism is supported by in silico modeling studies by Chen and 
Solomon (Chen, 2004) which suggests that long-range electron-transfer would be driven 
more effectively by the reduction potential of the deprotonated hydroxyl radical at CuM 
(c. 2.18 V) than by either superoxide (0.94 V) or hydroperoxide (0.46 V).  Although this 
is instructive with regard to reduction potentials, their mechanism assumed an initial 
“side-on” binding of dioxygen to CuM, with a subsequent ligation of a solvent water 
displacing one oxygen of the side-on-bound ROS to yield an “end-on” bound protonated 
superoxide.  However, a crystal structure of reduced PAM with bound substrate and 
molecular oxygen revealed that dioxygen initially binds to the E-S complex in an “end-
on” orientation (Prigge, 2004).  Nevertheless, this late electron-transfer step remains 
feasible. 
     Regardless of the timing of the second electron-transfer event, and to the nature of the 
ROS to which it is transferred, a reversible superoxide migration seems exceedingly 
unlikely.  It is possible, although improbable, that a solvated electron could migrate 
across a 7 to 8 Angstrom-wide solvent-filled cleft.  Moreover, if the electron-transfer 
from CuH to CuM occurs prior to or concomitant with oxygen activation (which is 
reversible), this would imply that the solvated electron-transfer is also reversible.  This 
too is very unlikely.  The most reasonable explanation seems to be a substrate-assisted 
electron-transfer step, either through the substrate itself via the salt-bridge with Arg240, 




group and to Gln170 and H108 (a CuH ligand).  This last case is supported by in silico 
electron-transfer dynamics simulations (de la Lande, 2007) of the active site with this 
bridging water molecule, also present in the PAM crystal structure.  Moreover, to prevent 
the leakage of reducing equivalents from the system, in conjunction with the fact that 
oxygen is not activated in the absence of substrate, it seems likely that the pathway for 
electron-transfer from CuH to CuM must include at least a portion of the substrate, either 
directly (i.e. through the substrate carboxylate and the glycyl methylene group to 
molecular oxygen) or through a water molecule hydrogen-bonded to the substrate 
carboxylate, in close proximity to molecular oxygen.  It also seems likely that the 
reducing equivalent from CuH is present before the first irreversible step of hydrogen 
atom abstraction.  This is perhaps a borderline teleological argument, but it seems 
unlikely that the evolutionary “history” of the enzyme would yield such tight control of 
molecular oxygen activation (requiring presence of substrate, and with no leakage of 
ROS evident during the catalytic cycle based on the strict one-to-one correspondence of 
oxygen consumption to product formation), only to allow for the electron from CuH to 
float about freely AFTER the hydroxylation reaction, potentially allowing a release of 
both an ROS from CuM and a solvated electron from CuH into the active site of the 
enzyme, and leading to potentially irreversible damage therein.  The various crystal 
structures, especially the most recent by Prigge et al., certainly allow for the possibility of 
the substrate/water-bridge pathway, outlined above. 
     The acrylate series of PAM inactivators, designed originally on the presumption of a 
cationic radical being formed during the course of the mechanism of natural substrate 




“radical trap” mechanism.  The pharmacaphore of the acrylates has several important 
structural differences from a glycyl residue.  First, the glycyl nitrogen present in peptide 
substrates is replaced with an sp2 carbon atom in molecules of the acrylate series.  This 
eliminates the possibility of the formation of a hydrogen bond with N316 of the PAM 
active site.  Certainly, this association greatly restricts the freedom of rotation of the 
carboxy-terminus of peptide substrates bound to the PAM active site, and likely plays the 
most important role in the orientation of the labile pro-S hydrogen of glycine toward the 
ROS generated at CuM.  Additionally, rotational freedom of peptide substrates is 
restricted by the partial double-bond character of the peptide bond.  This restriction is not 
readily apparent from the molecular structure of the acrylate series, although the 
conjugated nature of its α,β-unsaturated ketone functionality may lend some double-bond 
character to this moiety and serve to restrict its rotational freedom as well.  This would 
certainly be the case for a “common” unsaturated ketone, but the presence of the anionic 
carboxylate may lend further stability to this acrylate resonance form, stabilizing the 
developing positive charge.  To what extent the neutralization of this effect would occur 
once the carboxylate of the acrylate associates with the positively-charged guanidinium 
of R240 is currently unknown, as no other instances of this type of molecular 
substructure can be found in the literature (save for trans-benzoylacrylate esters, which 
are poor models of the circumstance where the charge of a free carboxylate is neutralized 
by salt-bridge formation with the guanidinium moiety of R240).  Nevertheless, it seems 
reasonable to expect that this resonance structure would be an important contributor to 




presented in this thesis show that the carboxy-terminus of the acrylates, including the α,β-
unsaturated ketone group, is largely coplanar. 
     Second, and perhaps more importantly, the sp3-hybridized carbon atom from which 
the pro-S hydrogen is abstracted from glycine-extended peptides is replaced by an sp2 
center in the acrylates.  Certainly, the acrylate sp2 C-H is a stronger bond than the peptide 
sp3 C-H bond, and, as such, homolytic cleavage would be more difficult in the case of the 
acrylates.  Coupled with the deuterium isotope data indicating an extremely large primary 
isotope effect for natural substrates, the possibility of the abstraction of the corresponding 
hydrogen atom from the acrylates is certainly in question.  Additionally, the superoxide 
anion radical has been shown to be insufficiently nucleophilic to productively undergo 
either 1,4 or 1,2-addition to α,β-unsaturated ketones.  Instead, the nascent tetrahedral 
addition product readily dissociates back to the original molecule and superoxide in the 
case of benzaldehyde or benzophenone (Sawyer, 1979).  Simple olefins are also 
unreactive, although chalcones have been shown to be susceptible (Frimer, 1976).  The 
olefin radical anion was directly observed by ESR in some of these systems.  However, 
this is the case only in aprotic solvents.  In aqueous media (and the nascent ROS is 
adjacent to a water molecule in the PAM crystal structure), the relative basicity of the 
superoxide anion would dominate over any possible addition reaction, yielding instead 
the protonated superoxide (Sawyer, 1979).  However, Gibian et al. (Gibian 1984) showed 
that aliphatic α,β-unsaturated ketones can be facilely reduced by superoxide, generating a 
carbon-centered radical/anionic oxygen species at the carbonyl functionality.  This 
radical species, when the acrylate is bound at the PAM active site, would be in close 




reaction between the acrylate inactivator and this active site residue.  In addition, 
dependent upon the order of electron transfer (i.e. either first from CuM or CuH), and the 
favorable reduction potential of the acrylates, it is also a possibility that the reducing 
equivalent from CuH, navigating a substrate-mediated electron-transfer pathway, could be 
subsumed by the acrylate PRIOR to any activation of molecular oxygen, generating the 
actual inactivating acrylate species (an anion radical).    In any event, the nature of the 





























































Figure 4.  Molecular structures of compounds tested as 
PAM substrates and/or inhibitors, and evaluated as PAM 
















































     TNP-YVG was synthesized according to previously described procedures.  (Katopodis 
1988, Katopodis 1990)  Briefly, 12 mg 2-4-6-Trinitrobenzenesulfonic acid hydrate and 
11 mg D-Tyr-Val-Gly were dissolved in 20 mL of MeOH/water (1:4) in a foil-wrapped 
round-bottom flask.  The reaction was initiated via the addition of 3 drops of Et3N, upon 
which the reaction mixture turned a deep orange.  After 30 minutes, 100 mL water was 
added and the reaction mixture was acidified to pH = 2.0 by the addition of 0.1 M HCl, 
turning yellow.  The reaction mixture was extracted three times with 25 mL EtOAc, and 
the extracts were pooled, dried over MgSO4, and evaporated to dryness under reduced 
pressure.  The residue was dissolved in a minimum volume of 1:1 Et2O:EtOAc, and 
hexanes were added until the solution turned cloudy.  After storage overnight at -20º C, 
the yellow precipitate was collected by vacuum filtration, dissolved in approximately 5 
mL of MeOH, and stored at -70ºC.  Concentration was determined by UV-Vis 
spectroscopy.  The extinction coefficient of TNP-YVG is 12.2 X 103 at 350 nm.  A yield 




     This compound is enzymatically synthesized by reaction of the PAM substrate, TNP-




used to create HPLC standard curves to quantify PAM product formation in kinetic and 
activity assays.  Briefly, 2.5 mL Catalase (65,000 U/mg, 20 mg/mL) was dissolved in 5.0 
mL TRIS buffer (pH 8.5).  The above was added to 50 mL 50 mM MES buffer (pH 6.2) 
containing 4 mM ascorbic acid and 4 μM CuSO4.  TNP-YVG in MeOH from the above 
synthesis was added, and the enzymatic hydroxylation was initiated via the addition of 
purified PAM.  The reaction was monitored at 344 nm on a C8 RP-HPLC column 
(eluting solvent 44.0% CH3CN, 55.9% water, 0.1% TFA) at a flow rate of 1.5 mL/min.  
Additional purified PAM and/or ascorbate was added as necessary until the reaction went 
to 100% completion.  The reaction mixture was then ultrafiltered through an Amicon 
YM-10 (10,000 M.W. cutoff) membrane.  Catalase and purified PAM are retained above 
the membrane.  The filtrate was rinsed once with 20 mL EtOAc (to remove any amide 
formed), acidified with 0.1M HCl (pH 2.0) and extracted three times with 20 mL EtOAc.  
The EtOAc solution was dried over MgSO4 and evaporated to dryness under reduced 
pressure.  The yellow film was dissolved in a minimum volume of MeOH and stored at -





     Methyl-N-Ac-(D)-Phe-Acrylate was synthesized according to a previously established 
procedure (Feng 2000).  Both Methyl-N-Ac-(L)-Phe-Acrylate and Methyl-N-Ac-(L)-




(L)-Met-OMe, respectively.  The methionyl derivative was synthesized and analyzed 




    First, 9.4 mL pyridine and 11.0 mL acetic anhydride were combined in a 100 mL 
round-bottomed flask at 0º C.  Next, 5.0 g (D)-Phe-OMe was dissolved in the above 
solution and the ice bath was removed.  The reaction was allowed to proceed overnight at 
room temperature, and turned a rich purple color.  The reaction was quenched by the 
addition of 100 mL water/ice slurry.  The resulting solution was again allowed to return 
to room temperature and then extracted four times with CH2Cl2.  The extracts were 
pooled and then rinsed three times each with saturated NaHCO3 solution, 0.1 M HCl 
solution, and water.  The methylene chloride solution was dried over MgSO4 and 
evaporated to dryness under reduced pressure, yielding 4.5 g of N-Ac-(L)-Phe-OEt as a 
white solid (yield 73%).  1H NMR ([2H]chloroform, tetramethylsilane (TMS) = 0.0 
p.p.m.):  δ 1.98 (s, 3H), δ 3.12 (q, 2H), δ 3.73 (s, 3H), δ 4.89 (m, 1H), δ 5.90 (broad, 1H), 




     In a 3-necked 250 mL round-bottom flask at -78º C under argon, 4.4 mL 
dimethylmethylphosphonate was added to 45 mL dry THF (dried over sodium metal).  




quantity of white precipitate was formed, which disappeared over 15 minutes.  Then, 4.5 
g N-Ac-(D)-Phe-OMe in 50 mL dry THF was added all at once.  The reaction was 
allowed to proceed overnight and come to room temperature, turning yellow-orange.  The 
reaction mixture was quenched by the addition of 100 mL water and washed twice with 
50 mL diethyl ether.  The aqueous layer was acidified by 0.1 M HCl (pH 1.0), and then 
extracted four times with 50 mL CH2Cl2.  The methylene chloride extracts were pooled, 
dried over MgSO4, and evaporated to dryness under reduced pressure, yielding a yellow 
oil.  The crude N-Ac-(D)-Phe-α-Ketophosphonate was purified by silica gel 
chromatography from chloroform/methanol (20:1 v/v) yielding a yellow oil (6.1 g, 96%).  
1H NMR ([2H]chloroform, TMS = 0.0 p.p.m.): δ 1.98 (s, 3H), δ 2.98-3.30 (m, 4H), δ 




     First, 3.6 g of glyoxylic acid monohydrate and 100 mg p-toluenesulfonic acid were 
dissolved in 4.6 mL methyl dimethoxyacetone in a 100 mL round-bottomed flask.  The 
reaction mixture was heated under reflux overnight.  The next morning, the reaction 
mixture was cooled to room temperature and 4 g phosphorous pentoxide were slowly 
added.  The reaction mixture was again heated to reflux (80º C) for 4 hours, allowed to 
cool to room temperature and then distilled under reduced pressure.  The product which 
distilled at 70º C was collected (3.0 mL) as a yellow oil.  1H NMR ([2H]chloroform, TMS 







     First, 6.1 g N-Ac-(D)-Phe-α-Ketophophonate was placed in a 100 mL round-bottomed 
flask over ice.  Then, 10 mL water and 2.5 mL methyl glyoxylate were added, and after 5 
minutes 20 mL of potassium carbonate solution (0.25 g/mL) were added.  A white 
precipitate formed immediately upon addition of the carbonate solution.  The reaction 
was allowed to proceed for 30 minutes.  The white solid was collected by vacuum 
filtration, rinsed with cold water, and recrystallized from ethanol/water.  The white solid 
was again collected by vacuum filtration and dried under vacuum over phosphorous 
pentoxide (1.1 g, 19%).  1H NMR ([2H]chloroform, TMS = 0.0 p.p.m.) δ 1.98 (s, 3H), δ 
3.00-3.22 (o, 2H), δ 3.80 (s, 3H), δ 5.05-5.12 (q, 1H), δ 6.02-6.07 (d, 1H), δ 6.76-6.80 (d, 




     Typically, 100 mg Methyl-N-Ac-(D)-Phe-Acrylate was dissolved in 8 mL EtOH, and 
slowly added to 40 mL 100 mM TRIS buffer (pH = 7.1) to prevent precipitation.  In a 
separate tue, 6 mg of reconstituted Pig Live Esterase (E.C. 3.1.1.1, 15 U/mg) in one mL 
of water was added to initiate the reaction.  The reaction was monitored on a C8 column 
at 260 nm (25.0% CH3CN/74.9% water/0.1% TFA) at a flow rate of 1.5 mL/min.  
Typically, the reaction went to 99% completion after 24 hours.  The reaction mixture was 
ultrafiltered through an Amicon YM-10 membrane, the filtrate was acidified (pH 2.0) by 




and evaporated under reduced pressure to yield a white solid.  The product was found to 
be pure by HPLC.  Typical yields for this reaction were greater than 75%.  1H NMR 
(DMSO-d6, DMSO = 2.49 p.p.m.): δ 1.78 (s, 3H), δ 2.72-3.07 (m, 2H), δ 4.70 (m, 1H), δ 
6.56 (d, 1H, J = 15.9 Hz), δ 7.09 (d, 1H, J = 15.9 Hz), δ 7.22 (m, 5H), δ 8.42 (d, 1H).  




     This compound was synthesized using the same experimental protocol outlined for N-
Ac-(D)-Phe-Acrylate above, except that the starting material here was (L)-Phe-OMe, 
whereas the ethyl ester was the reagent in the synthesis of N-Ac-(D)-Phe-Acrylate.  




     Briefly, 5 g (L)-Phe-OEt was dissolved in a solution of 11.0 mL acetic anhydride and 
9.5 mL pyridine at 4° C.  The reaction was allowed to proceed overnight and was 
quenched by the addition of 100 mL cold water.  The resulting solution was extracted 
four times with 25 mL methylene chloride.  The aqueous phase was discarded.  The 
combined organic extracts were then washed three times each with 25 mL 0.1 M HCl, 
water, and saturated sodium bicarbonate solution.   The organic phase was dried over 
magnesium sulfate, filtered, and evaporated to dryness under reduced pressure, yielding 




p.p.m.):  δ 1.25 (t, 3H), δ 1.97 (s, 3H), δ 3.13 (q, 2H), δ 4.16 (q, 2H), δ 4.87 (m, 1H), δ 




     Initially, 4.7 g N-Ac-(L)-Phe-OEt was dissolved in 50 mL THF dried over sodium 
metal.  Separately, 4.4 mL dimethylmethylphosphante was added to 50 mL THF dried 
over sodium, under an argon atmosphere at -78° C.  Dropwise, 16.5 mL of n-BuLi (2.5 M 
in hexanes) was added to the dimethylmethylphosphonate solution over the course of 30 
minutes.  A white precipitate formed, which disappeared over 15-30 minutes.  The N-Ac-
(L)-Phe-OEt solution was added all at once.  The reaction was allowed to proceed 
overnight and come to room temperature.  The reaction was quenched via the addition of 
100 mL cold water and rinsed twice with diethyl ether.  The aqueous phase was acidified 
to pH 1.0 with dilute HCl, and extracted four times with 50 mL methylene chloride.  The 
pooled organic extracts were dried over magnesium sulfate, filtered, and evaporated 
under reduced pressure to yield a pale yellow oil.  The oil was purified by silica gel 
chromatography from chloroform/methanol (20:1 v/v), yielding 6.0 g of yellow oil.  1H 
NMR ([2H]chloroform, TMS = 0.0 p.p.m.):  δ 1.98 (s, 3H), δ 2.99-3.15 (m, 4H), δ 3.75 










     First, 6.0 g N-Ac-(L)-α-ketophosphonate was placed in a round-bottomed flask over 
an ice bath.  Next, 10 mL water and 2.5 mL methyl glyoxylate were added and the 
solution was allowed to equilibrate for 5 minutes.  Then, 20 mL potassium carbonate 
(0.25 g/mL) was added to initiate the reaction.  A white precipitate formed immediately 
and the reaction was allowed to proceed for 30 minutes.  The white precipitate was 
collected by vacuum filtration, washed with cold ethyl ether, recrystallized from 
ethanol/water, collected again by vacuum filtration, and dried over phosphorous 
pentoxide in a vacuum desiccator (1.3 g).  1H NMR ([2H]chloroform, TMS = 0.0 p.p.m.): 
δ 1.99 (s, 3H), δ 3.00-3.24 (o, 2H), δ 3.81 (s, 3H), δ 5.09 (q, 1H), δ 6.03 (d, 1H), δ 6.78 




     First, 100 mg Methyl-N-Ac-(L)-Phe-Acrylate was dissolved in 8 mL EtOH, and 
slowly added to 40 mL 100 mM Tris buffer.  Then, 6 mg of reconstituted Pig Liver 
Esterase (E.C. 3.1.1.1, 15 U/mg) in 1 mL Tris buffer was added to initiate the reaction.  
The reaction was maintained at 37° C and monitored by RP-HPLC at 260 nm as 
described above.  After 24 hours, the reaction had gone to greater than 99% completion.  
The reaction mixture was then ultrafiltered through a YM-10 membrane to remove the 
enzyme.  The filtrate was acidified to pH 2.0 with dilute HCl, extracted four times with 




yield 70 mg of white powder, pure by HPLC.  1H NMR ([2DMSO-d6, DMSO = 2.9 
p.p.m.):  δ 1.78 (s, 3H), δ 2.71-3.07 (m, 2H), δ 4.70 (m, 1H), δ 6.56 (d, 1H, J = 15.9 Hz), 
δ 7.10 (d, 1H, J = 15.9 Hz), δ 7.22 (m, 5H), δ 8.42 (d, 1H); mass spectrum (ESI) m/e = 




     Initially, 2.0 g recrystallized 4-Phenyl-3-Butenoic acid (from boiling hexanes) was 
added to 20 mL MeOH.  Reaction was initiated by the addition of 2 drops concentrated 
HCl and heated under reflux overnight.  Then, 100 mL water was added, the reaction 
mixture was brought to pH 7.0 by addition of 0.01 M NaOH and extracted four times 
with 25 mL CH2Cl2.  The methylene chloride solution was dried over MgSO4 and 
evaporated under reduced pressure to yield a yellow liquid, pure by HPLC.  Typically, 
yields were greater than 90%.  1H NMR ([2H]chloroform, TMS = 0.0 p.p.m.) δ 3.23 (d, 
2H), δ 3.74 (s, 3H), δ 6.22-6.38 (m, 1H), δ 6.44 (d, 1H), δ 7.20-7.38 (m, 5H). 
 
Spodoptera Frugiperda Cell Culture 
 
     Spodoptera Frugiperda (Sf9) cells were maintained in monolayer cultures with TNM-
FH medium supplemented with 10% v/v fetal bovine serum (FBS) and 1% v/v 
antibiotic/antimycotic solution (10,000 U/mL penicillin G (sodium salt), 10 mg/mL 
streptomycin sulfate, and 25 μg/mL amphotericin B) in Falcon T-flasks at 27º C.  




transferred to suspension culture in 500 mL Bellco Spinner flasks, and conditioned over 
two cell passages from 100% TNM-FH media to 100% serum-free Ex-Cell 401 
containing 1% v/v antibiotic/antimycotic solution.  Prior to use, 0.1% w/v Pluronic F-68 
was added to suspension cultures to prevent cell aggregation.   Cells were subcultured 
every 84 hours. 
 
Expression of X. Laevis Skin AE-1 
 
     Suspension cell cultures were treated with a Baculovirus Expression Vector (BEV) 
containing the gene for AE-1 created by Nishikawa et al.  Cells were counted via 
hemocytometer and infected at 10 plaque-forming units per cell.  Briefly, the cell 
suspension was centrifuged at low speeds to pellet the Sf9 cells, which were then 
resuspended with the appropriate volume of virus solution.  Cells were incubated  for one 
hour with end-over-end rocking and Ex-Cell medium was added such that the final cell 
concentration was approximately 1 X 106 cells/mL  Cells were incubated in suspension 




     AE-I was isolated from Sf9 suspension-cultured medium using a procedure developed 
by Suzuki (Suzuki 1990) and modified by Feng (Feng 2000).  Typical starting volumes 
were 500 mL to 1 L.  Cells were pelleted by low-speed centrifugation.  The supernatant 




Pharmacia) equilibrated with 50 mM MES-sodium, pH 6.2.  After the medium was 
loaded, the column was eluted for 120 min at a flow-rate of 1.5 mL/min to remove non-
adsorbed material.  The column was then eluted with a stepwise NaCl gradient:  0-150 
mM NaCl over 30 min, 150-250 mM NaCl over 200 min, 250-500 mM NaCl over 50 
min, and 500 mM NaCl for 300 min.  Fractions were assayed for activity using the 
standard PAM Assay solution.  Fractions with activity were pooled and concentrated over 
a 10,000 molecular-weight Amicon YM-10 membrane, and the buffer was exchanged to 
50 mM TRIS-Cl, pH 8.5 buffer. 
     The concentrated AE-1 solution was then applied to a MonoQ HR 10/10 column 
(Pharmacia) equilibrated with 50 mM TRIS-Cl, pH 8.5 buffer.  The column was washed 
for 30 min at 1.0 mL/min with starting buffer, and then eluted with a step-wise NaCl 
gradient:  0-50 mM NaCl for 15 min, 50-200 mM NaCl over 90 min, 200-500 mM NaCl 
over 30 min, and 500 mM NaCl for 30 min.  Fractions with PAM activity were pooled 
and concentrated over an Amicon YM-10 membrane and applied to a Superose-12 HR 
10/30 gel-filtration column (Pharmacia).  Activity was eluted with HEPES pH 7.0 at a 
flow-rate of 0.5 mL/min for 90 minutes.  Purified AE-1 eluted as a single peak over 
several fractions.  Activity was pooled and concentrated, and stored as a 1:1 
buffer/ethylene glycol solution at -20º C.  Activity is expressed in mU/mL, where 1 U is 








Standard PAM Activity Assay 
 
     The assay conditions for PAM activity are similar to those described in the enzymatic 
synthesis of TNP-YV(OH)G above.  Briefly, the assay solution contains 1 mg/mL 
catalase, 4 mM ascorbic acid, 4 μM copper sulfate, and 35 μM TNP-YVG in 250 μL 50 
mM MES-Na, pH 6.5 at 37º C.  The conversion of TNP-YVG to TNP-YV(OH)G was 
kept to under 30% in order to obtain consistent initial rates.  The reaction was quenched 
by the addition of 10% v/v 3M HClO4.  Samples were centrifuged at 10,000 g for 30 min 
and the supernatant was assayed by RP-HPLC.  Product concentrations were determined 
by RP-HPLC analysis on an Alltech Allsphere C8 column (250 mm x 4.2 mm, 5 μm 
particle size) with an authentic product standard curve.  Mobile phase was 44.0/55.9/0.1 
acetonitrile/water/trifluoroacetic acid at a flow rate of 1.5 mL/min.  Absorbance was 




    Purified PAM was initially incubated in the above assay solution (37º C) at various 
concentrations of inactivator, also containing 0.1% v/v Triton X-100 and 80 mM KI.  
Inactivation reactions were initiated by the addition of purified PAM.  Aliquots of 10 μL 
were withdrawn over an appropriate time course and reincubated in the standard PAM 
assay solution described above, containing saturating concentrations of TNP-YVG (50 




and analyzed as described above.  Residual PAM activity was measured as % initial 
activity of untreated control enzyme. 
 
Progress Curve Assay 
 
     Purified PAM was incubated in the presence of varying concentrations of TNP-YVG 
(2.0 – 15 μM) and the appropriate inactivator species (20 – 100 μM) in 5 mL of the 
standard PAM assay solution containing 0.1% v/v Triton X-100 and 80 mM KI.  
Reaction was initiated by the addition of enzyme and 250 μL aliquots were removed 
every minute, quenched with 10% v/v 3M HClO4, centrifuged, and the supernatant was 
analyzed for product concentration according to the chromatographic conditions 
described above. 
 
Circular Dichroism Spectropolarimetry 
 
     Circular Dichroism (CD) spectropolarimetry measurements were acquired on a Jasco 
J-810 150-S spectropolarimeter.  The measurement range was from 190 nm to 350 nm, 
and all measurements were collected at room temperature.  Resolution and bandwidth 
were 1 nm; scanning speed was 50 nm/min; sensitivity set at 10 mdeg.  N-Ac-(L)-Phe-
Acrylate and N-Ac-(D)-Phe-Acrylate were dissolved in pure acetonitrile.  The Cotton 






HPLC Chiral Chromatography 
 
     Chiral separations of Methyl-N-Ac-(L)-Phe-Acrylate and Methyl-N-Ac-(D)-Phe-
Acrylate were carried out on a Phenomenex D-Penicillamine column. Compounds were 
dissolved in methanol prior to injection.  Absorbance was monitored at 260 nm on a 
Waters LC-Module 1 Plus.  Flow rate was 1.0 mL/minute.  Mobile phase was 74.5/25/0.5 




     All simulations were run using Molecular Operating Environment (MOE) software, 
Chemical Computing Group, Inc. (Montreal, Canada).  Additional code “more_dock.svl” 
was obtained from the SVL Exchange website (http://syl.chemcomp.com). 
     All ligands were constructed using the MOE Builder module and built from the 
coordinates of the side chain phenyl ring of the crystal structure ligand IYG (Prigge, 
1998), thereby placing the side chains of all ligands in the hydrophobic pocket of the 
enzyme at the start of each docking run.  Polar hydrogens were added to the ligands 
(including sp2 hydrogens) and each ligand was minimized using the Engh-Huber force 
field with default parameters and “solvation” enabled.  Non-bonded and bonded cutoffs 
were changed to 5.5 and 4.5 Å, respectively. 
    The receptor used for molecular docking was the oxidized PAM crystal structure 
(Prigge 1998).  All water molecules, carbohydrates, and metal ions except for CuH and 




were added to the PAM crystal structure receptor, heavy atoms were locked, and the 
structure was energy-minimized using the Engh-Huber force field.  Default energy 
parameters were used for the minimization and “solvation” was enabled.  Non-bonded 
and bonded cutoffs were changed, as for the ligand minimization, to 5.5 and 4.5 Å, 
respectively. 
     Docking simulations were performed using the Simulated Annealing algorithm (Engh-
Huber force field), with all default parameters except that “solvation” was enabled and 
the non-bonded and bonded cutoffs were changed to 5.5 and 4.5 Å, respectively.  The 
docking box was centered at 40.4032 x 25.3060 x 40.4527 (x,y,z) of the crystal structure 
receptor and had arbitrary dimensions of 60 x 60 x 60 (x,y,z).  All residues that were at 
least partially within the confines of the docking box were selected, and then all residues 
within 5.5 Å (the non-bonded cutoff) of those residues were selected.  All other atoms 
were deleted. 
     Minimized ligands were then subjected to a non-random start simulation, and all 
bonds that are able to undergo rotation were allowed to deviate continuously ± 30º from 
the minimized configuration.  Initial temperatures were 1,000 K.  Typically, twenty-five 
runs were performed for each ligand, resulting in 25 docked conformations per ligand.  
Each run included 6 cycles of decreasing initial temperature, with 8,000 iterations per 










     The three atoms of the carboxylate group were fixed in each ligand.  Flexible 
Alignment module was used to determine the optimum energy-minimized overlay of 
each pair of ligands tested.  Default parameters were used in all cases.  MMFF94 force 

























     The conditions of this protein isolation were initially those of Suzuki (Suzuki, 1990), 
and include optimizations developed by Dr. Jun Feng (Feng, 2000), as described in 
Methods.  The results of a typical X. Laevis AE-1 isolation are presented in Table 3.1.1 
below.  The specific activity increases from 64.0 mU/mg protein in the initial cell-free 
extract to 13,500 mU/mg protein after the Superose-12 gel-filtration column, a 211-fold 
purification.  The only other point which requires explanation is the increase in total 
activity from the MonoQ pool to the Superose-12 pool, which should necessarily 
decrease rather than increasing.  One possible explanation for this paradoxical 
phenomenon is the presence, in the less pure Mono-Q pool, of proteins which interfere 
with either the substrate, copper, or ascorbate in the assay mix (by decreasing their 
effective concentration).  It is evident from the chromatograms that the concentration of 
substrate does not decrease from the “blank” (no added fractionated enzyme) to those 
assays where protein solution from the isolation fractions is included for assay.  
Therefore, no proteolytic degradation of substrate from contaminating enzymes occurs.  
The most likely explanation is the presence of a chelator (proteinaceous or not) which 
sequesters copper and thus reduces the rate of PAM hydroxylation in the less pure 










Table 1.  Isolation table of PAM (AE-1) expressed from Sf9 cells.  Total protein 
concentrations calculated from bovine serum albumin standard curves using Coomassie 
Brilliant Blue spectrophotometric assay.  “Volume” refers to the total sample volume 
after the purification step was completed (e.g. after centrifugation and pelleting of cells in 
“Cell Free”).  mU are defined as the amount of PAM required to convert 1 nmol of TNP-
YVG substrate to TNP-YV(OH)G per minute at 37 °C.  Yield refers to percent activity 




Samples Volume  
PAM 





 (mL) (mU/mL) (mU) (ug/mL) (mg) (mU/mg)   
         
Cell Free 715 6.36 4560 99.5 71.2 64.0 100 1.000 
         
SP-
Sepharose 41.0 38.7 1590 106 4.34 365 34.8 5.712 
         
MonoQ 4.50 135 609.0 80.0 0.360 1690 13.4 26.5 
         
Superose-




Synthesis and Characterization of N-Ac-(L)/(D)-Phe-Acrylate 
 
     Figures 5 shows the structures of the various reagents and products of the several steps 
of the syntheses of N-Ac-Phe-Acrylate.  In the case of N-Ac-(D)-Phe-Acrylate, the 
starting material is (D)-Phe-OMe, whereas (L)-Phe-OEt was the initial starting material 
in the case of N-Ac-(L)-Phe-Acrylate.  In some instances, the initial ester starting 
material was synthesized from (L)-Phe or (D)-Phe employing a simple Fisher 
esterification.  Briefly, proceeding from the starting material, the initial reaction 
acetylates the free amine using pyridine and acetic anhydride, yielding N-Ac-(L)-Phe-
OEt or N-Ac-(D)-Phe-OMe.  The pyridine acts as a catalyst, and has been suggested to 
activate the acetic anhydride via nucleophilic attack, yielding a pyridinium acetate which 
is then subjected to nucleophilic attack by the free amine of the amino acid ester.  The 
next reaction involves the deprotonation of methyl dimethylphosphonate by n-BuLi, 
creating a nucleophilic carbanion which displaces the ester group from the carboxylate of 
the N-Acetyl ester, yielding an α-ketophosphonate.  The following reaction, a 
Wadsworth-Emmons, deprotonates the ketophosphonate to again yield a carbanion, 
which then reacts with the aldehyde functionality of methyl glyoxylate to yield Methyl-
N-Ac-Phe-Acrylate.  Lastly, Pig Liver Esterase is used in MES buffer, pH 7.1, to 
hydrolyze the ester, yielding the final product N-Ac-Phe-Acrylate.  Yields, NMR and MS 
data, and optical rotation data are related in Methods.  The circular dichroism (CD) 
spectrum of N-Ac-(D)-Phe-Acrylate and N-Ac-(L)-Phe-Acrylate is shown in Figure 6., 




     Finally, chiral chromatography was employed to resolve the enantiomeric pair.  
Unfortunately, the free acid enantiomers could not be resolved on the (D)-penacillamine 
column which was employed.  However, the enantiomeric Methyl-N-Ac-Phe-Acrylate 
enantiomeric pair was able to be resolved by this column, with the (D)-enantiomer 
eluting at 21 minutes and the (L)-enantiomer at 28 minutes under the conditions 
described in Methods (Figures 7 and 8, respectively).  The CD results indicate that the 
compounds are enantiomerically pure prior to the enzymatic hydrolysis, and the 
polarimetry and circular dichroism data indicate that the compounds are enantiomerically 
pure subsequent the Pig Liver Esterase-catalyzed hydrolysis.  As expected, both 
enantiomers had identical NMR spectra and mass spectral analysis (ESI) indicated a 
molecule mass of 261.2 for both compounds.  Both the ester and free acid enantiomeric 
pairs coeluted under multiple different compositions of mobile phase on achiral RP-






































































































pH = 7.3, 50 mM MES-Na










Figure 6.  Overlaid Circular Dichroism spectra of N-Ac-(L)-Phe-
Acrylate and N-Ac-(D)-Phe-Acrylate in acetonitrile.  The Cotton 
effect is evident from 190 nm (the UV-cutoff of acetonitrile) to 
197 nm.  No further effect is evident at longer wavelengths, tested 
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Figure 7.  Chromatogram of Methyl-N-Ac-(D)-Phe-
Acrylate in MeOH, applied to a (D)-penacillamine chiral 
column.  The (D)-enantiomer elutes at 21 minutes.  
Monitored at 260 nm, 1 mL/minute.  Mobile phase 
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Figure 8.  Chromatogram of Methyl-N-Ac-(L)-Phe-Acrylate in 
MeOH, applied to a (D)-penacillamine chiral column.  The 
(L)-enantiomer elutes at 28 minutes.  Monitored at 260 nm, 1 









     The efficacy of a mechanism-based irreversible inactivator may be fully described, in 
the simplest mechanistic case, by both the dissociation constant (KI) which represents the 
binding affinity, and by kinact which represents, in this case, the second-order rate constant 
of inactivation.  Figure 9 graphically depicts all possible mechanistic events, both 
reversible and irreversible, which may occur along the inactivation/inhibition pathway.  
The simple case above corresponds to an inactivation pathway which involves only the 
inhibitor species and the free enzyme, either in the complete absence of substrate, or in 
the presence of a relatively poor substrate where Km >> KI.  In the latter case, one may 
reasonably assume that the concentration of the ES complex is negligible in comparison 
to the concentration of the EI complex, if the working concentrations of substrate and 
inhibitor are fairly close to the Km and KI values, and that the system can be 
mathematically treated as a “single substrate” system.  The former case, inactivation 
occurring in the complete absence of substrate, will be explored via the performance of 
the “Dilution Assay”, to be discussed below. 
     In contrast, when utilizing a kinetic assay where both substrate and inactivator are 
present, and are at concentrations relative to their binding constants which are not 
representative of the limiting case discussed in the above paragraph, it is important to 
recognize the possibility that several competing pathways may exist besides the direct 
inactivation reaction involving only inactivator and enzyme.  Obviously, so long as the 
concentrations of substrate and inhibitor are reasonably close to their Km and KI values, 
respectively, any enzyme which has yet to be inactivated will continue to engage in 












Figure 9.  Possible Mechanistic 





pathways which may occur when enzyme is incubated in the presence of both substrate 
and inactivator, represented by the top horizontal reaction in Figure 9 and the leftmost 
vertical reaction, respectively.  Briefly, these reactions provide for free enzyme to bind 
with either product or inactivator to reversibly form the ES and EI complexes.  The ES 
complex may then either dissociate back to free enzyme and substrate or undergo 
catalysis to yield an EP complex which subsequently dissociates to yield product and free 
enzyme.  If product dissociation is fast relative to kcat or k1, then [EP] will be negligible 
and will not measurably affect the concentrations of either free enzyme ([E]) or the 
enzyme-substrate complex ([ES]).  As will be explained in the Progress Curve Assay 
section to follow, the values of k2 and Km will be derived from a separate enzyme-
substrate assay (generated from a Michaelis-Menten plot of initial velocities at various 
substrate concentrations in the ABSENCE of inhibitor) where the actual value of k2 
represents the contributions of both the catalytic step AND the product dissociation step.  
Hence, the product dissociation rate is not explicitly included in these figures/calculations 
although, theoretically, the rate of product release may in fact be equivalent to or slower 
than the actual catalytic step.  However, the fact that the rate of product formation 
remains linear with respect to time, even at exceedingly high substrate concentrations 
(e.g. 20-fold greater than Km) and high conversion percentages (i.e. when [P] becomes 
equal or greater than [S]) strongly suggests that there is no change in [ES] or any 
significant product inhibition of the enzymatic reaction, even at these exceedingly high 
concentrations of substrate.  Therefore, the rate of product release is greater than the rate 




indicating that the Kd  value for EP formation is much greater than the Km value for the 
ES complex or that the rate of association of E and P is very, very slow (or both). 
     Logically, there are two different methods by which to perform an enzyme 
inactivation study:  first, by incubation of the inactivator with the enzyme, substrate, and 
all requisite catalytic cofactors; and secondly, by a preincubation of the inactivator with 
the enzyme and cofactors in the absence of substrate, followed by a measurement of 
residual activity.  The first case describes the procedure of the Dilution Assay, while the 





     As stated above, the dilution assay involves the preincubation of enzyme with 
inactivator and cofactors in the absence of substrate.  The inactivation reaction was 
initiated by the addition of enzyme to several preincubation solutions containing different 
concentrations of the inactivator.  Aliquots were taken at various time points and 
“diluted” into an assay solution identical in all regards to the preincubation solution, save 
for the inclusion of saturating concentrations of substrate and lack of inactivator.  
Obviously, there is no way to discriminate between inactivator and enzyme in drawing 
these aliquots from the preincubation solution and, therefore, there is some trivial 
(although nonzero) concentration of the inactivating species present in the assay solution.  
In all cases in this thesis, the “dilution” results in at least a 50-fold decrease in the 
concentration of enzyme and inactivator relative to the preincubation solution.  The 




relative magnitude, 3-fold that of the resultant KI value.  Therefore, the highest possible 
concentration of inactivator in the assay solution would be 3/50 the value of KI.  In 
addition, the concentration of substrate in the assay solution was 10-fold greater than its 
measured Km value and the final conversion of substrate to product never consumed more 
than 30% of the initial substrate present.  Moreover, the Km of the substrate, TNP-YVG, 
is approximately 1/5 of the KI value for any of the inactivators tested.  So under the 
saturating concentrations of substrate present in the assay solution, it is highly unlikely 
that the inactivator will be bound to the active site of the enzyme to any appreciable 
extent.  All of these factors indicate that although some nominal concentration of the 
inactivating species is present in the assay for residual enzymatic activity, the rate of 
inactivation is likely to be immeasurably small. 
     The olefinic peptide (N-Ac-Phe-Gly) analog, N-Ac-(L)-Phe-Acrylate, has been shown 
previously by this laboratory to be a potent, time-dependent, turnover-dependent 
inactivator of PAM via the Dilution Assay.  As stated above, this assay is performed by 
preincubating enzyme and inhibitor in the presence of all cofactors, and then removing 
aliquots at allotted time points and “diluting” them into an assay solution containing 
saturating concentrations of substrate and all requisite cofactors followed by incubation 
for a set time and measurement of residual activity via the amount of product formed.  
However, the use of this assay with different inhibitor preparations or different enzyme 
preparations, or simply in the hands of different experimenters, has yielded significantly 
different results with regard to both the KI and kinact values from assay to assay.  
However, the Dilution Assay is typically much more reproducible in specifying the 




First, the values of KI and kinact are represented by –1/x-intercept and 1/y-intercept, 
respectively.  Therefore, as the kinact value approaches one or greater the error in the value 
of 1/kinact (the y-intercept of the double-reciprocal plot) may begin to approach to value of 
the y-intercept itself.  This error in the y-intercept translates to a correspondingly high 
error in the x-intercept, from which the value of KI is determined.  Secondly, when the 
points of the double-reciprocal plot are fitted by regression analysis to the equation of a 
line the slope and the y-intercept (and the x-intercept) are covariant.  However, the slope 
of the fitted line (equal to the reciprocal of kinact/KI), because of its hugely greater 
magnitude relative to the values of the x- and y-intercepts, is affected to a much lesser 
degree by fluctuations in the data introduced via experimental error.  Indeed, the slope is 
greater than 100 in all cases here while the y-intercepts are all approximately one and the 







     Figure 10 is a plot of log (% initial activity) vs. time, showing that N-Ac-(L)-Phe-
Acrylate is a potent concentration and time-dependent inactivator of PAM.  The 
inactivation was strictly first-order, as evidenced by the linearity of the data points, until 
residual activity dropped below approximately 30%.  As the residual activity fell below 
30% the plots began to deviate significantly from linearity indicating the possibility that 
complete elimination of enzyme activity is not possible under the conditions used for 
these assays.  It is, naturally, not reasonable to speculate that as enzyme is inactivated 
and/or inhibitor is consumed, that the observed rate of inactivation would remain constant 
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Figure 10. Semi-log Plot of Percent Initial Activity versus 
Time Following Preincubation of PAM with Various Concentrations 
of N-Ac-(L)-Phe-Acrylic Acid.  The slope of each line represents the 
value for kobs at that inactivator concentration.  The reaction is 





over the entire range of residual activities.  Interestingly, the departure from linearity (i.e. 
a change in the observed rate constant of inactivation) is more marked at higher inhibitor 
concentrations and begins to develop when residual activities are much higher relative to 
lower inactivator concentrations. 
     While this assay (as performed) cannot provide information as to the type of inhibition 
(competitive, uncompetitive, mixed), previous work in this laboratory (Feng, 2000) has 
shown that when substrate is present along with inhibitor in the preincubation solution 
the enzyme is in fact protected from inactivation by the various acrylate derivatives 
described previously.  In addition, inactivation does not occur in the absence of either 
copper ions (as copper (II) sulfate) or ascorbate, both of which are absolutely required for 
substrate turnover.  These effects, along with others to be described in Progress Curve 
Assay section, are strongly indicative of competitive inhibition. 
     A Kitz and Wilson plot of 1/kobs vs. 1/[N-Ac-(L)-Phe-Acrylate] (Figure 11) with a 
weighted linear fit provides the values of both kinact and KI.  All kinetic parameters of 







     Previous studies by this lab have demonstrated the absolute stereospecificity of PAM 
with regard to the spatial orientation of its glycine-extended peptide substrates.  Since 
glycine is prochiral, the stereospecificity with regard to peptide substrates is only material 
with regard to residues in the P2, P3, etc. positions.   Only amino acid residues of 
absolute (L)-configuration at the P2 position are accepted as substrates by PAM. (Ping, 
1992; Ping, 1995)  Just as N-Ac-(L)-Phe-Acrylic Acid is an analog of N-Ac-(L)-Phe-Gly, 
its enantiomer has the same stereoconfiguration as N-Ac-(D)-Phe-Acrylic Acid.  
Although we assumed that (D)-enantiomer would not be able to bind productively to 















Figure 11.  Kitz and Wilson Double-Reciprocal Plot of 1/kobs Vs. 
1/[N-Ac-(L)-Phe-Acrylate.  The reciprocal of the slope is equal to 




synthesized and incubated with PAM in both the Progress Curve and Dilution assays in 
order to determine if the trans-alkene functionality and/or lack of the amide nitrogen in 
the acrylate inactivators would serve to maintain or degrade this stereospecificity. 
     Contrary to expectations, the (D)-enantiomer not only evinced measurable inactivation 
but did so on a level comparable to that of the (L)-enantiomer.  Percent initial activity 
versus time is plotted in Figure 12.  The Kitz and Wilson plot is shown in Figure 13.  The  
kinact/KI values for the (L) and (D)-enantiomers, respectively, are 7,300 and 4,100 μM-1 
min-1, less than a 2-fold difference in efficacy.  Compare the above results with the Phe-
Acrylate enantiomeric pair with previous results for the N-Ac-Phe-Gly enantiomeric pair 
and, because N-Ac-(D)-Phe-Gly is not a substrate at all, the measured apparent KI values 
for both N-Ac-(L)-Phe-Gly and N-Ac-(D)-Phe-Gly when tested in the presence of 





















































Figure 12.  Semilog Plot of Percent Initial Activity versus 
Time Following Preincubation of PAM with Various 
Concentrations of N-Ac-(D)-Phe-Acrylic Acid.  The slope of 







     Previous work in this lab with the pure enantiomer N-Ac-(L)-Thienyl-Acrylate 
indicated that sulfur-containing analogs were able to bind more avidly to the PAM active 
site than derivatives lacking a potential copper-binding sulfur-containing moiety.  KI 
values for the (L)-Thienyl derivative were approximately 3-fold lower than that of  the 
(L)-Phe derivative (32 and 90 μM, respectively).  On the other hand, the kinact values for 
the (L)-Thienyl compound were approximately one-half those of the (L)-Phe derivative 
(1.1 and 0.56 min-1, respectively), suggesting that while the potential copper-ligating (L)-















Figure 13.  Kitz and Wilson Double-Reciprocal Plot of 1/kobs 
Versus 1/[N-Ac-(D)-Phe-Acrylate].  The reciprocal of the slope 




rate of inactivation may indicate that the very act of copper ligation, unsurprisingly,  
interferes in some regard with the inactivation mechanism.  It is evident from the PAM 
crystal structure (Prigge, 1997) that any ligand which does engage and ligate to CuB 
cannot concurrently occupy the space in the hydrophobic picket of the enzyme which the 
benzyl moiety of N-Ac-(L)-Phe-Gly occupies.  The amino acid methionine contains a 
sulfur atom which is γ−positioned relative to Cα, and as such is in the same relative 
position as the sulfur atom in the Thienyl derivatives, but which lacks the aromaticity of 
the thienyl derivative.  Moreover, the terminal methyl group of the methionyl side chain 
would correspond to the 3’ carbon of the thienyl ring.  Therefore, with regard to sterics, 
the two compounds should behave in much the same regard.  Electronically, thiophene is 
an electron-rich aromatic compound and the sulfur therein is a “harder” ligand than the 
sulfur in the thioether moiety of methionine.  All else being equal, the (L)-Thienyl 
derivative should bind more strongly to CuB (if in fact it ligates the copper atom at all) 
than the (L)-Met derivative.  As such, we reasoned that any loss in binding affinity for the 
(L)-Met derivative might be compensated via an increase in the kinact value. 
     Percent initial activity versus time is plotted in Figure 14.  The Kitz and Wilson plot is 
shown in Figure 15.  As the results indicate, the (L)-Met derivative was the most potent 
PAM inactivator of the three derivatives tested in the present dilution assays (kinact/KI = 
8.14 M-1 min-1), intermediate in potency between the (L)-Phe derivative and the 
previously investigated (L)-Thienyl derivative (Feng, 2000).   Insofar as the (L)-Thienyl 
analog has a bulkier side chain (than Met) and is aromatic to boot (very similar in these 
regards to the (L)-Phe derivative), one could reason that the energy difference between 




energy of the sulfur/copper ligation less the loss of the aromatic hydrophobic associations 
in the P2 enzyme pocket.     Owing to previously mentioned difficulties in separating the 
individual kinetic components in the Dilution Assay (KI and kinact), one cannot really 
make any pertinent observations regarding the actual effects of any sulfur ligation or 
changes in side chain composition on the relative binding strengths or inactivation rates 
of the individual kinetic components.  The Progress Curve Assay, which allows all 
possible kinetic elements of the inactivation process to be determined in one assay, will 








































Figure 14.  Semi-log Plot of Percent Initial Activity 
versus Time Following Preincubation of PAM with 
Various Concentrations of N-Ac-(L)-Met-Acrylic 
Acid. The slope of each line represents the value for 
kobs at that inactivator concentration.  The reaction is 







Progress Curve Assay 
 
     The Progress Curve Assay (PCA), also known, inter alia, as the Product Formation 
Assay, has several benefits over the Dilution Assay, along with one glaring deficiency.     
Firstly, the PCA is performed in the presence of varying concentrations of both substrate 
and inhibitor which allows for a more reasonable approximation of the environment that 
would be seen with the drug candidate in in vivo experiments (recall that the inactivation 
process in the Dilution Assay takes place in the ABSENCE of substrate).  Secondly, ALL 


















Figure 15.  Kitz and Wilson Double-Reciprocal Plot of 1/kobs 
Versus 1/[N-Ac-(L)-Met-Acrylate].  The reciprocal of the slope 




via the PCA, including KI’, k’2 and k’inact, which represent inactivator binding to the ES 
complex (to form the ternary ESI complex), conversion of the ESI complex to the 
inactivator/enzyme complex and product (EI + P),  and the conversion of the ESI 
complex to an inactivated enzyme complex (ESI*), respectively (Figure 9). The rate 
constant k2 and the Michaelis constant Km must be obtained from a separate assay 
involving only enzyme, substrate, and requisite cofactors.  The downside to the PCA vis-
à-vis the Dilution Assay lies in the potential magnification of experimental error 
throughout all of the replots of the original data.  Furthermore, owing to the 
discontinuous nature of this assay, it is simply not possible to perform the entire assay on 
any given day with one enzyme substock.  Instead, the assay is typically broken up over 
the course of 5 days (one day for each substrate concentration) which requires the use 
either of a freshly prepared enzyme substock or the use of the previous day’s substock 
less any activity lost overnight.  Either way, extra error is introduced into this assay 
relative to the dilution assay which is performed all at once with a given substock of 
enzyme solution and under identical environmental (laboratory) conditions (temperature, 
relative humidity, ambient molecular oxygen concentration, pressure, etc.).  That having 
been said, a well-performed PCA returns more precise results with a smaller associated 
degree of error, and with a more exhaustive treatment of all possible inactivation events 







     The N-Ac-Phe-Gly substrate analog N-Ac-(L)-Phe-Acrylate had previously been 
synthesized and assayed by both the PCA and Dilution Assays in this laboratory.  
However, because we were seeking to compare the kinetic parameters of the 
enantiomeric pair of the N-Ac-Phe-Acrylates the L-enantiomer was resynthesized and 
subjected to both kinetic assays (PCA and Dilution) such that all compounds tested could 
be analyzed with the same enzyme preparation. 
     The PCA is initiated when an enzyme aliquot is added to a solution of assay mix 
containing varying levels of substrate and inactivator and fixed concentrations of the 
cofactors ascorbic acid and Cu(I).  Aliquots are then removed periodically from the assay 
mix, quenched with 10% v/v 3M HClO4, and the product concentration at each time point 
quantified by RP-HPLC based on previously performed standard curves.  Each initial plot 
(Figure 16) of product concentration vs. time is representative of one fixed concentration 
of substrate, with each of the progress curves representing a varying concentration of N-
Ac-(L)-Phe-Acrylate.  When the data are fit to the equation ([P] = [P]inf(1-e-kt)), both kobs, 
the observed rate constant of inactivation at a given concentration of substrate and 
inactivator, and [P]inf, the product concentration at time infinity, are obtained. 
     What follows mathematically is a divergent series of replots and secondary replots, 
one stemming from the [P]inf values to ultimately yield the value of kinact/KI and the other 
stemming from the kobs values to ultimately yield the value of KI.  Although the slope of 
the line which provides the kinact/KI value is, like that in the Kitz and Wilson plot of the 
Dilution Assay, covariant with regard to those two kinetic parameters, the gamma plot 
provides the value of KI directly (reciprocal slope) with a very small relative error.  




each others values, and obtained from different data transformations (from Pinf and kobs, 
respectively), we can state with confidence the value of kinact, even though unlike KI it is 
not specifically enumerated as “its own value” by this assay. 
     As mentioned above, replots involving the Pinf  values obtained from curve-fitting of 
the initial HPLC data ultimately lead to the value of kinact/KI.  The first replot is of Pinf vs. 
1/[I] (Figure 17).  Each line is representative of a constant substrate concentration with 
varying concentrations of inactivator.  Immediately evident is the convergence of all lines 
at the origin indicating that, at any given substrate concentration, as the concentration of 
N-Ac-(L)-Phe-Acrylic Acid approaches infinity the final product concentration will 
approach zero, let the reaction be allowed to continue so long as it will.  So, as the 
concentration of inactivator becomes sufficiently high no product will ever be formed at 
finite substrate concentrations.  The y-intercept of this plot is, when numerator and 
denominator are multiplied through by KI*KI’, represented by the following expression: 
 
     y-intercept = (k2’/KI’[E]o[S])/(kinactKm/KI’) + (k’inact[S]/KI’) 
 
Since the y-intercepts of all of the lines are clearly equal to zero, that means that either 
the numerator of the above expression is equal to zero, or the denominator approaches 
infinity, or both.  In the first case, supposing the numerator of the above is equal to zero 
provides the following equation: 
 





Since [E]o, and [S] are both, obviously, representative of nonzero values, the value of k2’ 
must either approach or equal zero or the value of KI’ must approach infinity, or both.  In 
the second case, were the denominator to approach infinity the expression would read: 
 
     ∞ = (kinactKm/KI’) + (k’inact[S]/KI) 
 
So, either the expression kinactKm/KI’ or k’inact[S]/KI must approach infinity, or both.  
Clearly the terms kinact, Km, KI, and [S] are not infinite.  That means that either k’inact must 
approach infinity or KI’ must approach zero, or both.  It is obvious from the assays that 
k’inact does not approach infinity because product is formed at each concentration of 
substrate and inactivator.  If k’inact approached infinity, no product would be formed 
under any of the assay conditions described herein.  Since k’inact is not infinite, then for 
the above expression to approach infinity, KI’ must approach zero.  This would obviously 
lead to a nonsensical situation where the EI complex would not be formed at all and all 
inactivation would take place via the ESI intermediate complex alone (with a rate 
constant of k’inact..  But from the Dilution Assay, we know clearly, since substrate is 
absent from that reaction mixture, that any inactivation which occurs must proceed 
through the EI complex.  Moreover, previous research has shown, and the research 
presented herein clearly demonstrates, that increasing the concentration of substrate in the 
Progress Curve Assay actually reduces the observed rate constant of inactivation (kobs), 
and the inclusion of substrate in the incubation mixture of the Dilution Assay protects 
PAM from inactivation by the various acrylate compounds.  All of these lines of 




infinity.  Therefore, the numerator must be equal to zero and the value of k2’/KI’ must 
approach zero.   In this case, it is very likely that k2’ is equal to zero and that the value of 
KI’ approaches infinity.  In terms of mechanistic implications, this means that even if the 
ESI complex forms to some infinitesimal concentration no product will be formed and 
the concentration of substrate would remain unchanged. 
     The subsequent replot of reciprocal slope from Figure 17 vs. reciprocal substrate 
concentration (TNP-YVG) is shown in Figure 18.  As with the lines in the previous plot, 
it is immediately evident that the line passes through the origin, with a y-intercept value 
of zero.  The y-intercept of the plot is represented by the following expression: 
 
 y-intercept = k’inact/KI’k2[E]o 
 
Since the line passes through the origin and the y-intercept is thusly zero, it is clear from 
the above expression that either k’inact approaches zero or that the denominator 
approaches infinity, or both..  If the denominator approaches infinity, then since, 
experimentally, neither k2 nor [E]o is infinite, it must be KI’ which is infinite.  Again, as 
shown above with the previous replot, all lines of reasoning indicate that k’inact 
approaches zero and KI’ approaches infinity.  So, since k2’ and k’inact are both zero and 
KI’ approaches infinity (or is extremely large relative to KI) the ESI complex does not 
form to any appreciable extent.  To the limited extent that it may form, no product 
formation or enzyme inactivation may take place from the ESI complex.  The slope of the 





 Slope = kinactKm/KIk2[E]o 
 
Recall that k2[E]o is equal to Vmax.  The values of Km and Vmax are known from a prior 
experiment plotting rate vs. concentration of substrate.  Since the ratio of enzyme used in 
the progress curve assay vs. that used in performing Michaelis-Mentin kinetics is known, 
we can use this ratio and the value of Vmax (along with the Km value) to determine the 
value of kinact/KI.  Further below, the replots involving kobs values obtained from the 
original data will yield a value for KI alone.  Once KI is known, the value of kinact can be 
obtained from kinact/KI given here. 
     A plot of 1/kobs vs. 1/[N-Ac-(L)-Phe-Acrylic Acid] is shown in Figure 19.  Each line 
represents various inactivator concentrations at a fixed concentration of substrate.  The 
slope of each line varies, but all lines converge at the same positive y-intercept value.  
This indicates that the observed rate constants of inactivation (kobs), for all substrate 
concentrations around the Km value, will converge at the same value as inactivator 
concentrations are increased toward infinity.   Also, the denominator for the y-intercept in 
this figure is identical to that of the denominator from Figure 18.  Since the y-intercept 
value for the 1/kobs vs. 1/[N-Ac-(L)-Phe-Acrylic Acid] plot is not zero, this indicates that 
the expression k’inact/KI’ approaches zero AND NOT INFINITY as was a possibility from 
the evaluation of the y-intercept from Figure 18.  Therefore, this proves that k2’ is zero 
and indicates that k’inact is also zero.  Again, there is no indication that KI’ has a finite 
value.  Therefore, either the ESI complex is not formed at all or if it is formed to some 
trivial extent, no product formation or inactivated ESI* complex is formed.  This 




     Finally, the ratio γ, of y-intercept/slope from Figure 19, is plotted vs. [S]/[S] + Km in 
Figure 20 where the value of Km has been determined via Michaelis-Mentin kinetics 
performed in a separate assay (the same used to obtain Vmax above).  The y-intercept of 
this line is equal to 1/KI and the slope is equal to 1/KI’ – 1/KI.  Since we have shown that 
the value of KI’ likely approaches infinity, the value of 1/KI’ should approach zero and 
therefore the slope of the line of this figure should be equal in absolute value to that of 
the y-intercept.  Although some small deviation is evident between the absolute values of 
the slope and the y-intercept, this is likely more indicative of experimental error 
propagating though the replot and secondary replot than of an actual non-infinite value 
for KI’.  The inverse of the y-intercept, since it represents KI alone, was used to determine 
the value of KI for N-Ac-(L)-Phe-Acrylic Acid. 
     In addition to N-Ac-(L)-Phe-Acrylic Acid, the two derivatives N-Ac-(D)-Phe-Acrylic 
Acid (the enantiomer) and N-Ac-(L)-Met-Acrylic Acid were subjected to kinetic analysis 
via the Progress Curve Assay.  Both followed the well-behaved kinetics seen above with 
the L-enantiomer and proceed through the same inactivation mechanisms.  In neither case  
do any of the kinetic parameters of the results indicate that the inhibition is anything 
other than strictly competitive, and does not proceed via any other mechanism than direct 
inactivation of the EI complex.  The Progress Curve Assay plots for N-Ac-(D)-Phe-
Acrylate are displayed in Figures 21 through Figure 25 below, and for N-Ac-(L)-Met-
Acrylate in Figures 26 to 30.  All pertinent kinetic parameters and values are collected for 
comparison in Table 1.2.1. 
     A Hanes-Woolf plot of [S]/v versus [S], under the same conditions of cofactors and 




experiment, both potassium iodide (KI) and Triton X-100 were included in the incubation 
mixture.  Figure 32 is a Hanes-Woolf plot of [S]/v versus [S] where neither potassium 
iodide (KI) nor Triton X-100 were added to the assay mixture.  It is evident from the 
results of both of the above that the inclusion of these two components results in a 
significantly lower Km value (1.34 μM vs. 10.1 μM without KI or Triton X-100) with a 
concomitant, and proportional, decrease in the value of Vmax (0.074 μM/min vs. 0.84 
μM/min without), each value changed by approximately a factor of ten.  Owing to the 
fact that Vmax = k2[E]o, and that the portion of the expression kinactKm/KIk2[E]o which 
must be obtained via the separate Michaelis-Menten assay is Km/k2[E]o, and substituting 
Vmax for k2[E]o yields Km/Vmax, the resulting value of kinact/KI is not significantly different 
(factor of 1.5) whether these parameters are used from the results of one Km 
determination vs. the other.  The results presented herein use the data from the Km assay 


























































Figure 16. Product Concentration versus Time At Various Concentrations of 
N-Ac-(L)-Phe-Acrylate at Fixed [TNP-YVG] (5.86 μM).  The values of 
[P]inf and kobs were obtained using iterative computer analysis to fit data to 





























































Figure 17.  Plot of [TNP-YV(OH)G]∞ versus 1/[N-Ac-(L)-Phe-
Acrylate] at Various [TNP-YVG]. Linear regression of the data 












































Figure 18.  Plot of 1/slope (from Figure 1.3.14) versus 
1/[TNP-YVG].  Linear regression yields a straight line 
which passes through the origin.  The slope of the line is 













































Figure 19.  Plot of 1/kobs versus 1/[N-Ac-(L)-Phe-Acrylate] 
at Various Fixed Substrate Concentrations.  Linear regression 






































Figure 20.  Ratio of Intercept/Slope from Figure 1.3.16 Vs. [TNP-YVG]/(Km + [TNP-
YVG]).  Assuming KI’ approaches infinity, KI = 1/y-intercept = 53.7 μM. 



















































Figure 21. Product Concentration versus Time At Various 
Concentrations of N-Ac-(D)-Phe-Acrylate at Fixed 
[TNP-YVG] (18.4 μM).  The values of [P]inf and kobs were 
obtained using iterative computer analysis to fit data to 































































Figure 22.  Plot of [TNP-YV(OH)G]∞ vs. 
1/[N-Ac-(D)-Phe-Acrylate] at Various [TNP-YVG]. 
Linear regression of the data yields four lines passing 










































Figure 23.  Plot of 1/slope (from Figure 1.3.19) versus 
1/[TNP-YVG].  Linear regression yields a straight line 
which passes through the origin.  The slope of the line is 













































Figure 24.  Plot of 1/kobs versus 1/[N-Ac-(D)-Phe-
Acrylate] at Various Fixed Substrate Concentrations.  














































Figure 25.  Ratio of Intercept/Slope from Figure 1.3.22 
Versus [TNP-YVG]/(Km + [TNP-YVG]).  Assuming KI’ 





















































Figure 26. Product Concentration versus Time At Various 
Concentrations of N-Ac-(L)-Met-Acrylate at Fixed 
[TNP-YVG] (8.82 μM).  The values of [P]inf and kobs were 
obtained using iterative computer analysis to fit data to 



















































Figure 27.  Plot of [TNP-YV(OH)G]inf versus 1/[N-Ac-(L)-
Met-Acrylate] at Various [TNP-YVG]. Linear regression of 











































Figure 28.  Plot of 1/slope (from Figure 1.3.25) versus 
1/[TNP-YVG].  Linear regression yields a straight line which 
passes through the origin.  The slope of the line is equal to 












































1/[ - c-( )- et- crylic cid] (μ -1) 
Figure 29.  Plot of 1/kobs versus 1/[N-Ac-(L)-Met-
Acrylate] at Various Fixed Substrate Concentrations.  












































Figure 30.  Ratio of Intercept/Slope from Figure 1.3.27 
Versus [TNP-YVG]/(Km + [TNP-YVG]).  Assuming KI’ 















































Figure 31.  Hanes-Woolf Plot of [TNP-YVG]/v vs. 
[TNP-YVG] in the Presence of Potassium Iodide 
and Triton X-100.  Km = -x-intercept = 10.1 μM and 









































Figure 32.  Hanes-Woolf Plot of [TNP-YVG]/v 
vs. [TNP-YVG] in the Absence of Potassium Iodide and 
Triton X-100.  Km = -x-intercept = 1.34 μM and Vmax = 
1/slope = 0.837 μM/min. 
Table 2.  Collected kinetic parameters from dilution and 






     When performing molecular simulations using a given module, it is important that a 
reliable system is created that maximizes the consistency of results.  After testing several 
modeling programs, we found that the program Molecular Operating Environment 
(MOE) provided results consistent with the expectations of various potential ligands, 
whether they are known to be substrates, inhibitors, or neither.  The first consideration is 
the selection of an appropriate force field, of which, in the case of protein/ligand docking, 
the consensus choice is the Engh-Huber force field.  Engh-Huber uses empirical 
crystallographic radii from various proteins, and requires the addition of polar hydrogen 
atoms to the both the ligand and the receptor.  Polar hydrogens include those bound to 
heteroatoms (S, N, O, etc.) and also sp2 hydrogen atoms (as found in many of the ligands 
tested in these docking simulations).  The following is a brief recapitulation of the 
procedure for the preparation of the receptor and ligands involved in a docking 
simulation (see Materials section).  First, all non-essential molecules/ions (e.g. heavy 
metals not involved in catalysis or bound nonspecifically to the enzyme, carbohydrates, 
glycerol, waters, etc.) are deleted from the protein structure, including any bound active-
site ligands (i.e. N-Ac-Diiodo-Tyr-Gly in 1OPM).  Second, appropriate charges are 
assigned to metal ions (i.e. +2 for copper ions in 1OPM).  Third, all heavy atoms (i.e. 
non-hydrogens) are “fixed” such that they will not engage in translational movement in 
the course of any minimizations or simulations.  The receptor is then subjected to a 
“tethered minimization,” under the appropriate force field.  The Energy Minimization 




but are required elements of the docking simulation using the Engh-Huber force field) 
where applicable and calculates the partial charges on all of the atoms in the crystal 
structure receptor.  The result is a receptor where all heavy atoms have the same 
coordinates as in the published crystal structure, with the addition of polar hydrogens 
whose orientations and coordinates are determined via the tethered energy minimization.  
At this point, the receptor is completely ready for use in docking simulations. 
     The desired ligand is constructed using the “Builder Module.”  Appropriate charges 
are added (i.e., carboxylate oxygen assigned a charge of –1) and the ligand molecule is 
energy-minimized, during the course of which the non-polar hydrogen atoms are deleted 
(the builder constructs the ligand such that ALL hydrogen atoms expected in the structure 
are initially present).  At this point, the ligand is fully prepared for use in docking 
simulations. 
     The docking run is then performed using the Simulated Annealing method, in 
conjunction with the more_dock.svl module.   This module was written to supplement the 
default docking code with various parameters which allow for recognition of transition 
series metal ions, such as copper.   Briefly, a database of 25 docking “runs” is generated.  
A “run” involves a specified number of temperature cycles (six, in all cases here), each 
with a specified number of iterations/cycle (6,000, in all cases here).  Each cycle involves 
a temperature gradient (high to low, from beginning to end of the cycle, starting at 1,000 
K for the first cycle) and each subsequent cycle utilizes a lower starting temperature than 
the previous one.  In this way, the ligand is “annealed” into the active site of the receptor.  
At the beginning of a cycle, when the temperature is high, it is relatively easy for the 




drops, the ligand settles (ostensibly) into a “more global” energy minimum.  Typically, 
one sees radical changes in the orientation of the ligand only in the first one or two cycles 
as local minima are explored in search of a global energy minimum.  Subsequent cycles 
are for “fine-tuning” of conformations as the lower initial temperatures prevent the 
ligands from escaping global energy wells they have entered.  Typically, any significant 
translational motion of the ligand through the active site ends after the first or second 
cycle and rotational movements predominate as the cycles progress toward the end of the 
“run.” 
     During a docking run, ONLY the atoms of the ligand molecule are allowed to move.  
Translational and rotational movement of receptor atoms is explicitly forbidden.   The 
ligand is allowed complete translational and rotational movement, the latter within 
constraints set by the user.  Indeed, via the Ligand Flexibility tool, the user may specify 
to what degree the ligand conformations may deviate from the initial minimized ligand 
structure.  In all cases in this thesis, a ± 30-degree freedom of movement about rotatable 
bonds was allowed (maximum allowed by the software).  Even if no freedom of 
rotational motion is allowed with this module, the ligand remains unconstrained with 
respect to translational movement, as a rigid body in this limiting case. 
     A “docking box” must be created which limits the translational freedom of movement 
of the ligand throughout the active site of the enzyme.  In the interests of minimizing 
computational time, the box should encompass only those residues directly involved in 
binding and catalysis of substrates and/or competitive inhibitors/inactivators of the 
enzyme, to the exclusion (as possible) of all others.  The box, using the coordinates from 




and formed a cube of 60 x 60 x 60 (arbitrary units).  The user may specify the 3-
coordinate origin of the docking box, and the width, depth, and height of the box in each 
of the x, y, and z axes.  Although the ligand may not escape the box during the 
simulation, receptor residues outside of the box still influence the docking, in a manner 
determined by the setting of the bonded- and non-bonded cutoffs specified in the Engh-
Huber force field parameters.  In all cases in this thesis, the bonded cutoff was set “on” at 
4.5 Å and “off” at 5.5 Å.  These cutoffs were selected empirically to minimize 
computation time while still allowing for the effects of van der Waals’ contacts (typically 
4.0 Å maximum).  After the Docking Box is delineated, all residues toward the periphery 
of the receptor which lie outside of the “off” cutoff are deleted and, as such, do not 
contribute at all to the docking simulation. 
     The last consideration prior to the initiation of the docking run is whether to bias the 
initial location of the ligand (or any particular part thereof) in the active site of the 
enzyme within the docking box.  To this end, the user may either enable a “random start” 
or not.  If enabled prior to the initiation of the docking simulation, a number of initial 
conformers (based on quick calculations by the docking module which seek to exclude 
nonproductive, high-energy conformers) will be generated which are equal to the number 
of specified “runs” in the simulation.  If “random start” is disabled, all runs will originate 
with the ligand in the coordinates specified by the user.  In all cases in this thesis, 
“random start” was NOT used and the ligands were biased with regard to the 
placement/orientation of the P2 residue in the protein.  In other words, all of the ligands 
used in the docking simulations herein were constructed from the coordinates of the 




and, as such, their P2 side chains share coordinates with the crystal structure ligands, to 
the maximum extent possible.  This was based empirically on the quality of the results of 
initial docking runs with a variety of different ligands.  The reason that we chose to use 
this bias is as follows: the Engh-Huber force field lends more weight to electrostatic and 
van der Waal’s contributions than to energetically favorable desolvations of hydrophobic 
groups located in hydrophobic enzyme pockets.  It is important to note that this bias will 
NOT lead to energetically unfavorable conformations being generated and DOES NOT 
serve to “lock” the P2 residue in the hydrophobic P2-binding site of the PAM active site.  
The ligand is allowed to migrate freely about the docking box, the initial coordinates of 
the ligand at the outset of the run notwithstanding.  Indeed, in the case of several of the 
ligands with D-amino acids at the P2 position, the ligand P2 side chain is expelled 
completely from the hydrophobic pocket of the active site, regardless of this initial bias. 
     After the completion of all “runs” in the docking simulation, an output database of 
conformers is generated.  Individual contributions of the energy of electrostatics, van der 
Waal’s, the inherent energy of the ligand conformer, and solvation  are included and 
serve, in toto, to provide the total energy of the ligand/receptor interaction.  Taken 
together, the energy contributions of the electrostatics and van der Waal’s fields represent 
the “energy of binding.”  Top scorers from the output database are identified by the total 
energy of these two components.  Finally, the top scorers are subjected to a final energy 
minimization in the active site of the receptor.  In these minimizations the coordinates of 
all the atoms of the receptor (including polar hydrogens) are fixed.  No atoms of the top-
scoring ligand are fixed, but a weighted heavy-atom tether is used such that gross 




conformation/orientations generated from this final minimization represent those shown 




     In order to compare the orientations and conformations of various docked ligands of 
interest in a meaningful manner, it is exceedingly important that the Docking module is 
able to reasonably reproduce the conformation of a ligand that has been crystallized with 
the protein of interest.  Obviously, if no such reproduction is possible the importance, 
reliability, and conclusions from protein/ligand docking simulations are obviated.  To this 
end, we initially performed a docking simulation on the ligand/substrate which is 
cocrystallized with the oxidized PAM catalytic core (PDB ID: 1OPM), namely N-Ac-
Diiodo-Tyr-Gly. 
     In Figure 33, the IYG molecule in red represents the minimized crystal structure 
ligand in which all heavy atoms were fixed such that only the added polar hydrogens 
were subjected to energy minimization.  Therefore, all heavy atoms are in positions 
identical with the coordinates of the corresponding published crystal structure ligand.  
The IYG molecule in green represents the tethered minimization of the crystal structure 
ligand where both the heavy atoms and the polar hydrogens were allowed to alter their 
positions.  Note the excellent agreement between the two structures, indicating that the 
final energy minimization, performed also upon the best scorers of each ligand 
subsequent to the docking simulation, does not significantly alter the heavy atom 




represents the best scorer provided by an actual docking simulation using the crystal 
structure ligand.  Note, again, the good agreement between the docked IYG (in blue) and 
the original crystal structure IYG (in red), especially the atoms of the terminal glycine 
residue.  Some very minor deviations are noted between the diiodophenol side chains of 
the docked and crystal structure ligands.  The deviations between the N-Acetyl groups are 
slightly more significant, but as the specificity of binding is driven by the P2 side chain 
and the terminal glycine residue, the deviation at the N-terminus of this dipeptide is 
relatively inconsequential, especially in light of the fact that physiological PAM 
substrates, such as SP-Gly, contain ten or more amino acid residues.  This space in the 
active site pocket must accommodate the main chain atoms of the P3 residues of these 
peptides, so there is a great deal of space available in this vicinity. 








































































Figure 33.  IYG docked to PAM active site  Red: Crystal Structure 
IYG with polar hydrogens added, only hydrogens minimized into 
active site.  Green:  Crystal structure IYG with polar hydrogens 
added, entire molecule minimized into active site.  Blue:  Best 


















    Based on the crystal structure IYG orientation, the three main residues involved in the 
binding of the glycyl residue are R240, N316, and Y318.  The carboxylate of the ligand 
forms a tight salt bridge to the guanidinium moiety of R240.  The phenolic hydrogen of 
Y318 forms a hydrogen bond to an oxygen atom of the ligand carboxylate, and the 
hydrogen atom of the glycyl amide bond forms a hydrogen bond with the amide oxygen 
of the side chain of N316.   These three interactions are necessary to orient the ligand 
such that the pro-S glycyl hydrogen is directed toward the copper center.  The P2 
diiodophenol side chain of IYG makes close contacts with a number of residues in the 
hydrophobic pocket of the receptor, including (but not limited to) F112, K134, L206, 
M208, I306, M314, and Y318. 
     For comparison, the carboxylate oxygens of the crystal structure IYG lie within 1.8 
and 1.7 Å of the R240 guanidinium hydrogen atoms whereas the oxygens of the docked 
IYG molecule lie within 1.6 and 1.5 Å of R240.  The hydrogen bond between the glycyl 
amide and N316 has a length of 2.0 Å in the crystal structure IYG, with the bond 
lengthening to 3.2 Å in docked IYG.  The hydrogen bond length between Y318 and the 
ligand carboxylate is 1.8 Å for both the crystal structure and docked IYG.  Subsequent 
(post-docking) addition of the nonpolar glycyl methylene hydrogen atoms (not shown) 
shows the pro-(S) hydrogen directed toward the reactive copper center.  On the basis of 
the close similarity between the positions of the docked IYG ligand and the crystal 
structure ligand, a number of further docking simulations were performed with various 






N-Ac-(L)-Phe-Gly and N-Ac-(D)-Phe-Gly 
 
     PAM is known to be only reactive toward glycine-extended peptides with penultimate 
residues of the L-configuration.  The corresponding peptides with P2 residues in the D-
configuration are not substrates, and are, moreover, exceedingly poor competitive 
inhibitors.  To see if our MOE docking protocol could distinguish between enantiomeric 
pairs, both enantiomers of N-Ac-Phe-Gly were docked to the 1OPM active site. 
     Figure 34 depicts N-Ac-(L)-Phe-Gly docked to 1OPM.  The similarity of the 
orientation of docked N-Ac-(L)-Phe-Gly to that of the crystal structure ligand IYG is 
quite striking.  The two ligand carboxylate oxygens are both 1.5 Å from the 
corresponding guanidinium hydrogen atoms of R240, again forming a tight salt bridge.  
The hydrogen bond length between Y318 and ligand carboxylate is 1.8 Å, and the 
hydrogen bond length between N316 and the glycyl amide is also 1.8 Å.  Again, the pro-
(S) hydrogen is oriented toward the copper center (the Engh-Huber force field does not 
explicitly include non-polar hydrogen atoms, so the pro-(S) and pro-(R) hydrogen atoms 
are not shown).  The phenyl ring of N-Ac-(L)-Phe-Gly is directed into the same 
hydrophobic pocket as was the corresponding diiodophenol moiety of IYG and is packed 


















































































































Figure 35 shows the results of the nonsubstrate ligand N-Ac-(D)-Phe-Gly docking 
simulation.  This molecule binds in a very different manner from its enantiomeric 
substrate counterpart.  At this point, it is important to point out the following: because of 
the restrictions placed on these simulations by the use of the Docking Box, ligands which 
do not in actuality bind at the active site of the enzyme will nevertheless remain within 
the confines of the Box.  This is not to be assumed to imply that they would, as a result of 
the conformation given by the best scorers of the simulation, occupy this space in an in 
vivo or in vitro situation and, importantly, should not lead the reader to believe that they 
would be competitive inhibitors in the active site with respect to substrate.  Significant 
deviations from the orientation of IYG, such as lack of salt bridge formation between 
ligand carboxylate groups and R240 guanidinium moieties, are assumed to be hallmarks 
of poor substrates/inhibitors.  All docked ligands in these simulations which fail to form a 
salt bridge with R240 or a hydrogen bond with Y318 are known, in vitro, to fail to act as 
PAM substrates or competitive inhibitors. 
     Here, the carboxylate is oriented toward the positively charged side chain of K134.  
No salt bridge is formed with R240 and there are no interactions with either N316 or 
Y318.  The phenyl ring remains in the hydrophobic pocket.  Again, this conformation, 
with so few active site interactions, is not necessarily indicative of a “true” binding site 








N-Ac-(L)-Leu-O-CH2-COOH and N-Ac-(D)-Leu-O-CH2-COOH 
 
     In addition to catalyzing the α-hydroxylation of glycine-extended peptides, PAM has 
been shown by this laboratory to undergo competitive inhibition by the corresponding O-
glycolate esters.  The N-Ac-Leu-O-CH2-COOH enantiomeric pair was found to exhibit 
the same stereochemical requirements as corresponding N-acetyl dipeptides terminating 
in glycine, namely that the L-leucyl compounds are competitive PAM inhibitors whereas 
D-Leucyl compounds are not (P2 subsite stereospecificity).   
      By modeling this enantiomeric pair, we are able to further probe the ability of our 
model to distinguish between pairs of enantiomers where the (L)-enantiomer is a PAM 
substrate and the (D)-enantiomer is not.  Figure 36 displays N-Ac-(L)-Leu-O-CH2-






Figure 36: N-Ac-(L)-Leu-OCH2-COOH docked to PAM active site. 
 
     There are two major differences between glycine-extended dipeptides and these O-
glycolate esters.  Firstly, the glycyl esters are able to rotate freely about the carbonyl-
oxygen bound whereas the corresponding carbonyl-nitrogen bond of the dipeptide 
compounds is constrained in its rotation due to the partial double-bond character of the 
amide.  Secondly, the amide nitrogen of the dipeptides has a hydrogen bond donor that 
forms a hydrogen bond with the side chain amide of N316.  Instead, the ester compounds 
have a hydrogen bond acceptor oxygen in the corresponding position and therefore 
cannot form a hydrogen bond with N316 in the same manner as the dipeptides with (L)-
















     As evident from Figure 36, the L-Leucyl compound binds to the active site of 1OPM 
in much the same way as does N-Ac-(L)-Phe-Gly.  The carboxylate is oriented towards 
and forms a salt bridge with the guanidinium side chain of R240, with the two oxygen 
atoms of the carboxylate at a distance of 1.5 Å from the guanidino hydrogens.  Y318 
forms a hydrogen bond (1.8 Å) with the carboxyl oxygen of the ligand, again similar to 
the docked dipeptide N-Ac-(L)-Phe-Gly.  The sec-butyl side chain of the L-Leucyl 
compound is found, as expected, in the hydrophobic pocket of 1OPM.  As discussed 
above, there is no hydrogen bond formed between the ligand and N316.  Furthermore, the 
methylene glycyl carbon is oriented outward toward the viewer rather than inward toward 
N316 as was the case for N-Ac-Phe-Gly.  This may help to explain why these compounds 
do not undergo PAM-catalyzed hydroxylation, and instead behave as potent competitive 
inhibitors. 
     Figure 37 below displays N-Ac-(D)-Leu-O-CH2-COOH bound to the active site of 
1OPM.  The carboxylate moiety of the ligand does not interact with R140 or form a 
hydrogen bond with Y318.  In addition, no hydrogen bond is formed between the amide 
of the ligand and N316.  Indeed, the entire glycyl portion of the molecule is oriented 
completely away from the PAM glycine-binding site.  The hydrophobic leucyl side chain 
remains in the hydrophobic pocket of the enzyme.  None of the interactions indicative of 
substrate or inhibitor binding are evident with the D-enantiomer of this compound.  



































































N-Ac-(L)-Phenylglycine-Gly and O-Ac-(R)-Mandelyl-Gly 
 
     These compounds have been tested in vitro as PAM substrates/inhibitors by our 
laboratory.  Stereotopically, the (L)-derivative is the same as (L)-phenylalanyl and the 
(R)-mandelyl derivative is stereotopically the same as (D)-phenylalanyl compounds.   
They differ only in that the mandelyl compound has an O-acetyl, rather than an N-acetyl, 
group.  Keeping to the trends established above, the (R)-mandelyl derivative is neither a 
substrate nor inhibitor of PAM, whereas the (L)-derivative is indeed a PAM substrate.  
The fact that the mandelyl compound possesses an O-Acetyl group at the “N-terminus” 
whereas the Phe-Gly compounds and the Leucine compounds are N-acetylated at the N-
terminus is expected to have little effect on receptor binding.  The N-acetyl group does 




      
Figure 38.  N-Ac-(L)-Phenylglycine-Gly docked to PAM active site. 
 
Figure 38 below displays N-Ac-(L)-Phenylglycine-Gly bound to the active site of 1OPM.  
As can be seen in the figure, this compound binds in the manner typical of a known PAM 
substrate.  The salt bridge with R240 is evident with both carboxylate oxygen atoms at a 
distance of 1.5 Å from the guanidinium hydrogens.  Y318 forms a hydrogen bond with 
one of the carboxylate oxygens (1.8 Å).  The mandelyl phenyl group is directed into the 
hydrophobic active site pocket, but appears to have been pulled upward and to the right in 
the active site, relative to the phenyl ring of N-Ac-(L)-Phe-Gly, bringing it into closer 
proximity with F112 and Y318.  It appears likely that the lack of the methylene spacer 















of this effect (such that aromatic hydrophobic interactions between ligand and receptor 
are maximized).  This results in a much greater distance (4.4 Å) between the amide 
hydrogen bond donor of the ligand and the amide hydrogen bond acceptor of the side 
chain of N316, and therefore the hydrogen-bonding interaction is lost in the case of the 
(S)-mandelyl compound.  Again, a rendering of all hydrogens (rather than just polar 
hydrogens) places the pro-(S) hydrogen atom of glycine in closer proximity to the copper 
center than the pro-(R) hydrogen atom. 
 
 
      
















O-Ac-(R)-Mandelyl-Gly docked to 1OPM is shown in Figure 39.  This compound was 
neither a substrate nor inhibitor of PAM in our in vitro studies, and the docking result 
below is consistent with this fact.  The molecule floats freely in the active site of the 
enzyme and displays no specific interactions whatsoever.  The glycyl end of the molecule 
does not associate with R240, Y318, or N316 and is in no position to undergo catalysis. 
 
N-Ac-(L)-Phe-Acrylate and N-Ac-(D)-Phe-Acrylate 
 
     As related in the kinetics results section, N-Ac-(L)-Phe-Acrylate is the most potent 
turnover-dependent inactivator of PAM currently known (based on kinact/KI values) and is 
isoelectronic with N-Ac-Phe-Gly.  Two major structural differences exist; first, rather 
than the glycyl sp2-nitrogen, the acrylate compound possesses an sp2-carbon and, as 
such, cannot form a hydrogen bond with the side chain of N316.  Secondly, the N-Ac-
Phe-Gly sp3-glycyl carbon is replaced with a second sp2-carbon atom.  These changes 
result in a molecule containing an α,β-unsaturated ketone functionality.  Because of this 
conjugation, rotational freedom is likely limited about the C3-C4 bond, whereas N-Ac-
Phe-Gly is able to freely rotate about this bond.  Moreover, freedom of rotation is also 
restricted, obviously, about the alkenyl double bond of N-Ac-(L)-Phe-Acrylate.  It is 
unclear whether or not the carboxylate functionality can be considered to be conjugated 
to the α,β-unsaturated ketone, especially in the negatively-charged deprotonated state at 





      
Figure 40.  N-Ac-(L)-Phe-Acrylate docked to PAM active site. 
 
The best scoring conformer of N-Ac-(L)-Phe-Acrylate docked to 1OPM is shown in 
Figure 40.  Immediately, it is evident that this compound binds in a manner quite similar 
to N-Ac-(L)-Phe-Gly, with the benzyl group of the phenylalanine residue protruding into 
the PAM hydrophobic pocket and its carboxylate group directed towards the guanidinium 
moiety of R240.  Interestingly, the negatively charged carboxyl group of the ligand is no 
longer coplanar with the positively charged guanidinium moiety of R240, although the 
two ligand oxygens remain in close proximity (1.6 and 1.8 Å).  The phenolic hydrogen of 
















of interest is the appearance of a weak hydrogen bond (3.2 Å) between the N-acetyl 
oxygen of the ligand and the terminal amide of the N316 side chain. 
     Surprisingly, the N-Ac-(D)-Phe-Acrylate enantiomer appears to bind in a manner very 
similar to N-Ac-(L)-Phe-Acrylate and N-Ac-(L)-Phe-Gly, with respect to the carboxylate 
end of the molecule.  Recall that N-Ac-(D)-Phe-Gly was not able to bind in a productive 
manner to the 1OPM active site and bore no similarities in binding to N-Ac-(L)-Phe-Gly.  













































     The C-terminus of the ligand is oriented in the same manner in the active site as was 
seen for both N-Ac-(L)-Phe-Acrylate and N-Ac-(L)-Phe-Gly, forming a tight salt bridge 
with R240 (1.5, 1.6 Å), and a hydrogen bond with Y318 (1.9 Å).  The phenyl ring still 
protrudes into the enzyme’s hydrophobic pocket but a comparison with its enantiomeric 
counterpart shows some differences in orientation.  The N-acetyl group is directed 




     The two sets of enantiomeric pairs of N-Ac-Thienyl-Acrylate and N-Ac-Met-Acrylate 
were evaluated with our MOE docking protocol.   These molecules differ from the 
ligands evaluated above because the sulfur atoms in their side chains have the potential to 
ligate to the copper(II) ion in the active site.  Obviously, however, transition metal 
chemistry and ligation are extremely complicated processes (relative to simple 
electrostatics and van der Waal’s calculations) and we are uncertain as to whether such 
interactions can be effectively modeled by this software.  Moreover, the active site 
copper depicted in these results is already 4-coordinate (M314, HIS242, HIS244, 
hydroxide) and, because all receptor atoms/residues are static in these modeling 
simulations, it is impossible to create a situation where a ligand sulfur moiety (whether a 
thiophene or a thioether) would displace one of the coordinating ligands.  That being said, 
it certainly remains appropriate to run docking simulations to see if the various 





N-Ac-(L)-Met-Acrylate and N-Ac-(D)-Met-Acrylate 
 
     These compounds are very interesting in that their side chains are identical to one of 
the ligands for Cu+2, namely M314.  Both contain a thioether functionality, and the 
possibility exists that these compounds, in the proper orientation, could theoretically 
displace M314 as a ligand to CuB.  Again, this would require the movement of atoms and 
residues in the receptor itself, which is not possible in these docking simulations.  
However, it is certainly possible to investigate whether or not these sulfur-containing 
compounds can dock in a manner similar to the Phe-acrylates and other PAM substrates 
and competitive inhibitors. 
      N-Ac-(L)-Met-Acrylate is shown docked to the active site of 1OPM in Figure 42.  It 
is evident that this compound binds similarly to other known PAM substrates and 
inactivators.  The carboxylate functionality of the ligand forms a salt bridge with R240 
(1.7 and 1.8 Å), although a slight departure from coplanarity with the guanidinium group 
is evident.  Y318 forms two hydrogen bonds, one with each carboxylate oxygen (2.9 and 
3.1 Å).  The methionyl side chain rests in the PAM hydrophobic pocket, with the 
thioether sulfur atom over 9.0 Å distant from the reactive copper center.  There is no 
evidence in these simulations of the sulfur atom of N-Ac-(L)-Met-Acrylate engaging in 
any type of interaction with the Cu+2 ion, although the limitations described above must 







Figure 42.  N-Ac-(L)-Met-Acrylate docked to 1PAM active site. 
 
     The top scoring N-Ac-(D)-Met-Acrylate candidate docked to 1OPM is shown in 
Figure 43.  Again, the orientation is indicative of the productive binding of a substrate, 
competitive inhibitor, or inactivator.  However, the carboxylate of the ligand does not 
associate as strongly with the R240 guanidinium moiety (oxygen atoms 1.5 and 2.6 Å 
distant).  A hydrogen bond between the ligand carboxylate and Y318 is also present (3.0 
Å).  Although the methionyl side chain is again found in the active site hydrophobic 
pocket, the orientation is different than that seen in N-Ac-(L)-Met-Acrylate, and is 

















Figure 43.  N-Ac-(D)-Met-Acrylate Docked to PAM active site. 
 
 
was not synthesized, it is difficult to declare definitively whether or not it would behave 
as a PAM inactivator in vitro as does its enantiomer, N-Ac-(L)-Met-Acrylate. 
 
N-Ac-(L)-2’-Thienyl-Acrylate and N-Ac-(D)-2’-Thienyl-Acrylate 
 
     Spatially, the thienyl compounds are very similar to the Phe-Acrylate compounds as 
both groups contain an aromatic ring of similar size (5-membered in the case of the 
















methylene side chain group.  Electronically, however, both classes of compounds differ 
significantly in that the thiophene ring is classified as “electron-rich” in that there are six 
p-orbital electrons in a five-membered aromatic ring, where the phenyl ring has six p-
orbital electrons in a six-membered ring.  As a result of the electron-rich nature of the 
thiophene ring, any pi-cation interactions will be more pronounced than for a 
corresponding phenyl group.  Moreover, the sulfur contains an extra lone pair of  
electrons (which are not part of the aromatic pi-system) which, theoretically, could 
participate in metal cation ligation.  Indeed, ligation of a Cu+2 cation could proceed with 
either a direct coordination to the thienyl sulfur atom, or via a pi-system/cation 
interaction.  We reasoned (Feng 2000) that if the thienyl side chain were able to 
coordinate the active site copper ion which is responsible for dioxygen activation, this 
inhibitor would bind more tightly and yield a lower KI value than the corresponding 
phenyl compounds, even though this coordination would likely result in an orientation 
different from that seen for the N-Ac-(L)-Phe-Gly compound.  The (L)-thiophene 
compound is indeed a potent mechanism-based PAM inactivator, but any direct 
interaction with the active site copper cannot be proven or discounted based solely on the 
kinetic data. 











Figure 44.  N-Ac-(L)-Thienyl-Acrylate docked to PAM active site. 
 
Strikingly evident is the similarity in binding of N-Ac-(L)-Thienyl-Acrylate to that of N-
Ac-(L)-Phe-Acrylate.  The docked conformation yields a side chain in the active site 
hydrophobic pocket, a salt bridge between the inactivator carboxylate and the R240 
guanidinium moiety (each oxygen 1.5 Å distant from the corresponding guanidinium 
hydrogen atoms), and a hydrogen bond between a carboxylate oxygen and Y318 (2.0 Å).  
Again, it is not possible in these simulations to allow for a displacement of an active site 
ligand (H242, H244, or M314) since all enzyme residues/atoms must remain static.   
     Oddly, N-Ac-(D)-Thienyl-Acrylate, shown in Figure 45, deviates significantly from 


















         Figure 45.  N-Ac-(D)-Thienyl-Acrylate docked to 1PAM active site. 
 
 
Instead of adopting the conformation of the corresponding enantiomer of N-Ac-Phe-
Acrylate, N-Ac-(D)-Thienyl Acrylate deviates completely from the orientations shown 
for all actual (and hopefully potential) substrates, inhibitors, and inactivators.  There is no 
interaction between the carboxylate of the ligand and R240; instead, the carboxylate 
moiety interacts with the positively-charged side chain of K134.  The thienyl ring, instead 
of being directed into the hydrophobic pocket of the enzyme, projects toward the space 
normally reserved for the substrate/inhibitor carboxylate and Cα.  As mentioned 
















including salt-bridge formation and the side chain in the hydrophobic pocket of the 
enzyme, implies that this compound will either not be an inhibitor/inactivator at all, or an 
exceedingly poor one relative to those compounds which bind productively. 
 
N-Ac-(L)-Phe-Crotonate and N-Ac-(D)-Phe-Crotonate 
 
     These compounds differ from the Phe-acrylates via the inclusion of a methylene 
spacer between the carbonyl group and the proximal carbon atom of the alkenyl 
functionality.  The effects of this inclusion are three-fold.  First, the compound no longer 
contains an α,β-unsaturated ketone.  Secondly, the location of the methylene group 
results in the addition of two freely rotatable bonds, one on each side of the new 
methylene group.  Finally, the carbon bearing the benzyl functionality is one carbon 
further distant from the terminal carboxylate, which would disturb the position of the 
phenyl ring in the hydrophobic pocket of the enzyme if these compounds bind in a 
productive fashion similar to the Phe-Acrylates (requiring, or course, the salt bridge 
formation between the ligand carboxylate and R240 of the enzyme). 
     The top scorer of N-Ac-(L)-Phe-Crotonate in the 1OPM active site is shown in Figure 
46.  The first striking feature of this association is the orientation of the ligand 
carboxylate downward toward CuB, rather than being directed toward R240.  The second 
striking feature is that the phenyl ring of N-Ac-(L)-Phe-Crotonate occupies virtually the 
same space as the phenyl ring of N-Ac-(L)-Phe-Acrylate and N-Ac-(L)-Phe-Gly.  This 
hydrophobic interaction appears to predominate, from a binding standpoint, over the 




bridge with R240 and drive the phenyl ring further “to the left” in the hydrophobic 
pocket.  This results in a compound which appears to be tightly bound to the active site.  
Since the compound has not been investigated experimentally, it is uncertain whether or 
not it would be a competitive PAM inhibitor or inactivator, but it appears to be a 
promising candidate.  The possibility of maintaining the phenyl/hydrophobic pocket 
interaction while exchanging the carboxylate/R240 ionic interaction with a 

























Figure 47.  N-Ac-(D)-Phe-Crotonate docked to PAM active site. 
 
     By contrast, N-Ac-(D)-Phe-Crotonate appears to bind unproductively or not at all to 
the PAM active site (Figure 47).  This enantiomer not only fails to form a salt bridge with 
R240 but no interactions between the ligand carboxylate and the copper ion are evident.  
Furthermore, the favorable association of the phenyl ring seen for the L-enantiomer in the 
active site hydrophobic pocket has been altered.  Based on these factors, it is unlikely that 


















N-Ac-(L)-Phe-Propiolate and N-Ac-(D)-Phe-Propiolate 
 
     These compounds differ from the N-Ac-Phe-Acrylates in two concrete ways.  First, 
from an electronic standpoint, the α,β-alkenyl group is oxidized to an α,β-alkynyl group.  
Secondly, the structure of the C-terminal end of the inactivator has been altered spatially 
from a trans-alkene to a linear moiety across the triple bond and carboxylate.  Obviously, 
the two sp2 hydrogens of the N-Ac-Phe-Acrylates are gone altogether, which results in a 
smaller molar volume at the C-terminus for the Phe-Propiolate compounds.  These 
compounds have not been investigated experimentally. 
     Figure 48 displays the top scorer of N-Ac-(L)-Phe-Propiolate bound to the PAM 
active site.  Here, we see the carboxylate/R240 salt bridge characteristic of PAM 
substrates/inhibitors (carboxylate oxygens 1.6 and 1.7 Å distant from the terminal 
guanidinium hydrogen atoms) and the typical hydrogen bond between the carboxylate 
oxygen and the phenolic hydrogen of Y318.  The phenyl moiety appears to be offset 
slightly relative to that seen for N-Ac-(L)-Phe-Gly and N-Ac-(L)-Phe-Acrylate, but lies 
in essentially the same position.  The β-carbon of the N-Ac-(L)-Phe-Propiolate, owing to 
the linear nature of the alkynyl moiety, is pushed “upward” relative to the corresponding 
carbon in the N-Ac-(L)-Phe-Acrylate, resulting in a greater distance between the copper 
(which ligates dioxygen in the reduced form of the enzyme) and this carbon atom.  If this 
compound is found to be an inactivator of PAM, this increased distance from CuB may 








Figure 48.  N-Ac-(L)-Phe-Propiolate docked to the PAM active site. 
 
     The N-Ac-(D)-Phe-Propiolate enantiomer is shown bound to 1OPM in Figure 49.  
Here, we see that the carboxylate has disengaged from R240 and the phenyl ring of the 
ligand has been displaced “to the left” relative to the (L)-enantiomer.  This results, 
overall, in a conformation/location which would be expected to be unfavorable with 
regard to affinity to the PAM active site, relative to the (L)-enantiomer.  N-Ac-(D)-Phe-
Propiolate appears to be a poor inhibitor/inactivator of PAM based upon its active site 
location. 



















Figure 49.  N-Ac-(D)-Phe-Propiolate docked to PAM active site. 
 
PBA (4-Phenyl-3-Butenoic Acid) 
 
     PBA differs from the other inactivators/inhibitors (potential and theoretical) modeled 
above in that it is an analog of hippuric acid (N-Benzoylglycine) rather than N-Ac-X-Gly.  
It lacks the carbonyl group common to all of the other compounds, and is not 
isoelectronic with regard to other peptide-based substrates and inhibitors.  Furthermore, 
unlike the Acrylates, Crotonates, and Propiolates, PBA IS analogous to glycine at the C-
















alkene whereas the others contain a 2-alkene (or alkyne).  PBA is an inactivator of PAM 
under standard assay conditions, although one with a high partition ratio, and therefore 
was expected to dock in the same manner as other PAM substrates/inhibitors/inactivators.  





Figure 50.  PBA docked to PAM active site. 
 
     Indeed, PBA bound to the active site in the expected manner.  The two carboxylate 
oxygens of PBA are both 1.5 Å distant from the R240 guanidinium nitrogens, and Y318 
















not oriented into the same site of the enzyme’s hydrophobic pocket as other known 
substrates/inactivators.  This is due to the fact that PBA is “short” two carbons relative to 
N-Ac-(L)-Phe-Gly and N-Ac-(L)-Phe-Acrylate; because of this, the PBA phenyl ring is 
bound to the carbon atom which would correspond to the carbonyl carbon of both of the 






















Chapter 4: Kinetics and Modeling Discussion 
 
     Kinetic analyses and molecular modeling studies of the three acrylate compounds 
reinforced certain known aspects about PAM substrate/inhibitor specificity, while 
illustrating a number of important new aspects to the discussion of the active site residues 
involved in catalysis and stereospecificity.  First, the sulfur-containing N-Ac-(L)-Met-
Acrylic Acid was shown to bind slightly less favorably to the enzyme’s active site than 
the hydrophobic N-Ac-(L)-Phe-Acrylic Acid (KI = 53.7 μM vs. 56.5 μM, respectively).  
Previous work in this laboratory had demonstrated a 3-fold lower KI value for the (L)-
thienyl derivative relative to the (L)-phenylalanyl derivative (Feng, 2000).  The thienyl 
compound is both aromatic and sulfur-containing, and was expected to bind potently to 
the PAM active site by virtue of both characteristics.  The methionyl compound, on the 
other hand, while hydrophobic, lacks the aromaticity of both the phenylalanyl and thienyl 
derivatives.  As mentioned previously, the P2 residues of peptide substrates tend to 
contribute most heavily to the overall binding affinity of dipeptide or tripeptide 
substrates, and sulfur-containing and hydrophobic residues at this position tend to result 
in the most tightly-bound compounds.  Although both the (L)-thienyl and (L)-methionyl 
acrylates bind tightly to the active site, in both cases the rate constant of inactivation is 
depressed relative to the (L)-phenylalanyl derivative (by approximately 50% in both 
cases).  The most obvious interpretation of these lower inactivation rates would be a 
disturbance of the CuM ligand environment by the sulfur compounds, indicating that these 
side chains are able, at least transiently, to ligate CuM.  Any disturbance of the catalytic 




enzyme inactivation.  On the other hand, the lowered rate constants of inactivation could 
be the result of an electronic effect, rather than an effect of copper ligation.  Relative to 
the benzyl side chain of the phenylalanyl derivative, both the thioether of methionine and 
the 5-membered aromatic sulfur-containing ring of the thienyl derivative are clearly less 
electron-withdrawing and, as such, may be less effective regarding the generation of the 
inactivating intermediate, compared to the phenylalanyl derivative.  Nevertheless, the 
relatively equipotent binding affinities of the (L)-Met and (L)-Phe acrylates was not 
unexpected, especially since the corresponding glycine-extended peptides with Met or 
Phe in the P2 position exhibit much the same behavior. 
     Unexpectedly, and in contrast to the earlier analyses of both peptidyl substrates and 
competitive inhibitors, both N-Ac-(L)-Phe-Acrylate and N-Ac-(D)-Phe-Acrylate have 
nearly identical KI values, with the (D)-Phe actually binding more avidly than the (L)-Phe 
derivative (60.0 μM vs. 53.7 μM, respectively).  All previously explored dipeptide 
enantiomers with glycine at the C-terminus have consistently shown that only the (L)-
compounds are either substrates or competitive inhibitors.  In contrast, the rate constant 
of inactivation for the (L)-Phe acrylate was 2-fold greater than for the (D)-Phe acrylate 
(0.383 min-1 vs. 0.185 min-1, respectively).  These results imply that the structure of the 
acrylates is sufficiently different from that of their corresponding dipeptide analogs that 
the established stereochemical requirements for peptide substrates do not apply to the 
acrylates.  Structural differences, between N-Ac-(D)-Phe-Gly and N-Ac-(D)-Phe-
Acrylate, for instance, can explain this abolition of binding stereospecificity with regard 
to the acrylates and will be explored more fully when the modeling results are discussed 




are nearly identical, the (D)-enantiomer is only ½ as potent insofar as the rate constant of 
inactivation is concerned.  This implies that while both compounds are able to bind 
equipotently to the PAM active site, they may indeed bind differently, such that, once 
bound, the (D)-enantiomer is in a less favorable orientation for mechanistic inactivation.  
This difference will also be explored in the modeling discussion. 
     All of the above kinetic parameters were derived from the Progress Curve Assay, in 
which varying concentrations of substrate and inactivator are simultaneously incubated 
with enzyme and product formation is measured with respect to time of incubation.  The 
kinact /KI values for the (L)-Phe, (D)-Phe, and (L)-Met compounds were found to be 7130 
± 240, 4750 ± 100, and 2440 ± 80 M-1 min-1, respectively.  In contrast, the same results 
from the Dilution Assay, where enzyme is preincubated with inactivator for varying 
times prior to transfer into assay mix with saturating substrate concentrations, yielded the 
following values: 7320 ± 140, 4090 ± 100, and 8140 ± 210 M-1 min-1 for (L)-Phe, (D)-
Phe, and (L)-Met, respectively.  The specificity constants from both assays are either 
within or very close to the margin of error in the cases of both the (L)-Phe and (D)-Phe 
acrylates, but is inflated by 3-fold in the case of the (L)-Met compound in the Dilution 
Assay.  This was also the case for the sulfur-containing (L)-thienyl acrylate derivative 
analyzed by Feng (Feng 2001) using the Progress Curve and Dilution assays, although in 
her hands, the (L)-thienyl derivative was only twice as potent in the Dilution assay; the 
(L)-Phe derivative, on the other hand, yielded approximately the same values in both 
types of assay.  These differences in results for the different assays employed, in both 
cases involving a sulfur-containing inactivating molecule, suggests that the absence of 




subject to a more efficient inactivation.  As mentioned in the Results section, analysis of 
kinetic data from the Dilution assay for compounds which yield an individual value for 
kinact of less than one, and owing to the covariance of the kinact and KI values, yields 
individual values for both of these parameters associated with very high error values.  In 
other words, repetition of the Dilution assay will yield consistent values of kinact/KI but 
often very different values, from assay to assay, for the individual components of that 
parameter.  Nevertheless, it appears that the value for kinact, and not so much KI, is the 
parameter that prompts such a drastic change in the value of kinact/KI  between the 
Progress Curve and Dilution assays.  So, the binding of these compounds to the active 
site, and their relative affinities, do not change dependent upon the presence or absence of 
substrate; however, the rate constant of inactivation does change, implying that the 
presence of substrate somehow affects the mechanism of inactivation, but only in the case 
of the sulfur-containing (and potentially copper-ligating) acrylates.  Likely, taking into 
account the generally lower rate constant of inactivation of the sulfur-containing acrylates 
(in both assay types) relative to the phenylalanyl acrylates, the substrate in the Progress 
Curve assay is able to displace the sulfur-containing inactivators before the inactivation 
event occurs, thereby reducing the number of productive binding events between the 
acrylate and the enzyme, thereby selectively reducing the inactivation rate relative to the 
Dilution assay.  This would be best expressed as E + I → E-I → E-I’ → E-I*, where an 
initial enzyme-inhibitor complex (E-I) forms quickly, followed by a slower step where 
the enzyme and inhibitor adopt the productive inactivation complex (E-I’), followed by 
the inactivation event itself to yield the (E-I*) inactivated enzyme.  If the conformational 




substrate in solution may be able to displace the sulfur-containing acrylate prior to the 
inactivation event.  In this case, kinact would be representative of the rate of this 
conformational change if indeed that step is slower than the inactivation event itself.  
Disruption and reorganization of the active site via copper ligation may be expected to 
take place on a relatively slower time-scale than electron transfer or reaction with the 
ROS at CuM, and would explain the discrepancy in results between these two assay 
methods, for the sulfur-containing acrylates.  In addition, it would be expected that 
copper ligation by the thioether moiety of N-Ac-(L)-Met-Acrylate would be less 
favorable than for the more potently-ligating thiophene of N-Ac-(L)-Thienyl-Acrylate.  
The greater discrepancy (3-fold) in kinact/KI values between the Dilution and Progress 
Curve assays in the case of (L)-Met-Acrylate may reflect this slower rearrangement of 
the E-I complex to the productive inactivating complex; the discrepancy is only 2-fold in 
the case of the potentially more powerful copper ligator (L)-Thienyl-Acrylate. 
     Once the crystal structure has been solved and the nature and orientation of residues in 
the active site have been determined, a much better understanding of substrate and 
inhibitor binding may be derived from computer-assisted molecular docking of ligands to 
the protein of interest.  Certainly, it is even more instructive when the enzyme is co-
crystallized with substrate bound to the active site, and the nature of the residues 
responsible for binding and catalysis are delineated.  In 1998, Prigge et al. solved the 
structures for PAM in the oxidized and reduced forms of the enzyme (Cu+2 and Cu+1, 
respectively), and the oxidized form with the substrate N-acetyl-diiodotyrosylglycine 
(IYG).  The residues Arg240, Tyr318, and Asn316 are the most important residues for 




the substrate, Tyr forming a hydrogen bond with the substrate carboxylate, and Gln 
forming a hydrogen bond with the peptide bond of the substrate.  Many hydrophobic 
contacts are formed with the active site residues Phe112, Lys134, Leu206, Met208, 
Ile306, Met314 (a CuM ligand), and Tyr318.  A modeling simulation run with IYG 
resulted in a placement and conformation of the molecule that was nearly superimposable 
upon the crystal structure ligand, with only a slight deviation in placement of the N-acetyl 
group.  The active site environment around the N-acetyl group is a relatively open space, 
so this slight deviation is not surprising.  All of the polar and electrostatic contacts 
present in the IYG-bound crystal structure were present in the case of docked IYG.  The 
close agreement of the two structures provides evidence that this simulation, and by 
extension simulations run with other similar molecules, is capable of closely 
approximating the orientations and placement of glycine-extended dipeptides and the 
corresponding acrylate-containing inhibitors. 
     The known PAM substrate N-Ac-(L)-Phe-Gly is very similar in structure to the IYG 
substrate bound in the oxidized PAM crystal structure.  Indeed, the molecules are 
identical save for the substitutions on the phenyl ring, with IYG containing two iodine 
atoms and a hydroxyl group which are oriented toward the side chains of the various 
residues lining the hydrophobic pocket of the active site.  The carboxyl ends of both 
molecule are identical, and the simulations demonstrated that the three main 
electrostatic/polar interactions are preserved in the case of N-Ac-(L)-Phe-Gly.  The salt 
bridge between substrate carboxylate, and the hydrogen bonds to Tyr318 and Asn316 are 
all maintained in IYG-docking simulation.  The unsubstituted phenyl ring does not 




close hydrophobic interaction with this residue.  The N-acetyl group of N-Ac-(L)-Phe-
Gly is rotated slightly with respect to that of IYG, but this does not affect the binding of 
the C-terminus of the substrate where hydroxylation occurs.  In both cases, the glycine Cα 
is oriented downward toward the copper complex with the pro-(S) hydrogen in a 
favorable position for abstraction.  The pro-(R) hydrogen is directed upwards away from 
the catalytic complex, in agreement with the substrate stereospecificity studies performed 
by this laboratory (Ping 1992, Ping 1995). 
     Previous work in this laboratory (Katopodis 1990) has shown unequivocally that the 
molecule N-Ac-(D)-Phe-Gly is not a PAM substrate and an exceedingly poor competitive 
inhibitor, indicating that not only is this enantiomer unable to bind productively for 
catalysis, but is also effectively unable to bind at all to the PAM active site.  Therefore, 
this molecule was not expected to bind to the active site in a manner at all similar to its 
enantiomeric substrate counterpart, and this turned out to be the case in the molecular 
docking simulation.  Indeed, this molecule failed to associate with any of the residues 
critical for catalysis, hydrogen-bonding, or electrostatic interactions seen for IYG or N-
Ac-(L)-Phe-Gly.  The change in stereochemistry prevents this molecule from adopting a 
productive conformation complementary to the critical residues of the active site. 
     The same trends were evident with the enantiomeric pairs N-Ac-(L)-Leu-OCH2-
COOH/N-Ac-(D)-Leu-OCH2COOH and (S)-O-Ac-Mandelyl-Gly/(R)-O-Ac-Mandelyl-
Gly (stereotopically equivalent to (L)-O-Ac-Mandelyl-Gly/(D)-O-Ac-Mandelyl-Gly).  In 
both cases, the (L)/(S)-enatiomers were found to bind in a manner very similar to IYG 
and N-Ac-(L)-Phe-Gly.  N-Ac-(L)-Leu-OCH2COOH is an ester analog of PAM dipeptide 




potent competitive inhibitor (Ping, 1995).  Unlike N-Ac-(L)-Phe-Gly, the (L)-Leu 
derivative does not possess a hydrogen-bond donor at the position analogous to the 
peptide bond.  Therefore, it cannot form a hydrogen bond with the side chain of Asn316.  
In addition, rotation about the ester bond is less restricted than that of the amide bond of 
the corresponding N-Ac-(L)-Phe-Gly.  Nevertheless, the carboxylate still associates 
closely with Arg240 and hydrogen bonds to Tyr318.  The leucine side chain occupies the 
same space in the hydrophobic pocket as the phenyl ring of N-Ac-(L)-Phe-Gly, 
associating closely with Phe112.  The pro-(S) hydrogen is still directed toward the CuM 
catalytic complex, with the pro-(R) hydrogen directed upwards toward Tyr318, but the 
position of this hydrogen does not appear to lie as closely to the copper complex as was 
the case for N-Ac-(L)-Phe-Gly, and may indeed exceed the maximum possible distance 
for catalysis to occur.  On the other hand, the electronic effects of the ester bond may be a 
major contributor to the lack of catalysis.  The glycolate ester of 4-methoxybenzoic acid 
also failed to undergo PAM catalysis where the corresponding amide was indeed a 
substrate (Katopodis 1990).  (S)-O-Ac-Mandelyl-Gly is very closely related, and 
stereotopically equivalent to N-Ac-(L)-Phe-Acrylate, the only differences being that 
whereas the side chain of the Phe compound is a benzyl group, that of the mandelyl 
compound is a phenyl moiety lacking the methylene group.  Since the acetyl group is 
oriented into an open area of the PAM active site, and not associated with any active site 
residues, it was not expected that this structural change would have much effect on the 
docking of the (L)-Mandelyl compound in the active site.  The phenyl group associates 
very closely with Phe112, and although the carboxylate end of the ligand still forms a 




amide nitrogen of the substrate cannot form a hydrogen bond with Asn316.  The loss of 
this interaction is reflected in the less favorable KM value of the (L)-Mandelyl derivative 
relative to the (L)-Phe derivative (170 μM vs. 7.9 μM, respectively).  Conversely, neither 
N-Ac-(D)-Leu-OCH2COOH nor (R)-O-Ac-Mandelyl-Gly are substrates or inhibitors of 
PAM.  Neither associated closely with any active site residues in the docking simulations. 
     Initially, the similar potencies of PAM inactivation by N-Ac-(L)-Phe-Acrylate and N-
Ac-(D)-Phe-Acrylate were very surprising in light of the previous results.  Indeed, the N-
Ac-Phe-Acrylates are the only enantiomeric pair corresponding to N-Ac-X-Gly 
dipeptides in which both species either undergo catalysis or competitively inhibit or 
inactivate PAM.  Exhaustive work with circular dichroism spectroscopy, polarimetry, and 
chiral chromatography all proved that the N-Ac-(L)-Phe-Acrylate and N-Ac-(D)-Phe-
Acrylate preparations used for inactivation kinetics were enantiomerically pure.  There 
exist several possibilities for the enzyme’s ability to process both of these enantiomers in 
an indiscriminant manner.  First, the absence of a hydrogen-bond donor or acceptor in a 
position analogous to the amide bond of peptide substrates eliminates a point of contact 
with the active site of the enzyme (Asn316).  Second, the conjugation of the bonds in the 
acrylate would be expected to severely restrict the rotational freedom and limit the 
number of possible conformers at the carboxylate end of the inactivator.  For the acrylate, 
the extra sp2 center (at the position analogous to Cα in N-Ac-Phe-Gly) influences the 
geometry of the rest of the molecule, and is coplanar with, at the minimum,  the 
carboxylate carbon atom and Cβ. 
     Docked N-Ac-(L)-Phe-Acrylate and N-Ac-(D)-Phe-Acrylate both form bidentate salt-




site.  The rest of the docked structures, to the amino side of Cβ, diverge significantly from 
one another.  The (L)-enantiomer binds in a manner almost identical to N-Ac-(L)-Phe-
Gly and IYG, with a close interaction of the phenyl ring of the inhibitor and Phe112.  The 
(D)-enantiomer has undergone a rotation of approximately 120º about the Phe Cα-C(=O) 
bond, directing the phenyl ring directly back into the hydrophobic pocket, rather than 
aligning to interact with Phe112.  The N-acetyl group remains generally in the same 
position for both enantiomers in the free space above and to the left of the CuM center.  It 
must be noted that the crystal structure employed for these studies does not contain 
molecular oxygen ligated to CuM.  The acrylates lack the sp3 glycyl methylene groups of 
standard glycine-extended peptides.  It is very likely that the mechanism (discussed 
below) proceeds differently for acrylate inactivation versus substrate hydroxylation.  This 
would be a function of the difference in bond strength between an sp2 C-H bond and an 
sp3 C-H bond (110 kcal/mol vs. 95 kcal/mol for propene and the secondary C-H bond of 
propane, respectively (Vollhardt 1994).  The PAM reaction, as evidenced by the large 
(10-12) deuterium kinetic isotope effect, is very sensitive with regard to the nature and 
strength of the C-H bond at Cα.  It is quite possible that PAM is unable to cleave an sp2 
C-H bond.  If this is the case, then the mechanism of inactivation would proceed through 
an alternate pathway (i.e. without hydrogen atom abstraction), possibly involving the 
initial reduction (by the superoxide generated at CuM) of the Phe-Acrylate to a radical 
anion, followed by reaction with an active site residue, such as Tyr318.  Under these 
circumstances, the stereochemical requirements may be obviated so long as there is 
sufficient room to accommodate the molecule in the active site, form the salt-bridge with 




     A “flexible alignment” simulation is one whereby the conformational space of a pair 
of related molecules can be explored in order to find the most energetically favorable 
conformations of each of the two molecules which provide the most favorable overlap of 
its various hydrophobic, acidic, alkaline, polar, and H-bond donor/acceptor moieties.  
These simulations were performed on the following pairs of molecules:  N-Ac-(L)-Phe-
Gly and N-Ac-(L)-Phe-Acrylate, N-Ac-(L)-Phe-Gly and N-Ac-(D)-Phe-Gly, and N-Ac-
(L)-Phe-Gly and N-Ac-(D)-Phe-Acrylate.  The results of these simulations are presented 
in Figures 51 – 53, respectively.  The carboxylate group of each ligand was “fixed” at the 
coordinates of the IYG molecule from the crystal structure (restricted from rotational or 
translational motion) and therefore each alignment pair has an obligate overlap of this 
functionality.  The salt-bridge which forms between the substrate/inhibitor carboxylate 
and the guanidinum group of Arg240 has been shown above to be present not only in the 
Prigge crystal structure, but also in every case presented in the docking results above of 
all known substrates and inhibitors tested.  This restriction was necessary to allow the 
evaluation of the orientations of the other portions of the various molecules, under the 
assumption that the positioning of the carboxylate is necessary but not sufficient in 














Figure 51.  Flexible alignment overlay of N-Ac-(L)-Phe-Gly and N-Ac-(L)-Phe-     
Acrylate.  Deviations in the alignment of the N-acetyl groups are evident.  The glycyl 
portions of the two molecules are well-aligned, with the pro-(S) hydrogen of N-Ac-(L)-












Figure 52.  Flexible Alignment overlay of N-Ac-(L)-Phe-Gly and N-Ac-(D)-Phe-Gly.  
The molecules deviate markedly across the amide functionalities and glycyl residues of 











Figure 53.  Flexible Alignment overlay of N-Ac-(L)-Phe-Gly and N-Ac-(D)-Phe-
Acrylate.  The glycyl portions of both molecules are well-aligned, with relatively minor 











productively as either a substrate or inhibitor.  This allows any deviations in overlap to be 
explored as conditions which may cause a particular enantiomer to fail to bind.  While 
these flexible alignment simulations would likely not be very instructive in vacuo, they 
are useful in the context of the modeling results. 
     N-Ac-(L)-Phe-Gly and N-Ac-(L)-Phe-Acrylate are both known in vitro to bind 
potently to the PAM active site, the first as a substrate, the second as an irreversible 
inactivator.  The in silico results established that both compounds bind to the enzyme in a 
very similar manner.  The results of the flexible alignment simulation shown in Figure 51 
indicate a nearly complete overlap of these conformers.  The C2 sp2 hydrogen of the 
acrylate aligns with the pro-(S) hydrogen of the dipeptide.  The benzyl groups and the 
stereocenters of both molecules overlap with only slight and likely insignificant 
deviations.  The acetyl groups show the most deviation, but results from the modeling 
indicate that there is sufficient space available in this area of the active site for relatively 
large deviations in the placement of this functionality.  The acrylate C3 and C4 atoms 
overlap the C and N atoms from the amide bond of N-Ac-(L)-Phe-Gly.  There is a slight 
deviation (less than 30º) between the C3 hydrogen of the acrylate and the amide 
hydrogen of the dipeptide, and between the C4 carbonyl oxygens of both compounds.  
Not surprisingly, all of the atoms or the acrylate carboxylate, C2 and C3, and carbonyl 
group are nearly coplanar, owing to the conjugated nature of the molecule. 
     The flexible alignment of N-Ac-(L)-Phe-Gly and N-Ac-(D)-Phe-Gly is shown in 
Figure 52.  The N-acetyl groups, benzyl groups, and carboxylate groups are all nearly 
perfectly aligned.  The stereocenters overlap, although the C-H groups point in opposite 




enantiomeric pair and their substituents.  The carbonyl groups of the peptide bond point 
directly opposite from each other (nearly 180º rotation vs. approximately 30º between N-
Ac-(L)-Phe-Gly and N-Ac-(L)-Phe-Acrylate), and the glycyl methylene carbon atoms are 
bent away from each other with one of the hydrogens from each molecule also directed 
180º from each other.    The deviation between the amide hydrogens is less pronounced.  
It is therefore reasonable to assume that it is the conformation of the glycyl residue, all 
else being fairly equal, that determines whether a given molecule is able to bind to the 
active site.  It is important to remember that the lack of turnover of N-Ac-(D)-Phe-Gly by 
PAM could be explained by an unproductive orientation of the C2 hydrogen atoms, such 
that this enantiomer would be able to bind to the active site but would fail to undergo 
catalysis.  However, in addition to being unable to function as a substrate, the (D)-
enantiomer is an exceedingly poor competitive inhibitor (Ping, 1995).  This implies that 
this molecule fails to bind at all to the PAM active site.  Therefore, the conformation 
adopted by the (D)-enantiomer precludes its catalysis and binding, and there is 
insufficient space in the portion of the active site responsible for glycine binding to 
accommodate the altered positions of C2-C4 and their substituents in the case of N-Ac-
(D)-Phe-Gly. 
     The next step was to investigate the overlap of N-Ac-(L)-Phe-Gly and N-Ac-(D)-Phe-
Acrylate (Figure 53).  As in the case of the N-Ac-(L)-Phe-Gly/N-Ac-(D)-Phe-Gly 
flexible alignment pairing, there is nearly perfect overlap between the benzyl groups and 
N-acetyl groups.  The stereocenters again overlap, with the hydrogen atoms oriented in 
opposite directions.  Interestingly, the overlap of C1-C4 and their substituents is in much 




groups are only about 15º out of plane, and the same is true of the nitrogen of the peptide 
bond and the C3 hydrogen of the acrylate.  Again, for the acrylate, the entirety of the 
“glycyl” portion of the molecule is coplanar.  This planarity allows the acrylate 
enantiomers to “thread the needle” between the extremes of the positions of the glycyl 
moieties of the Phe-Gly enantiomeric pair.  It seems from these results that the 
orientation of the carbonyl oxygen of N-Ac-(D)-Phe-Gly, and an unfavorable repulsive 
electronic interaction with the side chain carbonyl of Asn316 is the condition which 
explains its failure to act as either a competitive inhibitor or PAM substrate. 
     The sulfur-containing acrylates are more difficult to discuss in the context of 
molecular modeling owing to a limitation of the docking methodology.  The Molecular 
Operating Environment docking software requires that all atoms and functionalities of the 
receptor be static.  Only the ligand itself is allowed to undergo translational or rotational 
movement.  Normally, this does not lead to any problems. However, in the cases of N-
Ac-Met-Acrylate and N-Ac-Thienyl-Acrylate, where the inactivators were rationally 
designed in the hopes that ligation of their sulfur atoms to copper would increase their 
binding affinity, the inability of the software to displace a ligand from CuM precludes any 
detailed analysis of copper-sulfur interactions.  Likely, EXAFS or a crystal structure with 
a bound sulfur-containing acrylate would provide an answer to the question of whether 
the sulfur atoms indeed ligate active site copper, but those are beyond the scope of this 
research.  Regardless, the modeling shows that N-Ac-(L)-Met-Acrylate, N-Ac-(D)-Met-
Acrylate, and N-Ac-(L)-Thienyl-Acrylate bind in a manner consistent with PAM 
substrates and competitive inhibitors.  Only the (D)-Thienyl enantiomer was unable to 




(D)-Met derivative binds in a manner similar to substrates or inhibitors, it also displays 
the most significant deviation from a tight salt-bridge formation with Arg240.  This 
compound was not synthesized and therefore no data with regard to its in vitro efficacy as 
a PAM inactivator are available.  Likewise, the (D)-Thienyl compound was not 
synthesized, although a comparison of the kinetic parameters of the pure (L)-Thienyl 
derivative and the (D,L)-Thienyl racemate indicate that the (D)-enantiomer would be an 
exceedingly poor inactivator, with the effect more pronounced in the KI value than the 
kinact value (Feng, 2001).  Because of these limitations, the modeling is likely not as well 
able to predict the binding of potential copper chelators as it is for other compounds 
which do not have such a capability. 
     The time-dependent PAM inactivator PBA is a 3-alkenyl carboxylic acid, whereas the 
acrylate series are 2-alkenyl carboxylic acid derivatives.  The structural difference results 
in a “glycine-like” –CH2COOH functionality in PBA, which is lacking in the acrylate 
series of inactivators.  Additionally, incubation of PBA with PAM and the requisite 
cofactors results in two hydroxylated products (2-hydroxy-4-phenyl-3-butenoic acid and 
4-hydroxy-4-phenyl-2-butenoic acid).  The partition ratio for PAM inactivation by PBA 
was found to be approximately 90 (Driscoll 2000).  The most reasonable explanation is 
that PBA, like glycine-extended substrates, undergoes hydrogen-atom abstraction and, 89 
times out of 90, hydroxylation; one time out of ninety, however, an inactivation event 
occurs.  The formation of both 2- and 4-hydroxy products implies that PBA, owing to its 
relatively smaller size and fewer interactions with active site residues, has some freedom 
of movement in the active site subsequent to hydrogen-atom abstraction.  The presence of 




delocalization of the nascent radical, which explains the ability to form two different 
hydroxy products, and is presumably dependent upon the ability of C2 and C4 to position 
themselves in close proximity to bound molecular oxygen. 
     Docked PBA forms a close bidentate salt-bridge with Arg240 and a hydrogen bond 
between its carboxylate group and the phenolic group of Tyr318.  The C2 atom lies in 
closer proximity to CuM.  However, a 180º rotation about the C2-C3 bond of PBA would 
bring C4 into closer proximity with CuM, although relatively unfavorable steric 
interactions between the phenyl group of PBA and the ligated copper would occur.  
Somewhere between the two extremes, it would be expected that C4 would approach 
closely enough to the ROS at CuM for 4-hydroxylation to occur, but without the steric 
hindrance from the phenyl group.  Since PBA is relatively small, rotation about the C1-
C2 bond could render either the pro-(S) or pro-(R) hydrogen at C2 into a position 
favorable for hydrogen-atom abstraction.  Driscoll’s results showed that PBA 
hydroxylation is stereoselective ((S)-2-hydroxy-4-phenyl-3-butenoic acid is formed at a 
ratio of 70:30 compared to the (R)-enantiomer), but not stereospecific.  The modeling 
results presented here help to explain this phenomenon. 
     The enantiomeric N-Ac-Phe-Propiolate pair was also subjected to docking analysis.  
Attempts to synthesize the (L)-enantiomer with a reaction involving the acid chloride of 
N-Ac-(L)-Phe and methyl propiolate deprotonated by n-BuLi were unsuccessful, so there 
is no kinetic data with respect to PAM available for this compound.  However, this 
compound is an interesting prospect for three reasons.  First, this alkynyl derivative 
would likely be more reactive toward ROS generated at CuM than the corresponding 




opposed to the planarity and 120º bond angles of the acrylate results in a longer molecule, 
with perhaps interesting consequences as regards the positioning of the benzyl group, and 
especially the phenyl ring, in the active site.  Thirdly, there are no hydrogen atoms bound 
to either C2 or C3 in the case of N-Ac-(L)-Phe-Propiolate.  Therefore, if this compound 
were able, experimentally, to inactivate PAM it would be certain that the mechanism 
could not involve a hydrogen atom abstraction step.  As mentioned above, although the 
acrylates have a hydrogen at C2 which is positioned such that it could conceivably be 
abstracted by the ROS generated at CuM, the alkenyl C-H bond is approximately 15 
kcal/mol stronger than the corresponding glycyl C-H bond.  The large deuterium KIE 
noted above implies that hydrogen-atom abstraction is extremely sensitive to changes in 
bond strength. It is possible, however, that a large part of the KIE is accounted for by 
tunneling (Francisco 2002); all else being equal it is more problematic to tunnel the 
proton, neutron, and electron of deuterium than it is the proton and electron of hydrogen.  
Nevertheless, the change in the strength of the C-D/C-H bond must contribute, at least in 
part, to the KIE.  However, the potential for hydrogen atom abstraction from C2 of the 
acrylates remains, regardless of the increased difficulty in the homolytic cleavage of the 
bond.  In the case of the alkyne, this possibility can be ruled out, and inactivation, if it 
occurs, would have to proceed either by an alkynyl radical anion or by a nucleophilic 
attack by superoxide generated at CuM.   The docking results for N-Ac-(L)-Phe-
Propiolate are indicative of a productive binding to the PAM active site, with a 
carboxylate/guanidinium salt-bridge in clear evidence.  The benzyl group of the ligand is 
indeed forced further away from Phe112/Tyr318, as the molecule is almost perfectly 




     The N-Ac-Phe-Crotonates were used to probe the effect of the addition of an 
additional methylene “spacer” group between the stereocenter and the alkenyl 
functionality of the molecule.  We reasoned that this may provide more flexibility in the 
conformational space available to the benzyl group of the ligands, and allow, perhaps, for 
more potent association with the PAM active site, especially since the carbonyl group 
would be allowed to freely rotate, rather than being constrained by resonance, as is the 
case for the acrylate/propiolate derivatives.  Interestingly, the (D)-enantiomer failed to 
interact favorably with any part of the active site as was the case for the (D)-propiolate.  
It appears that the increased distance between the ligand carboxylate and the benzyl 
groups of both N-Ac-(D)-Phe-Propiolate and N-Ac-(D)-Phe-Crotonate affects the ability 
of these compounds to bind to the PAM active site.  The carboxylate of the (L)-Crotonate 
interacts closely with the copper ion at CuM, rather than the guanidinium of Arg240.  This 
is the only instance in all of the docking simulations where this copper/carboxylate 
interaction occurs.  This is an interesting case, because if this representation is indeed 
accurate, it is possibly that this would be an extremely potent competitive inhibitor of 
PAM owing both to this interaction and to the fact that the benzyl and N-acetyl groups 
seem to occupy a favorable area of the hydrophobic pocket.  However, the failure to 
associate with Arg240 would likely preclude electron-transfer from CuH and impede any 
potential inactivation mechanism, even though this molecule has the exact same C-
terminus as the known inactivator N-Ac-(L)-Phe-Acrylate. 
     The exact mechanism of catalysis by PAM remains elusive.  Most difficult to resolve 
is the question of how two reduced coppers, 11 Å apart, each donate one electron to 




formation.  While CuM is located in close proximity to the glycyl moiety of PAM 
substrates, CuH lies across the solvent-accessible cleft of the enzyme, with no clearly 
defined or evident path for electron transfer.  It has become evident in recent years that a 
CuM(II)-superoxo intermediate is responsible for the abstraction of the pro-(S) hydrogen 
from glycine-extended peptides and related compounds (Evans 2003, Francisco 2004).  A 
study with oxidized PAM and hydrogen peroxide in the presence and absence of 
molecular oxygen, yielded some very interesting results (Bauman 2006).  Hydrogen 
peroxide is the protonated form of the peroxo-species formed from a two-electron 
reduction of molecular oxygen, and if able to bind to CuM and hydroxylate PAM, does 
not absolutely require the input of any additional reducing equivalents from the enzyme.  
The authors showed that peptide substrate, oxidized PAM, and hydrogen peroxide were 
sufficient to catalytically yield hydroxylated product.   This was true both in the presence 
and absence of molecular oxygen, and the kinetic parameters were unchanged under 
aerobic and anaerobic conditions, indicating that hydrogen peroxide is not simply 
fulfilling a role as a copper reducing agent.  The reaction is catalytic in both cases.  
However, investigations with two histidine mutants, one a CuM ligand (H242A) and the 
other a CuH ligand (H172A), both known to reduce PAM activity by more than 99% 
(Jaron 2002), shows that neither mutant was catalytically competent using the hydrogen 
peroxide system.  This clearly indicates that hydrogen peroxide, and by extension a 
peroxo-bound CuM species, is not capable of directly catalyzing the PAM reaction.  This 
implies that the electron transfer from CuH is important not only for the PAM reaction as 
a whole, but also that (at least) a reduced CuH center is required for the reaction to occur.  




oxygen complex, but also that the manner in which it is transferred, and its pathway of 
transfer, is of equal necessity to catalysis. 
     The authors again suggest a superoxide channeling mechanism, whereby hydrogen 
peroxide reduces CuH(II) to CuH(I), and is itself oxidized to superoxide which channels 
back to CuM, and is then reduced back to hydrogen peroxide by the hydrogen peroxide 
ligated there, yielding a CuM(II)-superoxide with CuH being in the active reduced form.  
While this sounds feasible on its face, it conflicts with the 18O2 data which necessitates 
that all oxygen activation steps are reversible until hydrogen atom abstraction occurs.  
Moreover, why can’t hydrogen peroxide reduce CuM, form CuM(I)-superoxide, and 
perform the hydroxylation directly?  It is possible that this is precluded by the 
coordination chemistry and reduction potential at CuM, relative to CuH, but this 
mechanistic conjecture suffers from a lack of parsimony and again suffers from the 
requirement of a reversible migration of superoxide across the solvent-accessible cleft.  
Also, this mechanism leaves a reduced CuH and an oxidized CuM after each 
hydroxylation.  How is CuH(I) then oxidized back to its active (i.e. CuH(II)) form in this 
environment, especially when the system was shown to be catalytic?  CuH(I) reduction of 
hydrogen peroxide, if it occurred at all, would upon protonation produce two hydroxyl 
radicals (and CuH(II)), the generation of which would lead to a deleterious radical 
cascade that would presumably cause enzyme inactivation.  Nevertheless, the apparent 
requirement for a CuH(I) species, even in the seeming absence of any necessity for 
electron transfer in the case of the hydrogen peroxide system, has interesting mechanistic 




     The reduced PAM crystal structure with both bound substrate and molecular oxygen 
also argues against the necessity for the migration of superoxide from CuH to CuM.  
Instead, an electron-transfer pathway exists which involves H108 (a CuH ligand), a water 
molecule, and the substrate carboxylate.  The CuM system would then, either via a Cu(II)-
superoxo or a Cu(I)-peroxo species, abstract the pro-(S) hydrogen from the substrate.  
This would require only a thermal rotation of the O-O bond and the breaking of a weak 
VDW contact with M314 (Prigge 2004).  The electron from CuH is not necessarily 
obliged to have been transferred prior to the abstraction of the substrate hydrogen atom in 
this case.  The one-electron reduction of molecular oxygen to superoxide is -0.33 V, in 
the case of horseradish peroxidase, whereas the reduction potential of superoxide to 
peroxide (with protonation) is a more favorable 0.94 V and could drive the reaction 
forward (Courteix 1995).  However, here the same situation is reached as would be the 
case if hydrogen peroxide bound to oxidized CuM.  The Bauman paper shows that CuH is 
required for the hydrogen peroxide-catalyzed hydroxylation of peptide substrate in the 
case of the oxidized enzyme.  So, we have arrived at a paradoxical situation as regards 
the two explanations for electron transfer, and have two explanations available for this 
situation.  First, the protonation state of hydrogen peroxide is incompatible with hydrogen 
atom abstraction unless it is generated in situ at CuM.  Second, the electron from CuH 
does not arrive properly mechanistically unless it is actually conducted through the 
substrate.  This would occur subsequent to hydrogen atom abstraction, and potentially 
generate a carbanion at C2 of the peptide substrate which would then attack the 
hydroperoxide at CuM(II), generating hydroxylated peptide and a hydroxide anion (seen 




     The above relates to the potential mechanism of PAM inactivation by the peptidyl 
acrylates.  The paper on α,β-unsaturated ketones by Gibian (Gibian 1984) illustrates both 
the failure of superoxide to act as a nucleophile towards these compounds, and its ability 
to generate an anionic radical centered at the carbonyl carbon atom of the unsaturated 
ketone, with the negative charge carried by the carbonyl oxygen atom.  Assuming that 
superoxide cannot abstract the sp2 glycyl hydrogen atom of the acrylate, and the fact that 
it is unable to add productively to the C2 sp2 carbon via a nucleophilic attack upon this 
class of compound, it seems reasonable to assume that the radical acrylate anion is 
formed.  The source of the electron could be either CuM (via superoxide) or, alternatively, 
the electron could come from CuH.  If the latter is the case, instead of the electron being 
transferred to the ROS at CuM via the H108/water/substrate carboxylate, it could be 
subsumed into the acrylate, yielding the inactivating radical anion inactivating species.  
This argument is bolstered by the proximity in the active site of Tyr318 to the carbon-
centered radical.   The activation barrier for tyrosyl radicals is fairly low, and their 
stability relatively high, so it is possible that a hydrogen atom is abstracted from the 
tyrosyl phenyl group, leaving a tyrosyl radical in the active site.  In addition, the 
hydrophobic nature of the active site and the neighboring Phe112 and Leu206 residues 
could contribute significantly to the ease of formation and stability of a tyrosine radical in 
the PAM active site.  Studies on the tyrosyl radical generated in the hydrophobic pocket 
of the active site of the enzyme Ribonucleotide Reductase clearly indicate that the 
hydrophobicity of the environment is critical to the stability of the tyrosyl radical.  




I234N) to more hydrophilic residues significantly reduced the yield of the tyrosyl radical.  
(Ormo 1995) 
      Alternatively, a bond may form between the carbonyl carbon of the acrylate and the 
phenoxy group of the tyrosine, in which case the enzyme would be labeled by the 
acrylate suicide substrate.  In any event, the incubation of PAM with the alkynyl analog 
of N-Ac-Phe-Acrylate would certainly be useful in elucidating this mechanism of 
inactivation, since this molecule lacks any hydrogen atoms bound to C2.  Furthermore, it 
would be expected that the reduction potential of the alkynyl analog would be more 
favorable as regards formation of an anionic radical species.  As such, the alkynyl series 
could provide greater rates of inactivation than the acrylates.  The modeling results above 
indicate that N-Ac-(L)-Phe-Propiolate has a high probability of binding to the active site, 
bearing all of the associations with the enzyme that characterize the binding of N-Ac-(L)-
Phe-Acrylate, including salt-bridge formation with Arg240, a hydrogen bond between the 
carboxylate of the ligand and Tyr318, and association of the hydrophobic phenyl group 
with Phe112 and Tyr318. 
     Finally, an evaluation of the active site of the enzyme with various docked dipeptide 
analogs reveals that a great deal of space is available in the hydrophobic pocket of the 
enzyme beyond that occupied by the various P2 side chains.  This suggests that further 
modifications to the P2 side chain could significantly improve the KI values of these 
inhibitors.  Notably, it appears that the inclusion of a moiety, such as an additional 
carboxylate group, sulfonic acid group, or other type of anionic functionality which could 
form a salt-bridge with Lys134 would be desirable.  A two- or three-carbon chain 




of N-Ac-(L)-Phe-Acrylate may allow for the formation of this type of salt bridge.  
Alternatively, bulkier aromatic side chains such as napthylene or anthracene could 
increase the binding affinity, or such a side chain with an additional carboxylate group 
which might associate with Lys114 might be appropriate for investigation.  The acrylates 
are the most potent class of inactivators of PAM that are known at the present time.  
Certainly, any of these modifications to improve their efficacy are worthwhile pursuits. 
     The major question regarding the acrylate series of compounds was the question of 
why they appeared to lack the stereochemical requirements at the P2 position which are 
so stringent for their dipeptide analogs, and from thence, why the inactivation kinetics 
were so similar for the N-Ac-Phe-Acrylic acid enantiomeric pair.  We have shown that 
our Modeling protocol is effective in identifying those compounds known to be PAM 
substrates or inhibitors based upon two requirements:  first, that the carboxylate of the 
substrate/inhibitor be able to form a salt bridge with the guanidinium functionality of 
R240 of the PAM active site, and secondly, that the P2 side chain be oriented upwards 
(away from CuM) into the hydrophobic pocket of the enzyme.  In addition, for substrates, 
it is necessary that a hydrogen (always the pro-(S) in the cases studied herein) atom be 
directed toward the hydroxyl group ligated to that copper ion.  The acrylates lack the 
glycyl amide bond of corresponding dipeptide substrates, and, as such, are not subject to 
hydrogen bonding with N316.  This bond serves to orient PAM substrates into a position 
favorable for hydrogen-atom abstraction.  While the dipeptides with (L)-amino acids at 
the P2 position are all PAM substrates, those with (D)-amino acids are not (and poor 
competitive inhibitors as well).  The planarity of the acrylate through the C2-C3 double 




remain uninfluenced by N316 (the corresponding P2 dipeptides containing (D)-amino 
acids may be subject to electronic repulsion by this residue) and occupy the space 
available to dipeptides containing (L)-residues at the P2 position, whether that P2 residue 
is of (L)- or (D)-configuration.  The kinetic interchangeability of these enantiomers could 
be potentially important in forthcoming in vivo studies, especially as the 
pharmacokinetics of these compounds is concerned.  The (L)-acrylates more closely 
resemble naturally-occurring physiological peptides than the (D)-acrylates, and therefore 
may be subject to greater proteolytic degradation than the latter.  In addition, (D)-
acrylates, by the same logic, would be expected to interfere, perhaps, with fewer enzymes 
than the (L)-acrylates and may manifest, therefore, potentially fewer side-effects upon 
dosing.  This elegant and interesting class of compounds is certainly an exciting new 
breed of anti-inflammatory compounds with a great deal of potential in further animal 
experiments. 
      










































     Substance P (SP) is an 11-residue amidated peptide which is involved in cell-signaling 
pathways which control the expression and release of pro-inflammatory mediators and 
various mitogenic growth pathways which have been shown to be involved in the 
epigenetic progression of a variety of neoplastic conditions.  The bioactivation of 
Substance P from its glycine-extended precursor is catalyzed by the sequential activities 
of the enzymes peptidylglycine α-amidating monooxygenase (PAM) and 
peptidoamidoglycolate lyase (PGL).  PAM catalyzes the α-hydroxylation of the glycine-
extended peptide to stereospecifically form C-terminal (S)-hydroxyglycines, and PGL 
catalyzes the N-dealkylation of this intermediate to yield the desglycyl C-terminal 
amidated peptide and glyoxylate (Ping, 1992; Ping, 1995; Katopodis, 1990).  Substance P 
is categorized as a neuropeptide hormone, owing to its discovery (and the discovery of a 
variety of other neuropeptides) as a modulator of function and activity in the central 
nervous system (von Euler, 1931).  Since the discovery of neuropeptides, many have 
been found to have a variety of activities throughout the periphery, and have been shown 
to be released by a variety of non-neuronal cell types and affect the function of a variety 
of physiological processes.  Substance P is classified as a tachykinin (neurokinin), and 
exerts its effects via activation of the neurokinin-1 receptor (NK-1), a so-called 
serpentine receptor with seven transmembrane helical domains and an intracellular C-




1991).   These receptors are also called G-protein-coupled receptors (GPCRs) and their 
activation results in a cascade of events which lead to a variety of cellular stimulation 
processes (Hershey, 1990).  Most notably, through the activation of the intermediate 
phospholipase C (PLC) pathway, receptor occupation results in the downstream 
activation of nuclear transcription factors for a variety of pro-inflammatory mediators and 
cytokines, especially nuclear factor κB (Li, 1997).  Additionally, SP is classified as a 
mitogen (activator of mitosis), and activates a wide variety of cellular processes which 
lead to cellular growth and proliferation (Nilsson, 1985; Lotz 1987).  The activation of 
the Ras pathway is of particular concern, as it is well-established that a constituitively-
activated Ras pathway is present in a wide variety of cancers and tumor subtypes 
(Ahmadian, 2002; Hamad, 2002).  Therefore, SP has been found to be implicated in both 
chronic inflammatory diseases such as rheumatoid arthritis, and in neoplastic growth and 
metastasis (Firestein, 1996; Bresnihan, 1999).  Furthermore, chronic inflammation has 
been shown to potentiate the growth of a variety of neoplasms, implying that both the 
pro-neoplastic and pro-inflammatory properties of Substance P may mutually-reinforce 
both pathways and yield a pathologically synergistic effect in both cases. 
    During acute and chronic inflammation, the pro-inflammatory effects of SP are 
upstream of cyclooxygenase-2 (COX-2) which is eventually activated by SP through the 
PLC/PLA2 second-messenger pathways, yielding the pro-inflammatory products of 
arachidonic acid metabolism (prostaglandins).  During recent years, the COX-2 selective 
inhibitors (most notably Vioxx), which have had such a marked ameliorative effect on 
chronic inflammation and pain in rheumatoid arthritis and related conditions, have also 




from the marketplace, creating a therapeutic drug vacuum for these conditions.  
Currently, the COX-2 selective inhibitor Celebrex remains on the market.  However, this 
drug is still associated with adverse cardiovascular events.  Interestingly, the most 
promising drug currently available for the treatment of chronic pain and inflammation 
(excluding the opiates from the discussion, as these drugs are strongly addicting and 
subject to the phenomenon of increasing tolerance as treatment time continues) is Enbrel 
(Etanercept), which is a soluble tumor-necrosis factor-α (TNF-α) receptor which 
sequesters this pro-inflammatory mediator in the bloodstream and extracellular space.  
Since the drug is protein-based, it is not orally-active and requires a maintenance regimen 
of injections for administration.  Transcription, translation, and release of TNF-α are also 
at least partially under the control of the NK-1 receptor, so its levels may also be 
modulated by the inhibition of SP biosynthesis.  Again, NK-1 activation is upstream of 
the events leading to the synthesis and release of TNF-α. 
     Certainly, then, reduction of peripheral levels of SP can be readily seen as a desirable 
target for pharmacological intervention for both chronic inflammation and cancer, via the 
inhibition/inactivation of the enzyme(s) responsible for its bioactivation.  The thrust of 
the ensuing analysis hinges upon the development and evaluation of rationally-designed 
molecules which act as mechanism-based inactivators of PAM, the rate-limiting enzyme 
in the conversion of biologically-inactive SP-Gly to the pro-inflammatory/pro-neoplastic 
amidated SP.  SP is known to affect (activate) nearly all of the cells of the innate immune 
system (leukocytes such as macrophages, neutrophils, eosinophils, as well as mast cells, 
dendritic cells, etc.) and exerts pro-inflammatory effects on cells of the acquired immune 




expected to affect all neoplastic cells which express the NK-1 receptor, owing to its status 
as a mitogenic growth factor.  Hence, owing to its stimulatory effects in both cases, 
reduction of SP levels via inhibition of PAM is certainly a very attractive target for 
pharmaceutical agents.  Naturally, since PAM catalyzes the bioactivation of a wide 
variety of glycine-extended neuropeptides, inhibition of the rate-limiting monooxygenase 
leads necessarily to a depletion of all types of amidated neuropeptides.  Therefore, it is 
also important that PAM inhibitors be targeted as specifically as possible to areas of 
chronic inflammation and neoplastic growth to reduce side-effects resulting from 
depletion of other biologically necessary neuropeptides required for homeostasis and 
general health of the organism.  Moreover, it is of utmost importance that any PAM 
inhibitor not be able to penetrate the blood-brain barrier to any significant degree to avoid 
adverse neurological effects (treatment of brain tumors being one obvious exception).  
However, the work presented herein is interested primarily in evaluating these PAM 
inhibitors as anti-inflammatory and anti-cancer agents as proofs-of-concept, and further 
refinement to account for tissue-specific drug-targeting and prevention of CNS-
associated side-effects is beyond the scope of this thesis. 
     Our second-generation mechanism-based PAM inactivator N-Ac-(L)-Phe-Acrylate 
(and its methyl ester prodrug) was evaluated as an anti-inflammatory agent in a variety of 
experiments including:  acute inflammation initiated by carrageenan, chronic 
inflammation (adjuvant-induced polyarthritis), and mustard oil-induced neurogenic 
inflammation (MOINI).  This compound was also evaluated for its inhibitory effects on 
purified COX-1 and COX-2 and for inhibition of these enzymes in human whole-blood 




soluble PLA2 (V).  Finally, the first-generation mechanism-based PAM inactivator 4-
Phenyl-3-Butenoic Acid (PBA) (and its methyl ester prodrug) was evaluated for its 
ability to restore gap-junctional communication and a more normal phenotype to Ras-
transformed (WB-Ras) epithelial cells.  Its effects on the mitogen-activated protein kinase 
(MAP-K) pathway (involved in Ras activation) were also evaluated.  In all cases 
involving animal experiments or cells, residual PAM activity levels were also tested in an 
attempt to correlate the anti-inflammatory or anti-neoplastic effects of these compounds 
to PAM inhibition.  In all cases, the therapeutic effects of these inhibitors were indeed 
remarkable.  In the following section, the effects of Substance P on the activities of cells 
of the innate and acquired immune system will be discussed in detail, as will the 
pathways involved in the pro-inflammatory and pro-neoplastic properties of SP, 
including the downstream effects of the activation of NF-κB and the Ras-pathway. 
 
Substance P and Neurokinin Expression 
 
     Neurokinins are expressed from two separate genes, preprotachykinin-I (PPT-1) and 
preprotachykinin-2 (PPT-2).  All PPT-1 transcripts, of which there are four alternative 
splicing forms, encode for SP-Gly.  Two of the transcripts also encode for Neurokinin A 
(NKA), Neuropeptide K, and Neuropeptide-γ, the latter two of which are extended forms 
of NKA.  PPT-II does not code for SP.  The bioactive, amidated form of SP has the 
following sequence:  Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2.  All 
tachykinins share a similar sequence at the C terminus: Phe-X-Gly-Leu-Met-NH2, where 




virtue of the requisite C-terminal amide for complete bioactivation, undergo catalysis by 
PAM and PGL from their respective glycine-extended precursors. 
     Each of the three major tachykinins, SP, NKA, and NKB, preferentially activate one 
of the three known neurokinin receptors.  SP activates NK-1, NKA activates NK-2, and 
NKB activates NK-3 (Nakanishi, 1991).  Although there is significant cross-reactivity 
between the various neurokinins and the three receptors at high concentrations of ligand, 
selectivity is marked at lower concentrations.  The largely conserved carboxy-termini 
address the ligands to NK receptors in general, while the variable N-terminal regions 
dictate receptor subtype specificity.  The NK-1 receptor has a 100-fold greater affinity for 
SP than for NKA, and 500-fold greater for SP than for NKB (Gerard, 1991).  The NK-1 
receptor is, as is typical for GPCRs, transcribed at low levels from what is characterized 
as “low-abundance” mRNA.  The receptors are internalized after activation by SP, and 
are thus readily desensitized in the absence of any signals which increase either 
transcription of the receptor mRNA or translation of existing mRNA. 
     The human NK-1 receptor contains 407 amino acid residues and a molecular weight 
of 48,000 kDa (Hopkins, 1991).  The SP binding site is located between the second and 
third transmembrane-spanning α-helices of the receptor, while the third intracellular loop 
appears to be responsible for interaction with the coupled G-protein.  As with all GPCRs, 
agonist binding results in the exchange of bound (inactive) GDP for (active) GTP within 
the heterotrimeric G-protein, which precipitates the dissociation of the heterotrimeric 
complex into two subunits, Gα and Gβγ.  The Gα subunit remains bound to GTP, but 
possesses an inherent GTPase activity which eventually hydrolyzes GTP back to GDP, 




The activated Gα subunit may be one of several species, all of which serve to further 
activate different downstream pathways when dissociated from the Gβγ subunit, but NK-
1R activation results in the activation of the Gαq/11, which goes on to activate membrane-
bound Phopholipase C.  This results, via hydrolysis of membrane phospholipids, in an 
increase in diacylglycerol (DAG) and inositol triphosophate (IP3).  These second 
messengers in turn mobilize intracellular calcium stores and activate Phospholipase A2, 
which cleaves arachidonic acid from phospholipids, making them available as substrates 
for the COX enzymes (yielding the intermediate prostaglandin PGH2) followed by 
catalysis of one of several prostaglandin synthase enzymes, yielding a variety of 
prostaglandins including PGE2, PGF2α, PGI2 (prostacyclin), and TXA2 (thromboxane).  
Furthermore, Phospholipase C activity results in the activation of Protein Kinase C, 
which leads to further downstream effects. 
     The NK-1 receptor is rapidly desensitized via phosphorylation of a variety of Ser and 
Thr residues on the cytoplasmic tail, which encourage internalization (and deactivation) 
of the receptor.  However, Phospholipase C remains active on a longer-term basis and 
exerts powerful cellular effects, even after the initial signal wave (SP) has abated.  
Therefore, in the absence of other destimulating factors, PKC and other downstream 
mediators will remain active even after SP-stimulation has terminated (Li, 1997). 
 
Protein Kinase C and Downstream Cellular Signaling 
 
     Once Phospholipase C has been activated by the Gα subunit, the enzyme hydrolyzes 




and serves to liberate sequestered Ca+2 stores from intracellular reservoirs, and 
diacylglycerol (DAG), which remains associated with the plasma membrane.  Calcium 
binds to soluble PKC, which allows it to associate with membrane-bound DAG and 
results in the fully active kinase. 
     PKC phosphorylates and actives Raf-1, a mitogen-activated protein kinase kinase 
kinase (MAP-KKK).  MAP-KKK activates MEK (a MAP-kinase kinase), which in turn 
activates several Extracellular-Related Kinase-2 (ERK-2).  ERK-2 is designated as a 
MAP-kinase, and leads to several important cellular processes, including the activation of 
various transcription factors, translation enhancers (e.g. MNK-1 and MNK-2 which 
increase the rate of translation of extant mRNAs), calcium-independent PLA2, and other 
elements involved in cell survival and proliferation (such as p90RSK).  An important 
transcription factor, Nuclear Factor κB (NF-κB), which promotes the transcription of a 
variety of cytokines and pro-inflammatory mediators, is thusly activated by SP binding to 
the NK-1 receptor.  This will be discussed in further detail in the following sections. 
     In addition to the Raf-1-controlled pathway outlined above, another function of PKC 
is the activation of the Ras pathway.  The Ras gene is a proto-oncogene, meaning that 
certain mutations result in a constituitively-activated p21 Ras proteins that, once 
activated, lacks the inherent GTPase activity necessary to deactivate itself, ultimately 
leading to a cascade of events that enhances cell survival and proliferation, and tends to 
oppose any pro-apoptotic signals which are concurrently trying to cause the transformed 
cell to undergo programmed cell death (Cesen-Cummings, 1998). 
     Indeed, the Ras genes are the most frequently mutated genes in solid tumors and blood 




2002).  p21 Ras proteins require farnesylation (by the enzyme farnesyltransferase) and 
association with the plasmalemma for full activity (Hancock, 1989).  Permanent Ras 
activation results in potent downstream effects in the MAP-K pathway, also leading to 
upregulated transcription and translation of a variety of pro-growth genes and leading to 
the altered morphology typical of tumorigenic cells.  When p21-Ras is thus activated, a 
further notable effect is the loss of gap junctions on the cell membrane which allow 
neighboring cells to directly communicate with each other (Ruch, 1993).  As cells 
proliferate and begin to come into close contact with each other, various chemical signals 
may be passed between them via the gap-junctional pathway.  Under normal 
circumstances, these chemical signals prevent further proliferation among adjacent cells.  
However, under the pathological conditions arising for constituitive Ras activation, less 
information is able to pass between cells via gap junctions and the requisite anti-
proliferative signals are not “seen” as readily by these transformed cells.  In a nascent 
solid tumor, adjacent cells continue to proliferate even as they are crowded in close 
contact with neighboring cells, and mitotic division continues unchecked, leading to 
continued tumor growth.  Gap junctions are formed from connexin proteins, and the 
ability of these proteins to aggregate at the plasma membrane and form gap junctions is 
governed by the phosphorylation of connexin-43.  Reduction in phosphorylation results 
in reduction of gap junction formation. (deFeijter, 1996), and Ras-activation appears to 
inhibit this phosphorylation.  Previously, work performed on a variety of lung-tumor 
subtypes had shown that the proliferation of the tumorigenic cells was governed by 
autocrine growth loops controlled by gastrin-related peptide (GRP), which, like 




(Iwai, 1999).  Indeed, since this GRP-mediated GPCR activation event is upstream of the 
Ras pathway, inhibition of amidation could possibly interrupt the autocrine growth loops 
which detrimentally govern (via Ras activation itself and therefore its downstream 
activation of ERK-2) the rampant growth of tumor cells.  Hence, preventing the 
amidation of GRP (or SP, which controls many of the same pathways through the NK-1 
receptor) may in fact block the activation of the transcriptional factors which influence 
the expression of pro-growth mediators, and upregulate gap-junctional communication.  
Both of these effects would be predicted to inhibit the growth and proliferation of tumor 
cells. 
 
Nuclear Factor κB (NF-κB) 
 
     NF-κB is a transcription factor involved in the regulation of expression of a wide 
variety of pro-inflammatory mediators.  Under normal physiological conditions, NF-κB is 
present in the cytoplasm of the cell in association with IκB.  When these two molecules 
are thus associated, NF-κB is effectively sequestered and prevented from entering the 
nucleus to trigger the expression of the pro-inflammatory cascade.  When extracellular 
stimuli result in the activation of the MAP-K/ERK-1 pathway, an enzyme known as IκK 
is phosphorylated and activated.   The active form of IκK in turn phosphorylates IκB, 
which then dissociates from NF-κB, is ubiquinated and targeted for degradation by the 
proteasome.  Once this occurs, NF-κB migrates to the nucleus where it promotes the 




expression of these mediators is therefore the ultimate downstream event associated with 
(among others) the activation of the NK-1 receptor. 
     NF-κB can also be activated by activation of several Toll-like receptors, including the 
lipopolysaccharide (LPS) receptor.  LPS (or endotoxin) is a ubiquitous component of the 
cell-wall of Gram-negative bacteria, and thus bacterial infection is able, ultimately, to 
stimulate NF-κB activation and elicit an appropriate immunological response.  However, 
in a variety of autoimmune pathologies associated with chronic inflammation, such as 
rheumatoid arthritis (RA), NF-κB is active in the absence of any bacteriological infection.  
Over recent years, a large body of literature has implicated elevated levels of SP in the 
pathology of RA, and since NF-κB can be activated as a downstream event of the 
occupation of the NK-1 receptor by SP, it is exceedingly likely that this amidated 
neuropeptide may be a major contributor to the continuation of the chronic inflammation 
which characterizes the disease (Marshall, 1990; Menkes, 1993). 
     Gene transcription and subsequent mRNA translation resulting from NF-κB 
translocation to the nucleus results in the formation of an abundance of pro-inflammatory 
chemokines, cytokines, enzymes, and adhesion molecules that serve to further amplify 
the inflammatory signal ultimately initiated by the binding of SP to the NK-1 receptor.  
First, the cytokine proteins of the acute phase response, including interleukin-1β (IL-1β), 
interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) are produced and secreted.  In 
a positive-feedback loop, IL-1β and TNF-α, upon secretion by an NF-κB-active cell, may 
act in an autocrine or paracrine manner by occupying cell-surface receptors which, when 
activated, serve again ultimately to stimulate NF-κB activation.  When this occurs in the 




can result in unceasing activation and amplification of the expression of further pro-
inflammatory mediators, leading ultimately to serious pathological conditions of chronic 
pain, inflammation, and the destruction of healthy tissue. 
     Further damaging effects occur with the expression and release of chemokines, 
molecules which serve as chemoattractants for a variety of cells of the innate (and 
adaptive) immune system.  Most of these cells (macrophages, monocytes, granulocytes, 
dendritic cells, lymphocytes, etc.) also possess cell-surface receptors for the cytokines 
mentioned above, which are then also subject to NF-κB activation.  Additionally, 
coexpressed with chemoattractants such as interleukin-8 (IL-8), RANTES (Regulated 
upon Activation, Normal T-Cell Expressed and Secreted, more commonly known now as 
CCL5), microphage inflammatory protein (MIP-1α), and monocyte chemotactic protein 
(MCP-1), are a variety of immune/inflammatory cell adhesion molecules which are 
expressed on the surface of vascular endothelial cells that serve to allow more efficient 
recruitment of immune cells.  These include, but are not limited to, vascular cell-adhesion 
molecule (VCAM-1), intercellular-adhesion molecule (ICAM-1), and E-selectin.  
Coupled with the vasodilation induced by SP, which serves to slow blood flow in vessels 
near to the environment of the initial inflammatory stimulus, these adhesion molecules 
allow for even more efficient recruitment of immune cells from the circulation (Seidel, 
2007). 
     Finally, but not least importantly, is the expression of a variety of inducible enzymes, 
such as Phospholipase A2 (which liberates arachidonic acid, the COX-1/COX-2 
substrate), COX-2 itself, and inducible-nitric oxide synthase (iNOS).  Nitric oxide causes 




subjected to the products of the respiratory burst (from NADPH oxidase in neutrophils 
and macrophages) such as superoxide, forms peroxynitrite and other reactive species 
which can cause further local cellular damage in an inflamed area already beset by a 
variety of other cytotoxic mediators.  COX-2 catalyzes the formation of PGH2 which, as 
mentioned previously, is the substrate for a variety of prostaglandin synthase enzymes 
which form the several prostaglandins, molecules which also exert potent pro-
inflammatory effects.  The cell surface receptors for the short-lived (autocrine or 
paracrine-acting) prostaglandins are also GPCRs.  The COX isozymes themselves are 
integral membrane proteins of the endoplasmic reticulum and nuclear envelope.  PGE2 
and PGI2 (prostacyclin) potentiate the pain and edema-producing effects of bradykinin 
and histamine released from mast cells, cause further vasodilation (again facilitating 
leukocyte recruitment to the site of inflammation), and increase blood flow to the site of 
inflammation (bringing more leukocytes to the area).  Furthermore, a variety of 
prostaglandins, via interaction with cell-surface GPCRs on immune cells, also serve to 
activate the Phospholipase C pathway, which ultimately leads to further NF-κB 
activation. 
     Overall, the pro-inflammatory positive-feedback cascade initiated by activation of the 
NK-1 receptor is nothing short of astounding.  Inhibition of SP biosynthesis via 
inactivation of PAM (the rate-limiting step of peptide amidation) is therefore an 
extremely attractive target in the amelioration of the pathological conditions of a wide 






Effects of Substance P on Cells of the Immune System 
 
     The innate immune system is typically described as encompassing those populations 
of immune cells which are activated immediately upon insult to the organism, such as 
bacteriological invasion.  Among this population of cells are monocytes, macrophages, 
neutrophils, basophils, eosinophils, neutrophils, fibroblasts, natural killer cells, and mast 
cells, to the exclusion of lymphocytes.  Lymphocytes, on the other hand, are cells of the 
adaptive immune response, having generated immunity to specific pathogenic protein 
sequences or structures via interaction with antigen-presenting cells (APCs, e.g. 
macrophages and dendritic cells) and subsequent maturation and proliferation in the 
spleen or lymph-nodes.  The semantic distinction notwithstanding, all cells of the innate 
immune system are recruited or stimulated to some extent by the mature T- and B-cells of 
the adaptive immune system, whether by direct cell-to-cell contact with T-cells, or via 
interaction and phagocytosis of pathogens coated with specific antibodies generated by 
B-cells (O’Connor, 2004). 
     As the innate immune system responds to physiological insult, the immediate tissues 
begin to swell and redden as blood flow is increased to the area and neighboring blood 
vessels become “leaky” and allow for the extravasation of cells and the accumulation of 
fluid into the extracellular space.  Algesia is a secondary consequence of the infection or 
insult as nociceptive signals are transmitted along sensory neurons to the dorsal ganglia 
of the spinal cord.  The eicosanoid prostaglandin products of the cyclooxygenase 
enzymes contribute to this response, but Substance P is thought to play the most major 




SP in transmitted in an anterograde (and retrograde) motion back and forth to the spinal 
ganglion (Bayliss, 1901).  This SP cycle is characteristic of chronic pain.  SP released 
from nerve terminals in inflamed areas contributes to the activation of the cells of the 
innate immune system in the area; inflammation generated through this pathway is 
known as neurogenic inflammation.  Heat is a by-product of the vastly upregulated 
metabolic activity of immune cells in the area of inflammation.  Proteins of the acute 
phase response produced by liver cells in response to pro-inflammatory mediators 
generated and secreted by immune cells lead to the induction of fever by the 
hypothalamus. 
     SP, via interaction with the NK-1R expressed by immune cells, not only enhances the 
immune response via direct effects on the production of pro-inflammatory cytokines and 
induction of the COX-2 isozyme, but also potentiates the effects of many other cytokines 
and chemokines.  Generally, the role of SP is immunostimulatory but it has also been 
implicated in the resolution of inflammation as its mitogenic properties enhance the 
action of fibroblasts and other cell types which rebuild tissue damaged by injury or 
pathogenic invasion (Nilsson, 1985; Lotz, 1987; Ziche, 1990).  The following is a brief 
recapitulation of the effects of SP on some of the major cell-types of the innate and 
adaptive immune system. 
 
SP and Lymphocytes 
 
     SP is a powerful chemoattractant for lymphocytes, creating a chemical concentration 




(ICAM, ELAM, VCAM, etc.) in the area of inflammation or infection.  As these 
molecules are upregulated (on the plasma membranes of the vascular endothelium and 
the immune cells themselves), lymphocytes are recruited and extravasated into the 
affected areas.  SP is also a cofactor for the differentiation of B-lymphocytes and 
stimulates antibody secretion.  Also upregulated is the secretion of interleukin-2 (IL-2) by 
T-lymphocytes, an autocrine/paracrine factor which enhances CD4+ T-cell growth, 
enhances the natural killer activity of T-cells, and prolongs their life spans (Calvo, 1992).  
SP also stimulates the production and release of macrophage-inflammatory protein-1β 
(MIP-1β or CCL4) which not only attracts additional lymphocytes, but also activate 
granulocytes (neutrophils, eosinophils, etc.) and macrophages, upregulating their 
synthesis and secretion of the pro-inflammatory cytokines IL-1, IL-6, and TNF-α (Guo, 
1992; Croitoru, 1990).  This is one method by which SP affects the activities of the cells 
of the innate immune system via its interaction with cells of the adaptive immune system. 
     SP activates lymphocytes at concentrations as low as 0.1 nM, via interaction with the 
NK-1 receptor (Covas, 1994).  While there is some evidence that lymphocytes 
themselves express and secrete SP, it would be more accurate to say that these cells 
express the PPT-1 gene (which encodes SP).   In other words, it is known that the mRNA 
for PPT-1 is expressed in lymphocytes.  However, direct evidence of the production of 
SP has not been found.  In order for SP itself to be produced by lymphocytes, these cells 
would also have to express PAM/PGL, which generates amidated, bioactive SP from SP-
Gly (itself processed from the larger PPT-1 precursor).  Immunological techniques have, 
to my knowledge, used only polyclonal anti-SP serum which would be cross-reactive 





SP and Macrophages/Monocytes 
 
     As for lymphocytes, SP is a potent chemoattractant for monocytes and macrophages 
(Schratzberger, 1997).  It stimulates the production of IL-1, IL-6, and TNF-α, the three 
primary pro-inflammatory cytokines (Bill, 1979; Lotz, 1988).  Interleukin-1 is classified 
as an endogenous pyrogen (fever-promoter), and promotes the recruitment of leukocytes 
and the expression of intercellular adhesion molecules.  IL-1 also stimulates 
hematopoesis (myelocytes and erythrocytes) in response to infection.  IL-6 acts as both a 
pro- and anti-inflammatory cytokine, and has many of the same pro-inflammatory effects 
as IL-1.  TNF-α activates the apoptotic (programmed cell death) pathway, but also has 
many proliferative (pro-inflammatory) effects as well (activation of MAP-Kinase and 
NF-κB).  These three cytokines are the major stimulators/markers of the acute phase 
response, which serves to stimulate the liver to increase the production of a variety of 
anti-microbial/pro-inflammatory proteins.  These include C-reactive protein (an opsonin), 
whose plasma levels increase by nearly five orders of magnitude during the acute phase 
response, serum amyloid A (leukocyte recruitment, induction of matrix 
metalloproteinases (MMP)), the complement system (opsonin, components of 
“membrane attack complex” which lyse invading cells), ferritin (sequesters Fe+3 from 
pathogens), ceruloplasmin (oxidizes Fe+2 to facilitate sequestration by ferritin), and 
haptoglobin (binds hemoglobin, further iron sequestration.  It is interesting that 
ceruloplasmin is one of the upregulated proteins of the acute phase response.  Its normal 




acute phase response for iron processing would seem to require that it dissociate from 
copper in areas of infection or inflammation.  This could serve to increase local levels of 
copper ion, which is a requisite cofactor for PAM. 
     A more immediate effect of SP on macrophages/monocytes is the upregulation of 
phagocytic activity.  Indeed, macrophages may be activated insofar as the production of 
cytokines, but do not reach their full phagocytic potential unless activated by SP (Bar-
Shavit, 1980).  SP also upregulates arachidonic acid metabolism by stimulating PLA2 (via 
increase in free intracellular Ca+2 levels) activity and thus indirectly provides a greater 
substrate concentration for COX-2 catalysis, ultimately leading to the production of a 
wide variety of prostaglandins, leukotrienes, lipoxins, etc.  In another instance of the 
involvement of SP in pro-inflammatory positive-feedback loops, SP also upregulates the 
expression of the NK-1 receptor in monocytes and macrophages, thereby serving to 
amplify its own signal.  PPT-1 mRNA transcription is also upregulated.  As mentioned 
above, this is suggestive of SP-Gly, rather than SP itself which may only be produced in 
the presence of PAM/PGL and the requisite cofactors.  SP also upregulates the oxidative 
burst of macrophages/monocytes, the process whereby the enzyme NADPH oxidase 
reduces molecular oxygen to superoxide ion, the first in a chain reaction formation of 
reactive oxygen species (ROS) which include superoxide itself, peroxynitrite, hydroxyl 
radical, hydrogen peroxide, and a variety of halooxygen radicals such as hypochlorite 
(the anion of “bleach”).  All are bactericidal, but also serve to damage “self” cells as well 






SP and Neutrophils 
 
     Neutrophils are the most common leukocyte present in the bloodstream, and the first 
line of defense against infection.  These cells are a representative of the class of 
polymorphonuclear phagocytic cells (including eosinophils and basophils as well), also 
called granulocytes.  These cells are also very proficient at the oxidative burst 
mechanism, and upon degranulation (release of granule contents) deliver further 
molecular species which are toxic to pathogens, including lysozyme, myeloperoxidase 
(generates hypochlorous acid), acid hydrolases (including phospholipase A2), defensins 
(cationic, cysteine-rich proteins which form pores in bacterial cell walls), bactericidal 
permeability-increasing protein (BPI), elastase (degrades extracellular matrix), 
collagenase, and complement-activating factors (opsonins), among others (Haines, 1993; 
Serra, 1998).  Neutrophils are short-lived, surviving an average or one or two days 
subsequent to recruitment (macrophages may live for months to years) and are the major 
component of pus formed at sites of infection. 
     As for lymphocytes/monocytes/macrophages, SP is chemotactic for neutrophils.  In 
addition, SP induces the degranulation of neutrophils at sites of infection, leading to the 
release of a variety of products as described above.  The respiratory burst, as for 
macrophages, is greatly enhanced upon SP stimulation.  Through a process known as 
“neurogenic priming”, SP potentiates the effects of a variety of other pro-inflammatory 
mediators on neutrophils (Perianin, 1989).  As for other immune cells, SP stimulation 





SP and Other Cell Types 
 
     SP has profound effects on mast cells, which are related to the low-abundance 
basophils which circulate in the bloodstream.  These cells are rich in granules containing 
histamine (associated largely with allergy/anaphylaxis) and heparin.  Most notably, these 
cells are often in direct contact with sensory neurons, and can be drastically affected by 
the release of SP from these nerve terminals (Stead, 1987).  Thus, mast cells are 
important contributors to neurogenic inflammation and have been shown to be important 
in a variety of autoimmune conditions such as rheumatoid arthritis, whereby they recruit 
other immune cells to the joints thus amplifying the inflammatory condition therein and 
resulting in further damaging effects to the local tissues.  SP induces histamine and 
serotonin release by a receptor-independent mechanism (SP penetrates the cell membrane 
and interacts directly with the receptor-associated G-protein) (Shanahan, 1985).  As for 
other cell types, SP activation results in an upregulation in the expression and secretion of 
TNF-α. 
     SP has similar effects on eosinophils as other cells of the innate immune system 
(stimulation of degranulation, respiratory burst, prostaglandin synthesis, etc.) but is 
tangential to our discussion owing to their role (mostly) as anti-helminth cells and cells 
which are involved in allergy/anaphylaxis.  However, their activation may also lead to 
expression of pro-inflammatory mediators which affect other cells of the immune system 
or the acute phase response.      





SP and Apoptosis 
 
     Apoptosis is a programmed cell death which arises in response to potentially 
deleterious changes to the cell itself (internal signals) or from interactions with various 
molecular signals from without.  Although apoptosis can be triggered in response to a 
number of different conditions, perhaps the most notable function of programmed cell 
death is to prevent the proliferation and/or metastasis of transformed cells (i.e. cancer 
cells).  The inability of cancer cells to respond appropriately to pro-apoptotic signals 
results, oftentimes, in runaway growth (failure to recognize the spatial limitations of its 
surroundings, mechanical displacement of healthy tissue by proliferating cancer cells) 
and de facto immortality. 
     Apoptosis is characterized by a variety of controlled cellular processes which allow 
for an orderly disposal of cellular contents and structural material.  This controlled 
process differentiates apoptosis from a general, disorderly cellular necrosis which may 
result in a widespread dissemination of cellular contents and material into the 
surrounding extracellular space, often resulting in the release of a variety of potentially 
toxic mediators which may be deleterious to neighboring healthy tissue.  Cells 
undergoing apoptosis are efficiently phagocytosed and disposed of by macrophages.  
When an apoptotic signal is recognized by a transformed, fatally-damaged, or virally-
infected cell, a cascade of proteolytic activity governed by caspases (cysteine proteases) 
is initiated which leads to programmed cell death.  Apoptosis requires a functional cell 




at least some minimal cellular metabolism able to regulate the required biochemical 
events. 
     Mitochondria are intimately involved in apoptotic events.  Briefly, the equivalent of 
the membrane-attack complex (MAC) forms a pore in the mitochondrial membrane 
called the mitochondrial apoptosis-induced channel (also MAC).  Formation of this 
channel is under the control of various proteins from the Bcl2 family, which contains 
members which both promote and prevent the initiation of apoptosis in the 
mitochondrion.  The protein Bax (a component of the MAC channel) is a member of this 
family and its expression is under the regulatory control of the p53 tumor suppression 
gene.  Formation of the MAC allows for the leakage of cytochrome c (a member of the 
electron-transport chain) into the cytosol.  Cytosolic cytochrome c leads to caspase 
activation and the initiation of apoptosis.  The anti-apoptotic protein Bcl-2 prevents 
formation of the MAC and leakage of cytochrome c into the cytosol.  Caspase-9 is 
activated by cytochrome c and serves to activate various effector caspases of the 
apoptotic pathway, ultimately resulting, among others, in the activation of poly-ADP 
ribose polymerase.  This enzyme polymerizes nicotinamide adenosine diphosphate, 
effectively sequestering NADH from productive usage and restricting a wide variety of 
cellular processes. 
     Other notable pro-apoptotic pathways are the TNF-pathway and the Fas pathway, 
although TNF-α is able, as noted above, to initiate cell survival and pro-inflammatory 
pathways as well as sending pro-apoptotic signals.  Incoming stimuli, from different 
receptors, may be both pro- and anti-apoptotic simultaneously.  Indeed, it is unlikely that 




preponderance of the signal, pro or anti, through expression and/or sequestration of the 
Bcl-2 members determines the ability of the MAC to form in mitochondria or other 
organelles, and the ultimate activation of the various pro-apoptotic effector caspases 
(CASP3, CASP6, CASP7). 
     As outlined above, SP is mitogenic and pro-inflammatory.  In addition, SP has been 
shown to be directly anti-apoptotic in a variety of cell types, including macrophages, 
neutrophils, thymocytes, and small-cell lung carcinoma (deFea, 2000; Bockman, 2001).  
Treatment with NK-1R antagonists has been shown to increase levels of apoptosis in 
cultured small-cell carcinoma cells.  Treatment of various cell types with glucocorticoids 
induces apoptosis, and coincubation with SP has been shown to limit glucocorticoid-
induced apoptosis in these same cells.  It must be noted that the anti-apoptotic effects of 
SP are tissue-specific, and SP has been shown to be actively pro-apoptotic in other cell 
types; hepatocytes undergo more efficient apoptosis when incubated with both TNF-α 
and SP, than when incubated with TNF-α alone.  In other cases, SP has been shown to 
induce a caspase-independent non-apoptotic form of programmed cell death.  In addition, 
the anti-apoptotic effects of SP may be dependent on the inflammatory microenvironment 
of a given tissue. 
     Thus, given the number of pathways under the control of the NK-1 receptor, 
stimulated by SP binding, we sought to investigate whether our novel PAM inhibitors, by 
prevented the amidation and bioactivation of SP, could act as anti-inflammatory and anti-
cancer agents.  First, that these drugs could display an anti-inflammatory effect against 
acute (carrageenan-induced edema) and chronic (adjuvant-induced polyarthritis) 




inflammatory mediators under the control of the NK-1 receptor.   Second, that these 
drugs could inhibit inducible COX-2 activity without directly inhibiting COX-2 itself, 
thereby displaying an effect upstream of PLA2 and COX-2.   Third, by investigating 
whether PAM activity was indeed present in Ras-transformed cells (WB-Ras), and 
whether our PAM inhibitors were selectively cytotoxic toward the transformed cell line 
(versus a normal cell line, WB-Neo) or were able to help return the transformed cells to a 
more normal phenotype.  We also attempt to correlate the anti-inflammatory and anti-
























     All animals in these experiments were male Sprague-Dawley rats purchased from 
Harlan Sprague Dawley, Inc. (Indianapolis, IN).  All were allowed food and water ad 
libitum and allowed to acclimate for at least five days prior to experimentation at the 
Mercer University animal facility.  The Mercer University Institutional Animal Care and 




     4-phenyl-3-butenoic acid (PBA) and isothiocyanate were purchased from Aldrich 
Chemical Co. (Milwaukee, WI).  N-acetyl-(L)-Phe-acrylic acid, methyl N-Acetyl-(L)-
Phe-acrylate, methyl 4-phenyl-3-butenoic acid, and trinitrophenyl-(D)-Tyr-Val-Gly were 
all synthesized, and all reagents obtained for use in their syntheses procured, as described 
previously in Materials and Methods section 2.1.  Indomethacin, EDTA, Mycobacterium 
butyricum, type IV lambda carrageenan, formamide, capsaicin, dithiothreitol, 
lipopolysaccharide (from E. Coli serotype 0111.B4), sodium citrate, sodium phosphate, 
and MES buffer (enzyme grade) were all obtained from Thermo Fisher Scientific 
(Pittsburgh, PA).   Triton X-100 was purchased from Acros Organics (Pittsburgh, PA).   




MI).  Prostaglandin E2 ELISA kits were purchased from Oxford Biomedical (Oxford, 
MI).  All other chemicals and reagents used in these experiments were analytical grade.   
WB-Ras and WB-Neo cells were kindly donated by Dr. James F. Trosko at Michigan 
State University (Lansing, MI).  Alpha Modification of Eagle’s Media was purchased 
from Mediatech (Herndon, VA).  Fetal Bovine Serum (FBS), Neutral Red solution, and 
phenylmethylsulfonyl fluoride (PMSF) were obtained from Sigma Chemical Co. (St. 
Louis, MO). 
 
Preparation and Administration of PBA and APAA-OMe 
 
     PBA was recrystallized prior to use by dissolution in boiling hexanes and overnight 
precipitation at -20° C.  PBA was dissolved in phosphate-buffered saline (PBS) or water 
and the pH was adjusted to 7.4 with sodium hydroxide and hydrochloric acid.  All PBA 
doses were administered by subcutaneous injection.  Methyl-N-acetyl-(L)-Phe-acrylate 
was dissolved in 10/90 v/v DMSO/Ethanol. 
 
Collection of Blood/Serum from Sprague-Dawley Rats 
 
     Blood was collected from rats at specified time points by clipping the tail of ether-
anesthetized animals.  The tails were electrocauterized post-collection.  Briefly, 0.5 mL 
of blood was collected, allowed to clot at room temperature for 20 minutes, and 
centrifuged at 4° C for 5 minutes at 16,000 x g.  The supernatant was collected and stored 





Analysis of Serum PAM Activity 
 
     PAM activity was determined using a previously-described method (Katopodis, 1991).  
Serum was allowed to thaw at room temperature, and 50 μL of serum was incubated in 
200 μL of assay mixture containing saturating (greater than 50 μM) concentrations of 
TNP-YVG, 40 μM copper sulfate, 8 mM ascorbic acid, and 1 mg/mL catalase in 50 mM 
MES-Na buffer (pH 5.5).  Samples were incubated for 45 minutes at 37º C in a water 
bath and the reaction was quenched via the addition of 25 μL 3M HClO4.  The assay 
mixture was then centrifuged at 4º C for 20 minutes at 16,000 x g.  The supernatant was 
then assayed for product concentration (TNP-YV(OH)G and TNP-YV-NH2) by RP-
HPLC on an Alltech Allsphere C8 column connected to a Waters LC-Module 1 HPLC.  
50 μL of sample were injected and monitored at 344 nm in a mobile phase of 
44.0:55.9/0.1 acetonitrile/water/trifluoroacetic acid.  Both hydroxy intermediate and 
amidated TNP-YVG products were quantified using HPLC standard curves.  PAM 
activity is expressed in milliunits (mU) per mL, the amount of enzyme required to 
produce 1 nmol product per minute at saturating substrate concentrations. 
 
Induction of Adjuvant Arthritis and Carrageenan Edema 
 
     Adjuvant arthritis was induced by a subplantar injection of Freund’s Incomplete 
Adjuvant (1 mg/mL M. butyricum in mineral oil) into the right hindpaw.  Control animals 




alone.  Carrageenan edema was induced by the injection of 0.05 mL of carrageenan (20 
mg/mL in PBS) into the subplantar region of the hindpaw.  Control animals received 
injections of PBS only.  Changes in paw volumes were measured plethysmographically 
by mercury displacement at various times post-induction of edema or arthritis. 
 
WB-Ras and WB-Neo Cell Culture and PAM Activity 
 
     WB-Ras and WB-Neo rat liver epithelial cells derived from a WB-F344 cell line were 
subcloned from single cells to obtain WB-Neo3 (WB-Neo) and WB-Ras1 (WB-Ras) cell 
lines.  All cells used for the following experiments were between passages 5-20.  Cells 
were grown in Alpha Modification of Eagle’s Media supplemented with 2 mM L-
glutamine, 5% v/v fetal bovine serum (FBS), and 2% v/v G418 antibiotic solution (not 
used during experiments).  Cells were grown to confluence, underwent trypsinization, 
and were plated at 5-10% confluence during each passage.  Cells were incubated in an 
atmosphere of 5% CO2 at 37º C. 
     To determine the effects of PBA and PBA-OMe on PAM activity in WB-Ras and 
WB-Neo cells, cells were grown to greater than 90% confluence in 15 mL Eagle’s media 
including 150 μL of either vehicle or drug at the appropriate concentration.  Each 
treatment group consisted of two 75 cm2 T-flasks.  After the appropriate incubation time, 
cells were washed 4 times with 0.9% w/v PBS, scraped from the flask using a rubber 
policeman, and collected.  Cell suspensions were centrifuged for 20 minutes at 4,000 x g 
and the supernatant was discarded.  The cell pellet was then resuspended in 500 μL of 50 




the last thaw, the suspension was again centrifuged as above and the supernatant was 
collected as the soluble protein/enzyme fraction.  The pellet was then resuspended in 
MES buffer containing 1% v/v Triton X-100 detergent and allowed to sit for one hour.  
The suspension was then centrifuged again, as above, and the supernatant was collected 
as the membrane-associated protein/enzyme fraction.  PAM activity (including both the 





     All data are presented as the mean ± standard error of the mean (S.E.M.).  Statistical 
significance was determined using the Student’s t test when comparing means between 
two groups.  One-way analysis of variance (ANOVA) was utilized to test for statistically-
significant differences between repeated measures.  Tukey’s post-hoc test was then used 
to analyze statistical differences within groups.  All measurements denoted with an 











Chapter 7:  Results 
 
     Previous work by this group in has established that PBA is a potent mechanism-based 
time-dependent inactivator of PAM in vitro.  In addition, in later experiments in 
collaboration with Dr. Stanley Pollock at Mercer University, PBA was shown to have 
potent anti-inflammatory effects in vivo against carrageenan-induced edema, an acute 
inflammatory model (Ogonowski 1997).  These anti-inflammatory effects correlated well 
with inactivation and reduction of rat serum PAM activity.  Chronic inflammation, on the 
other hand, involves a variety of cells and mediators which do not participate on the short 
time-scale of acute inflammation, including, most notably, T- and B-lymphocytes.  
Therefore, the acute anti-inflammatory effects of a given compound do not necessarily 
translate into similar effects on a long-term basis.  To that end, we investigated the 
potency of PBA (60 mg/kg/h) as an inhibitor of chronic inflammation, using the 
adjuvant-induced polyarthritis (AIP) model in Sprague-Dawley rats.  AIP is characterized 
by three distinct phases.  In the first phase (recognition phase), the injection of the 
adjuvant (subplantar injection of 0.1 mL of 1 mg/mL M. butyricum in mineral oil) in the 
hindpaw initiates an acute phase of inflammation which results in significant swelling of 
the injected paw, and lasts for approximately two days.  Second, the proliferation phase 
(Days 2-10) is characterized by a plateau or modest reduction in the swelling of the 
injected paw.  In the third phase (effector), specific T-cell-mediated inflammation results 
in a second period of increased swelling of the injected paw, with a concurrent 
inflammation of the contralateral hind paw and other systemic inflammatory effects.  The 




PAM inactivator PBA was shown to diminish inflammation associated with AIP in each 
of the three phases of the progression of the disease, in both the injected and contralateral 
paws.  This was a proof-of-concept which established that potent PAM inhibitors are 
potent anti-inflammatory compounds. 
     Therefore, since PBA (a commercially-available compound which resembles, 
structurally, the PAM substrate N-benzoylglycine) had been shown to have potent anti-
inflammatory effects in both acute and chronic models of inflammation, we reasoned that 
our second-generation compound N-Ac-(L)-Phe-Acrylic Acid (and methyl ester 
prodrug), having shown greater in vitro potency as a mechanism-based PAM inactivator) 
should prove an even more potent anti-inflammatory drug.  To that end, we evaluated the 
ability of the acrylate to inhibit serum PAM in comparison to PBA, its effectiveness 
against acute inflammation (carrageenan-induced edema model), and attempted to assay 
its ability to reduce the inflammation associated with AIP in Sprague-Dawley rats.  Other 
experiments performed by our collaborators investigated the potency of this compound as 
inhibitors of purified ovine COX-1 and COX-2 and, in a human whole-blood assay, 
against the production of PGE2 by lipopolysaccharide (LPS)-induced COX-2.  Finally, 
we investigated, in collaboration with Dr. Diane Matesic (Mercer University), firstly, 
whether PAM activity was present in WB-Neo and WB-Ras-transformed epithelial cells, 
and secondly to what extent PBA could inhibit epithelial PAM and return the transformed 
cells to a more normal phenotype. 
          All animal experiments were performed at Mercer University, in collaboration with 
Professor Stanley Pollock.  Work was performed with the involvement of one or more of 




Interesting results from various experiments performed by one of the aforementioned 
researchers using chemicals synthesized by this researcher, but beyond which I was not 
directly involved will be presented in the Discussion section, in order to distinguish that 
work from such that I was involved with more directly and intimately, beyond 
synthesizing and providing the compound tested.  This is especially the case for a variety 
of assays on SP immunoreactivity, phospholipase assays, COX-1 and COX-2 assays 
(whole-blood and kits), and other in vivo assays such as the mustard oil experiments. 
 
Effect of PBA on Serum PAM Activity in vivo 
 
     PBA was administered to Sprague-Dawley rats either as a one-time dose of 500 
mg/kg, or every three hours at doses of 500, 250, and 125 mg/kg.  Blood samples were 
taken every three hours and the serum was assayed for PAM activity.  The results of the 
study are shown in Figure 54.  The one-time PBA dose resulted in a significant reduction 
(72%) of serum PAM activity after 3 hours, relative to time zero.  This effect was fairly 
short-lived, and the serum PAM activity increased to 90% of control levels by 9 hours 
post-injection.  By 24 hours, PAM activity was still at approximately 90% of controls.  
Dosing at 500 mg/kg every three hours, on the other hand, resulted in nearly 100% 
inhibition of PAM activity from six to twelve hours post-administration, after which the 
PAM activity began to rebound, even as maintenance doses of PBA continued to be 










Figure 54.  Inhibition of serum PAM by PBA in vivo.  PBA was administered to Sprague-
Dawley rats as a subcutaneous injection in aqueous PBS.  Control animals received only 
vehicle injections.  Blood was taken from the tail at various time points and the serum 
was analyzed for PAM activity as described in Experimental section.  PBA 500 mg once 
(○); PBA 500 mg/kg every 3 hours (●); PBA 250 mg/kg every 3 hours (▲); PBA 125 

















































15% of controls.  At 125 mg/kg and 250 mg/kg, reduction in PAM activity was 45% and 
65%, respectively, after three hours, and 30% and 45%, respectively, after 24 hours.  All 
dosing was characterized by an initial and robust inactivation of serum PAM, which  
peaked after approximately 12 hours, and which could not be maintained beyond this 
time.  This indicates that there is some mechanism by which PAM levels are able to 
rebound toward controls, even as the concentration of PBA is maintained (or even 
increased) in the bloodstream. 
     Continuous administration of PBA via osmotic pumps at 60 mg/kg/hr over the course 
of six days is shown in Figure 55.  By 12-24 hours, PAM activity had been reduced by 
65-70%.  After two days, the inhibition was nearly 100%, and serum PAM levels 
remained virtually undetectable through Day 3.  The final three days showed a slow 
decline in the inhibitory potential of the continuously administered PBA, and after 6 
days, this compound was only able to maintain serum PAM activity at approximately 
40% of controls (60% inhibition).  This experiment shows the same rebound in PAM 
activity described with the higher doses (one-time 500 mg/kg and 125, 250, and 500 
mg/kg every three hours) 
 
Effect of N-Ac-(L)-Phe-Acrylate on Serum PAM Activity 
 
     One-time doses of N-Ac-(L)-Phe-Acrylate were administered to Sprague-Dawley rats 
at 10, 50, and 100 mg/kg to evaluate their effects on the inhibition of serum PAM 




PAM activity was reduced by 20, 28, and 38%, respectively.  After one hour, the activity, 















































Figure 55.  Effect on serum PAM activity in Sprague-Dawley rats 
dosed continuously with PBA for six days with an osmotic pump at 
60 mg/kg/h.  Control animals were sham treated.  Serum samples 
were taken at time points between 0 and 6 days and assayed for PAM 
activity as described in “Methods”.  Data are presented as the mean ± 
S.E.M. for each group (n=3). 
* Statistically significant (P < .05) compared to controls for that day 























































Figure 56.  Effect of N-Ac-(L)-Phe-Acrylic Acid on serum PAM levels 
in Sprague-Dawley rats.  N-Ac-(L)-Phe-Acrylate was administered 
subcutaneously at three different concentrations to Sprague-Dawley rats 
in order to determine the degree to which serum PAM is inhibited.  
Control animals received vehicle alone.  Blood was collected and 
assayed for serum PAM activity over the course of six hours.  APAA 10 
mg/kg (●); APAA 50 mg/kg (■); APAA 100 mg/kg (▲).  Data are 
presented as the mean ± S.E.M. for each group (n=6).   











After six hours, inhibition was 16, 14, and 12% for the 100, 10, and 50 mg/kg doses, 
respectively.  Since these were one-time doses, it is not evident whether or not continued 
dosing would have allowed for a continued inhibition of serum PAM at peak levels. 
 
Effect of N-Ac-(L)-Phe-Acrylate Methyl Ester on Serum PAM Activity 
 
     As with the free acid analog N-Ac-(L)-Phe-Acrylate, one-time doses were 
administered to Sprague-Dawley rats at concentrations of 10, 50, and 100 mg/kg and 
serum PAM activity was monitored for six hours post-administration (Figure 57).  Only 
the free acid derivative is able to inactivate PAM in vitro, so presumably the ester analog 
requires in vivo hydrolysis prior to any PAM inactivation.  Interestingly, although the 
inhibition of serum PAM was nearly identical for the methyl ester and the free acid at the 
higher doses (50 and 100 mg/kg), the lowest concentration did not significantly inhibit 
PAM until six hours post-administration.  Also, the inhibition persisted for longer periods 
of time for the ester relative to the free acid.  At 100 mg/kg, PAM activity was reduced 
by approximately 37% after one hour, and remained at this level until three hours post-
administration, before declining to 25% of controls after six hours.  The graph for the 50 
mg/kg dose is nearly superimposable over that of the 100 mg/kg dose, although PAM 
activity levels were 5-7% greater in the former case.  The 10 mg/kg dose actually reached 




     A direct graphical comparison of the effects on serum PAM levels of the free acid 
acrylate and the methyl ester prodrug (both at 100 mg/kg) are shown in Figure 58.  
















































Figure 57.  Effect of Methyl-N-Ac-(L)-Phe-Acrylate on serum PAM 
activity in Sprague-Dawley rats.  Methyl-N-Ac-(L)-Phe-Acrylate was 
administered as a single subcutaneous dose at three concentrations to 
determine the effects on serum PAM activity in vivo.  Control animals 
received injections of vehicle only.  Time points were taken periodically 
over the course of six hours.  APAA-Me 10 mg/kg (●); APAA-Me 50 
mg/kg (■); APAA-Me 100 mg/kg (▲).  Data are presented as the mean ± 
S.E.M. for each group (n=3). 












































Figure 58.  Effect of APAA and APAA-Me on serum PAM activity in vivo.  Compounds 
were given as a single subcutaneous injection to determine their effect on serum PAM 
activity.  Control animals received injections of vehicle.  Serum was collected at time 
points between 0 and 6 hours.  PAM activity was analyzed as described in “Methods”.  
APAA 100 mg/kg (■); APAA-Me 100 mg/kg (▲).  Data are presented as the mean ± 
SEM for each group (n=3).  *Statistically significant (P < 0.05) compared to controls 














































activity rebounds more quickly toward basal levels in the case of the free acid.  After 
three hours, PAM inhibition by the free acid has decreased to 28% of controls while the 
prodrug maintains its initial inhibition (38%).  Between 3 and 4 hours post-injection, 
inhibition decreases sharply for both the free acid and the ester (by 20% and 15%, 
respectively).  No further rebound in serum PAM activity is evident for either compound 
between four and six hours post-injection. 
 
Anti-inflammatory Effect of APAA-OMe 
 
     As mentioned above, carrageenan-induced edema is an effective model of acute 
inflammation.  Typically, the injected paw volume tends to increase dramatically by one 
hour and continues to increase until four or five hours post-administration, at which point 
the swelling begins to subside.  Figure 59 shows the change in hindpaw volume after 
carrageenan administration in the presence and absence of N-Ac-(L)-Phe-Acrylate 
Methyl Ester at a dose of 150 mg/kg over six hours.  Paw volume measurements were 
taken every hour for six hours.  Remarkably, this compound completely abolished 
swelling and inflammation in the hindpaw throughout the entire time-frame of the 
experiment.  The anti-inflammatory effect is most pronounced four hours post-
administration, when untreated control paws had increased by 0.75 mL in volume while 





















































Figure 59.  Effect of Methyl-N-Ac-(L)-Phe-Acrylate on acute 
inflammation of the hindpaw in carrageenan-induced edema.  Methyl-
N-Ac-(L)-Phe-Acrylate was administered subcutaneously at 150 mg/kg 
30 minutes prior to the induction of carrageenan-induced edema.  
Control animals received vehicle only.  Injected and contralateral paw 
volumes were analyzed plethysmographically by mercury displacement 
at 0, 1, 2, 3, 4, and 6 hours.  Change in paw volume was calculated as 
the difference in injected and contralateral hindpaw volumes at each 
time point.  Vehicle treated animals (▲); APAA-Me 150 mg/kg (■).  
Data are presented as the mean ± S.E.M. for each group (n=6). 
* Statistically significant (P < .05) compared to controls for that time 
point (Student’s t test) 



























































Figure 60.  Effect of different doses of Methyl-N-Ac-(L)-Phe-Acrylate on acute 
inflammation in carrageenan-induced edema in Sprague-Dawley rats.  Various 
concentrations of Methyl-N-Ac-(L)-Phe-Acrylate were delivered by subcutaneous 
injection into the hindpaw of rats 30 minutes prior to the induction of 
carrageenan-induced edema.  Injected and contralateral hindpaw volumes were 
measured plethysmographically by mercury displacement at 0, 1, 2, 3, 4, and 6 
hours.  Change in paw volume was calculated as the difference in injected and 
contralateral hindpaw volumes at each time point.  a) Vehicle treated animals (□); 
APAA-Me 10 mg/kg (■); APAA-Me 50 mg/kg (●); APAA-Me 100 mg/kg (▲).  
Data are presented as the mean ± S.E.M. for each group (n=6). b) APAA-Me 10 
mg/kg (□); APAA-Me 50 mg/kg (●); APAA-Me 100 mg/kg (▲); APAA-Me 150 
mg/kg (■). 

























     Next, varying doses of N-Ac-(L)-Phe-Acrylate Methyl Ester (10, 50, 100 mg/kg) were 
administered to Sprague-Dawley rats injected with carrageenan.  The results are shown in  
Figure 60.  The top panel shows the change in paw volume with time.  The 10 mg/kg 
dose was unable to reduce the inflammation and swelling associated with the 
carrageenan-induced edema in a statistically-significant manner.  The 50, 100, and 150 
mg/kg doses were all effective in preventing the inflammation of the paw induced by the 
carrageenan.  The bottom panel shows the percent inhibition of swelling over a six hour 
time course.  The three highest doses all inhibited the swelling to varying degrees.  
Again, the 150 mg/kg dose resulted in nearly 100% inhibition three hours after 
administration.  After six hours, the 50, 100, and 150 mg/kg doses resulted in levels of 
inhibition of approximately 95%, 60%, and 40%, respectively.  The low 10 mg/kg dose 
was indistinguishable from controls after six hours. 
     Figure 61 presents a dose-response curve of % inhibition vs. log [N-Ac-(L)-Phe-
Acrylate Methyl Ester] (mg/kg).  The curve is linear for the four points tested.  A dose of 
50 mg/kg results in 70% inhibition of inflammation, while the highest dose was able to 
completely abolish the carrageenan-induced inflammation by 3 hours post injection. 
 
Effect of APAA-OMe on Adjuvant Induced Polyarthritis (AIP) 
 
     After our remarkable results with this compound in the amelioration of swelling 
associated with the acute inflammation induced by carrageenan injections, we attempted 

















































Figure 61.  Anti-inflammatory effect of Methyl-N-Ac-(L)-Phe-
Acrylate on carrageenan-induced edema three hours post-induction.  
The percent inhibition versus vehicle-treated animals was 
determined 3 hours post-induction of carrageenan edema for 
concentrations of APAA-Me ranging from 10 mg/kg to 150 mg/kg.  
Data are presented as the dose received versus the percent inhibition 




(recognition, proliferation, and effector), an animal model which more closely resembles 
the progression of rheumatoid arthritis in humans.  Owing to the solubility problems and 
the difficulty of delivery of the extremely hydrophobic N-Ac-(L)-Phe-Acrylate Methyl 
Ester, we were forced to opt for a vehicle which contained 90:10 ethanol/DMSO.  The 
subcutaneous injections of this compound in this particular vehicle resulted in local tissue 
necrosis and death in several of the animals over the course of the first 3 days of the  
experiment (Day 0, Day 1, and Day 2).  Therefore, the drug injections were discontinued 
after Day 2.  The results of the experiment are presented in Figure 62.  At the end of the 
recognition phase (Day 2), the drug-treated animals did exhibit significantly smaller 
injected paw volumes relative to the positive controls (about 40%).  The contralateral 
paw does not increase in volume during the recognition phase of adjuvant arthritis.  By 
Day 4, the injected paw volumes were still less than those of the positive controls, but the 
results were not statistically significant.  By Day 16 (the effector phase), both the injected 
and contralateral paws of the drug-treated animals were slightly higher in volume than 
the positive controls, although, again, this was not statistically significant.  We were 
forced, then, to abandon further adjuvant experiments with this compound until a more 
reasonable vehicle was found which did not cause local necrosis and mortality. 
 
PAM Activity in WB-Neo Cells and Inhibition by PBA 
 
     Intrinsic PAM activity in WB-Neo (rat liver epithelial) cells was calculated for both 
the membrane-bound and soluble fractions.  Subsequently, the extracts were analyzed for 
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Figure 62.  Effect of Methyl-N-Ac-(L)-Phe-Acrylate on Adjuvant-
Induced Polyarthritis in Sprague-Dawley rats.  Methyl-N-Ac-(L)-
Phe-Acrylate was administered subcutaneously on Days 0-2 at 150 
mg/kg to rats.  Injections ceased after Day 2 owing to acute local and 
systemic toxicity.  Injected (right) and uninjected (left) hindpaw 
volumes were measured plethysmographically by mercury 
displacement on day 0, 2, 4, and 16.  Open bars – vehicle-treated 
controls (n=4); solid bars – vehicle-treated arthritic animals (n=4); 
dashed bars – APAA-Me-treated animals (n=3).  Data are presented 
as the mean ± S.E.M. for each group. 
* Statistically significant (P < .05) compared to arthritic controls 






this source was susceptible to PBA inhibition.  The results are presented in Figure 63.  
Under normal culture conditions, in the absence of PBA, WB-Neo cells were shown to 
possess a significant amount of soluble and membrane-bound PAM activity.  Soluble 
PAM was found to be present at 8 nmol product/mg protein/hour, while PAM activity 
from the membrane-bound extract was slightly more than twice as high as for soluble 
controls, at 18 nmol product/mg protein/hour.  Incubation of the cell extracts with 250 
μM PBA reduced PAM activity in the soluble and membrane-bound fractions by 75% 
and 85%, respectively, to 2 nmol product/mg protein/hour in both cases.  Overall, for the 
WB-Neo cells, the ratio of membrane-bound/soluble PAM activity was found to be 2:1. 
 
PAM Activity in WB-Ras Cells and Inhibition by PBA 
 
     WB-Ras (transformed rat liver epithelial) cells were evaluated for soluble and 
membrane-bound PAM activity, and this activity was again evaluated in the presence of 
PBA to determine its susceptibility to inhibition by this known in vivo mechanism-based 
PAM inactivator.  Results are presented in Figure 63.  Soluble PAM activity was found to 
be 0.6 nmol product/mg protein/hour.  Coincubation of the soluble extract with 250 μM 
PBA in the PAM assay mix resulted in a 60% decrease in activity.  The membrane-bound 
extract had activity of 3.5 nmol product/mg protein/hour, which in the presence of 250 







Cultured WB-Neo and WB-Ras Cells: Inhibition by PBA/PBA-OMe 
 
     WB-Neo and WB-Ras cells were cultured in the presence of either 0.1 mg/mL PBA or 
0.01 mg/mL PBA-Methyl Ester.  Cells were evaluated for residual PAM activity after 
one day and again after four days, and compared to untreated controls.  Cells were 
harvested, counted, and the soluble and membrane-bound extracts were assayed for PAM 
activity as stated in the Experimental Section. 
     The results of the PBA-treated cells are presented in Figure 63.  Soluble WB-Neo cells 
showed a progressive decrease in PAM specific activity over the course of the 
experiment.  After 24 hours, the specific PAM activity in the PBA-treated cells had 
decreased by approximately 38%, and after 4 days incubation, had decreased by 43% 
relative to controls.  The membrane-bound PAM activity in the WB-Neo cells evinced a 
30% decrease relative to controls after the first day, with a sharp continued decline in 
activity after four days incubation (55%).  It appears that the membrane-associated PAM 
activity was susceptible to inactivation by PBA for an extended period of time relative to 
the soluble PAM activity, and was inactivated to a greater degree over the time course of 
the experiment.  In the WB-Neo controls, soluble PAM activity represented 58% of the 
total PAM activity, with 42% of the total activity found in the membrane-bound extract.  
After one day treatment with 0.1 mg/mL PBA, 56% of total PAM activity was found in 
the soluble extract, whereas 44% was present in the membrane-associated extract.  After 
4 days treatment, 63% of the activity was soluble and 37% membrane-associated. 
     The PBA-treated WB-Ras cells also showed a significant decrease in PAM activity 




PAM activity had rebounded relative the activity after 24 hours, with membrane-
associated PAM activity increasing to greater levels than were seen in the WB-Ras 
controls after 4 days treatment.  After 24 hours, the soluble PAM activity in the WB-Ras 
cells decreased to 35% of controls.  After 4 days, PAM activity was essentially the same 
as after 24 hours treatment (39% controls).  Conversely, the membrane-associated PAM 
specific activity had decreased to 50% of controls after 24 hours, but after 4 days had 
rebounded to over 110% of control PAM levels.  Overall, in the WB-Ras cells, 22% of 
the PAM activity in controls was found in the soluble extract, with 78% in the 
membrane-bound fraction.  After 24 hours, only 17% of the total PAM activity was 
located in the soluble extract, with 83% membrane-associated.  After 4 days, only 9% of 
the PAM activity was soluble, while 91% was membrane-bound.  The most intriguing 
aspects of these results are twofold.  First, that the PAM activity in the WB-Ras cells was 
able to return to control levels after 4 days treatment, whereas WB-Neo cells were not, 
implies that the WB-Ras cells are able to more efficiently upregulate PAM activity when 
incubated with an inactivating species than their WB-Neo counterparts.  Secondly, and 
perhaps even more striking, is the change in distribution of PAM activity between soluble 
and membrane-bound forms of the enzyme between the two cell lines.  In the WB-Ras 
cells, the membrane-associated PAM accounted for 78%, 83%, and 91% of the total 
PAM activity in the control, 24-hour PBA-treated, and 4-day PBA-treated cells, 
respectively.  For the WB-Neo cells, the membrane-associated PAM activity accounted 










Figure 63.  Effect of PBA on PAM activity in WB-Neo and WB-Ras cells. Each group 
consists of cells grown to 90-100% confluence from two 75 cm2 flasks.  Cell extracts and 
PAM assays were performed as described in “Methods”.  (A) Specific activity of PAM in 
soluble and membrane-associated extracts of WB-Neo Cells, with and without 250 μM 
PBA added to reaction mixture.  (B) Specific Activity of PAM in soluble and membrane-
associated extracts of WB-Ras cells, with and without 250 μM PBA added to reaction 
mixture.  (C) Combined specific activity of PAM in WB-Neo and WB-Ras cells treated 
with 0.1 mg/mL PBA for 24 hours and 4 days.  Data presented as mean PAM specific 
activity ± S.E.M. for each group (n=3).  *, Statistically significant (P<0.05) compared to 


































     As evident from the introductory remarks above, SP clearly plays a major role in the 
metabolic pathways which govern a wide variety of pro-inflammatory and pro-growth 
processes and functions.  Bioactive SP-NH2 is a product of the PAM reaction, the rate-
limiting step of peptide amidation outlined in the first section.  Therefore, interference 
with the enzyme responsible for the bioactivation of a species (SP) which lies near the 
upstream terminus of the activation of the PLC pathway, the COX-2 pathway, the MAP-
Kinase pathway, and the Ras pathway would surely be expected to ameliorate many 
inflammatory and neoplastic pathologies.  We have shown that our mechanism-based 
acrylate inhibitors are the most potent in vitro inactivators of PAM currently known, and 
the ability of these compounds to permanently inactivate PAM makes them especially 
desirable agents relative to simple competitive inhibitors.  Naturally, permanent 
inactivation of in vivo PAM activity requires that new PAM be transcribed, translated, 
and post-translationally modified/processed in order to return enzyme concentrations 
(and its products) to pre-dosing levels. 
     Currently, a widespread therapeutic interest in blocking the effects of SP (or related 
pro-inflammatory neuropeptides such as calcitonin gene-related peptide) has become 
manifest, with the development of compounds which act as antagonists toward the NK-1 
receptor (the receptor for SP), or compounds which deplete stores of SP from the vesicles 
of C-afferent nerve fibers (such as capsaicin).  Both approaches have been shown to be 
effective in the amelioration of certain pathological conditions.  However, the former 




therapeutic agent for the occupation of the NK-1 receptor.  It does not serve to deplete or 
reduce actual physiological concentrations of SP.  Indeed, SP has been shown to be able 
to initiate intracellular cascades via a receptor-independent mechanism in mast cells 
(cells which lie close to the C-afferent nerve terminals which contain stored SP), and thus 
these antagonists are of no account in preventing this type of activation.  Indeed, the 
phenomenon of neurogenic inflammation involves both mast cells and the innervating 
afferent nerve terminals.  SP released from the nerve terminals serves to activate a pro-
inflammatory response in these mast cells, which are a major source of histamine, 
bradykinin, and serotonin, all factors which further contribute to the pathology of chronic 
inflammation.  Capsaicin treatment, through interaction with a vanillin-like receptor, 
causes SP to be released from nerve terminals over a short time period, causing a sharp 
increase in the extracellular concentrations of SP.  Although the nerve terminals are 
thusly depleted of SP, levels of which may not return to baseline for an extended period 
of time, the topical treatment is painful on the one hand, and the initial depletion of SP 
into the extracellular space can potentiate, on short time scales, any pro-inflammatory 
processes which have already begun in earnest. 
     Certainly, the most effective way to interfere with the pro-inflammatory (or pro-
growth/neoplasticity) effects of SP is to prevent its formation in the first place.  
Inhibition/inactivation of PAM-catalyzed SP bioactivation obviates, in large measure, the 
needs for treatment with NK-1 receptor antagonists (which, as peptides, are not orally 
active and require hypodermic injection) or for the “scorched-earth” approach of 
capsaicin-induced SP depletion.   On the basis of these considerations, we naturally 




PAM in vivo and secondly, to see if this inactivation led to a blockade of the many 
downstream effectors of NK-1 receptor activation and indeed manifested as an anti-
inflammatory agent.  Our results clearly show that administration of PAM inhibitors 
(PBA, PBA methyl ester, N-Ac-(L)-Phe-Acrylate, and methyl N-Ac-(L)-Phe-Acrylate) is 
extremely effective in the amelioration of both acute inflammation (via the carrageenan-
induced edema model) and chronic inflammation (via the adjuvant arthritis model) in 
Sprague-Dawley rates.  Furthermore, the anti-inflammatory effects of these agents 
correlate strongly with a decrease in residual serum PAM levels post-treatment. 
     Finally, because SP is also a mitogenic growth factor, we reasoned that inactivation of 
PAM may also manifest an anti-neoplastic effect on transformed cells, possibly via the 
deactivation of the Ras pathway, an expected downstream effect of reducing 
physiological levels of SP.  As outlined in the results above, treatment of Ras-
transformed epithelial cells with the pro-drug of PBA, a first-generation, lipophilic 
mechanism-based PAM inactivator resulted in an increase in gap-junctional 
communication (i.e. cell-to-cell communication) via an increase in the phosphorylation 
levels of the gap-junction component protein connexin-43.  In this case, as in that of the 
anti-inflammatory studies mentioned, it must be stressed that inactivation of PAM by 
these compounds does not exclusively prevent the bioactivation of SP, but also that of 
any peptide which requires amidation for full biological activity.  Nevertheless, these 
results show that PAM inhibition/inactivation is a valid target for both anti-inflammatory 
and anti-cancer agents, and certainly warrants continued study and refinement, as the 




     Previous work by our laboratories has demonstrated that continuously-administered 
PBA (via osmotic pump) is able to significantly inhibit serum PAM activity in Sprague-
Dawley rats (Ogonowski, 1997).  These studies also showed that PBA was able to inhibit 
the swelling typical of carrageenan-induced edema in rats, in conjunction with a decrease 
in SP immunoreactivity in injected rat hindpaw tissue.  Taken together, these studies 
indicated that PBA was a bioactive PAM inhibitor, that serum PAM levels decreased 
commensurate with PBA dosing, and that the PAM product SP is also found to be 
decreased in the hindpaw tissues of rats that had been injected with carrageenan and 
dosed with PBA.  These three pieces of information (anti-inflammatory effect based on 
reduced paw volume of PBA-treated animals, correlation of the inhibition of serum PAM 
activity with the anti-inflammatory effect, and the correlation of reduced SP levels with 
reduced PAM activity in dosed animals) certainly provide remarkable evidence that PAM 
inhibition in vivo leads to the downstream effects which had been postulated. 
     While the carrageenan studies were certainly encouraging, these experiments are 
models of acute, rather than chronic, inflammation.  Certain diseases, most notably 
rheumatoid arthritis (RA), are characterized by a chronic type of inflammation that 
involves a specific cellular immune response which causes the long-term activation of 
pro-inflammatory pathways, and which is characterized by a failure to resolve the 
inflammation caused by the initial insult.  Indeed, RA can be characterized as an 
autoimmune disease, where unresolved inflammation in a given area has led to a cross-
reactivity with “self” cells of the joints and cartilage.  As T-cells become involved in the 
process, a positive-feedback loop is engaged whereby the T-cells may be releasing pro-




system as described above) in response to the recognition of self antigen in a process 
which simply cannot be resolved by current conventional treatments.  The processes 
which occur in acute inflammation are a major subset of the processes which occur in 
ongoing chronic inflammation, and many of these effector cells are influenced to 
continue the release of pro-inflammatory mediators by Substance P.  Indeed, research has 
shown that SP is directly involved in the pathogenesis of adjuvant-induced polyarthritis 
(AIP) in rats, which is seen as one of the best animal models of (human) RA itself 
(Donaldson, 1995; Walker, 2003).  Therefore, we reasoned the acute anti-inflammatory 
effect of PBA could translate into an amelioration of the chronic inflammation 
characteristic of AIP.  AIP is initiated by the administration of heat-denatured 
Mycobacterium butyricum in mineral oil, which causes an initial, acute phase of 
inflammation (Phase 1) in the injected paw which peaks after approximately two days, 
and is mediated by the cells of the innate immune system (macrophages, neutrophils, 
etc.).  The inflammation of the hindpaw plateaus at this point, and generally remains 
unchanged until nine or ten days post-adjuvant administration (Phase 2).  During this 
time, it is believed that a T-cell proliferation process occurs, where T-cells exposed to the 
antigen, and likely cross-reactive with the injected tissue, mature in the lymphatic system.  
As these cells are selected for and proliferate, they migrate to the area of insult and, via 
the co-stimulation of the effector cells of the innate immune system, potentiate the 
inflammation which has already occurred therein.  From Day 9 to Day 16 (Phase 3), the 
injected hindpaw swelling worsens, and in addition, the contralateral (non-injected) 
hindpaw begins progressively to inflame as well.  The inflammation of the contralateral 




T-cells engendered by the initial bacterial insult has allowed for the activation of pro-
inflammatory pathways at sites far removed from the site of injection.  The reported 
involvement of SP in the progression of this disease led us to believe that PBA would 
also be effective in the amelioration of this chronic inflammation.  Moreover, by 
choosing PBA-dosing regimens which administered drug to animals in Phase 1 (starting 5 
days prior to the adjuvant injection, through Day 2 post-injection), Phase 2 (from Day 2-
9), and Phase 3 (Days 10-16), we were able to investigate whether our PAM inactivators 
were effective in the different stages of the disease progression.  Also, by monitoring the 
volume (swelling or lack thereof) of both the injected and contralateral hindpaws, we 
were able to determine whether PBA dosing could affect the later-developing 
inflammation at sites far-removed from the initial site of injection. 
     Our results clearly indicate the phenomenal efficacy of PBA as an anti-inflammatory 
agent in all phases of AIP, and at both the injected and contralateral hindpaw at a dosing 
regimen of 60 mg/kg/hour.  Certainly, it was not surprising that the Phase 1 dosing would 
evince a profound anti-inflammatory effect, as this stage of the disease would be 
expected to be very similar to the acute inflammation caused by carrageenan injections.  
Also, the reduction in paw volume in the experimental animals was maintained 
throughout the proliferation phase of AIP (Phase 2) relative to untreated arthritic animals 
and continued into Phase 3 (the effector phase).  This shows that interfering with peptide 
amidation, very early in the experiment, results in a continued suppression of 
inflammation, even two weeks after PBA-dosing is terminated.  This was true for both 




     Dosing during Phase 2 (the proliferation phase) significantly decreased the swelling in 
PBA dosed animals by Day 9 by more than 50%.  This is an interesting result because it 
indicates that although the level of inflammation indeed plateaus during this period, it can 
still be positively affected by PAM inactivators.  Furthermore, it indicates an active 
process of inflammation in the injected paw during this phase, even though the injected 
paws of vehicle-treated arthritic animals do not undergo further increases in volume over 
this seven day period.  Based largely on the reduction in swelling effected by Phase 2 
dosing, the effects of PBA remain pronounced through Phase 3, although the slopes of 
the lines representing paw volume with time are very similar for the injected paws of 
both PBA-treated and vehicle-treated arthritic animals.  This Phase 3 effect is identical to 
that seen in animals dosed on Day -5 through Day 2 in the first set of animals outlined 
above.  The interpretation of these results is that PBA dosing in Phase 1 and Phase 2 do 
not significantly affect the progression of inflammation and paw swelling in Phase 3, but 
that the overall swelling is reduced exclusively during Phase 1 and Phase 2, and that 
during Phase 3, the observed anti-inflammatory effect is a result of the initial decrease in 
swelling during the earlier two phases.  Phase 2 dosing also significantly reduces the 
swelling in the contralateral paw during Phase 3.  It is unknown whether this is the result 
of local PBA effects at the site of the joints (which persist into Phase 3 after dosing has 
been terminated), or whether PBA is able to interfere (through an SP-mediated 
mechanism) with the proliferation or maturation of the T-cells which are involved in the 
effector phase (Phase 3). 
     Finally, Phase 3 dosing (Days 10-16) also demonstrated the anti-inflammatory effects 




no further swelling concurrent with dosing, and this effect seemed to be more pronounced 
that the anti-inflammatory effects when PBA was administered during Phase 1.  The anti-
inflammatory effect was also statistically significant in the contralateral paws of animals 
dosed during Phase 3, although some swelling was evident relative to the injected 
hindpaws during this time-frame.  As mentioned above, when serum PAM activity was 
monitored over the course of seven days at 50 mg/kg/hour PBA, residual enzyme activity 
was maintained at 30% or less of controls throughout the course of the experiment.  
Although we did not directly evaluate serum PAM activity during the course of our AIP 
experiment (to prevent further insult to the animal), the above indicates a strong 
likelihood that the anti-inflammatory effects of PBA are correlated in some manner to 
this decrease in activity.  In any event, this is the first evidence that a PAM inhibitor is 
effective in treating the chronic inflammation characteristic of AIP. 
     Owing to the success of the treatment of AIP by PBA, we next attempted to run 
another adjuvant experiment with our second-generation pro-drug ester, methyl-N-Ac-
(L)-Phe-acrylate.  However, we encountered solubility problems with this compound.  
Various cyclodextrins were employed to improve aqueous solubility but were 
unsuccessful.  Attempts to formulate a drug solution in corn oil or mineral oil were also 
unsuccessful.  Ultimately, we settled on a vehicle of 90:10 EtOH/DMSO.  It must be 
noted that to create the PBA drug formulation, the free acid of PBA was simply titrated 
into phosphate-buffered saline with sodium hydroxide.  This was not a problem with the 
achiral PBA, but because our acrylates are enantiomerically pure we were loath to 
employ this method for fear that base-catalyzed racemization might occur at the 




studies with this acrylate and its pro-drug methyl ester had indicated that the pro-drug 
produced more impressive in vivo results.  These concerns led to the rather undesirable 
vehicle formulation described above.  Unfortunately, the pro-drug/vehicle combination 
was found to be toxic, both locally (causing tissue necrosis at the injection site) and 
systemically, and resulted in a high mortality rate among the animals involved in the AIP 
study, and the study was therefore discontinued two days into Phase 1 of the experiment.  
Nevertheless, some anti-inflammatory effect was evident in the injected paws of drug-
treated animals after two days and after four days post-arthritis induction.  Unlike the 
PBA AIP experiment outlined above, this effect did not persist into Phase 3, and the 
injected and contralateral hindpaws of drug-treated animals were statistically unchanged 
relative to controls. 
     A recent experiment (data not included in this thesis) with a microparticle formulation 
of Methyl-N-Ac-(L)-Phe-Acrylate encapsulated with poly(cyclohexane-1,4-diyl acetone 
dimethylene ketal) (PCADK) clearly showed that this compound was effective, as was 
PBA, in treating inflammation associated with all three phases of AIP, as per the dosing 
regimen outlined above.  The particles were injected intra-peritoneally (IP), and it must 
be noted that the control animals were given ethanol vehicle, which caused early 
mortality.  Therefore, the control animals were adversely affected by this ethanol vehicle 
(IP) as were the animals in the original AIP experiment where Methyl-N-Ac-(L)-Phe-
Acrylate in 10:90 DMSO/ethanol was delivered subcutaneously.  However, there 
appeared to be no toxicity or necrosis associated with the particle formulation (delivered 
as a suspension in phosphate-buffered saline).  This indicates that the vehicle, and not the 




ongoing to maximize drug loading in the microparticles, in the anticipation of another 
AIP experiment with proper controls. 
     Since the PBA experiments on acute (carrageenan-induced edema) inflammation 
seemed to correlate the anti-inflammatory effects of the compound to the reduction in 
paw swelling, we reinvestigated the effects of different doses of PBA on serum PAM 
activity, and investigated the effects of N-Ac-(L)-Phe-Acrylate and its prodrug methyl 
ester as well.  Whether or not the drop in serum PAM activity is actually causative of the 
anti-inflammatory effect is beyond the scope of this thesis.  Nevertheless, an anti-
inflammatory effect of a PAM inhibitor has never been seen in the absence of this 
concomitant drop in serum PAM activity. 
     Both PBA and N-Ac-(L)-Phe-Acrylate are completely ionized at physiological pH 
(7.4).  It is, therefore, unlikely that either molecule is able to diffuse through the plasma 
membrane into cells and cause an anti-inflammatory effect via inactivation of 
intracellular PAM, which, to make matters more difficult for these anion species, is 
sequestered in secretory vesicles with the cell.  However, the methyl ester prodrug would 
likely be able to diffuse into cells by virtue of its neutral character and general 
lipophilicity.  Conversely, only the free acid is able to inhibit and inactivate PAM in 
vitro, so the effective concentration of the free acid in the bloodstream, when delivered as 
the methyl ester prodrug, is not readily known in the absence of further experimental 
data.  Therefore, comparing the ability of each of the three compounds (PBA, N-Ac-(L)-
Phe-Acrylate, and Methyl-N-Ac-(L)-Phe-Acrylate) to reduce serum PAM activity, and 
the time-course of that reduction in activity, relative to the anti-inflammatory effects of 




     We have seen that repeated dosing with PBA at 500 mg/kg (every three hours) results 
in a 70% reduction in serum PAM activity after two hours, a 95% reduction after six 
hours which is maintained until 12 hours after the initial PBA injection, and then a slight 
decrease to 80% inhibition after 24 hours.  On the other hand, the one-time dose of 500 
mg/kg, naturally, shows the same 70% inhibition after two hours, but the effect rapidly 
dissipates, with 45% inhibition after six hours and only 10% inhibition after nine hours.  
The increase in PAM activity after the one-time dose between two and nine hours post-
injection indicates that the enzyme is being replenished by some physiological source, 
owing to the fact that the inactivated enzyme cannot “reactivate” itself.  Additionally, 
since additional PBA (multiple dosing) maintains the decrease in serum PAM activity 
(which is not maintained by the one-time dose) it is evident that PBA is cleared rapidly 
from the bloodstream (or chemically altered to a form which does not inhibit/inactivate 
PAM).  Certainly, it is well-known that ionic species are more readily excreted by the 
kidneys than neutral species, which often require one or more passes through the liver 
before they can be efficiently excreted in the urine. 
     N-Ac-(L)-Phe-Acrylate, like PBA, is an anionic species at physiological pH.  
Although this compound was only administered as a one-time dose (subcutaneously) at 
10, 50, and 100 mg/kg, we can see from the resulting inhibition of serum PAM activity 
that the profile is much the same as was the case for the one-time PBA dose.  It must be 
mentioned that although doses for these studies are calculated as “mg/kg”, this is not the 
best metric for the actual concentration of the drug in the bloodstream (presuming, of 
course, that all of the administered drug enters the bloodstream).  Here, the molecular 




261, and 273 g/mol, respectively.  Therefore, equal doses of PBA and the free acid 
acrylate (in mg/kg), for instance, would provide for a greater concentration in the animal 
of PBA than the acrylate (about 1.6-fold greater).  Additionally, the highest dose of the 
acrylate was only 100 mg/kg (vs. 500 mg/kg for PBA), so the effective concentration of 
the highest acrylate dose would be, all else being equal, only about 1/8 that of the highest 
PBA dose.  Keeping that in mind, the 100 mg/kg dose of the acrylate evinced serum 
PAM inhibition of about 40% after one hour, which decreased to 10% inhibition after six 
hours.  As was the case for anionic PBA, it is evident that anionic N-Ac-(L)-Phe-Acrylate 
is cleared from the bloodstream fairly rapidly, and likely this contributes to the decrease 
in inhibition with time, along with PAM being replenished in the bloodstream at the basal 
rate, or at an upregulated rate as the homeostatic concentration of serum PAM is 
decreased below a certain level.  Further experiments are needed at higher concentrations 
of the free acid acrylate in order to determine whether this compound is able to inactivate 
serum PAM at the 95% levels seen with PBA at 500 mg/kg.  That being said, after three 
hours serum PAM was inhibited by approximately 30% in the case of N-Ac-(L)-Phe-
Acrylate, and similarly by about 25% in the case of 125 mg/kg PBA. 
     Finally, the methyl ester prodrug Methyl-N-Ac-(L)-Phe-Acrylate is uncharged at 
physiological pH and the ester must be cleaved (either enzymatically by an esterase or 
spontaneously at the alkaline pH of bloodstream) prior to inactivating/inhibiting serum 
PAM.  By virtue of its charge-neutrality, it would be expected a priori to persist longer in 
the bloodstream than the free acid analog, and, if this were the case, would be expected to 
maintain serum PAM inactivation for a longer time period.  Of course, contrary to the 




concentrations of the actual free acid drug (compared to the inactivity of the methyl ester 
prodrug as a PAM inhibitor) would, at the same initial dosage, be lower at any given time 
than when the free acid is delivered subcutaneously.  Which of these two contrary factors 
comes into play can be revealed by the serum PAM activity profile of the prodrug vs. that 
of the free acid.  First, the prodrug, injected at the same level (mg/kg; because the 
molecular weights of these compounds differ only by 12 Daltons out of 261 g/mol and 
273 g/mol the concentration differences are not as stark as between either one as 
compared to PBA) as the free acid yielded the approximately the same results as regards 
inhibition of serum PAM activity.  The 10, 50, and 100 mg/kg prodrug doses caused 
serum PAM activity to drop to 10%, 30%, and 35% of controls three hours post-dosing, 
respectively.  Compare this to drops in activity of 10%, 20%, and 30% for the free acid at 
the same three doses.  This would seem to indicate that, by three hours after dosing, the 
effective concentration of the free acid are the same, whether the free acid is delivered 
directly to the animal, or whether the prodrug is administered. Conversely, after six 
hours, serum PAM levels in animals given the prodrug at 10, 50, and 100 mg/kg are 15%, 
25%, and 25%, respectively, compared to 10%, 10%, and 15% for the free acid at these 
same dosing regimens.  This indicates a paradoxical situation:  on the one hand, the 
inhibitory effect of the prodrug persists for a much longer period, at a much higher level 
of efficacy than the free acid; on the other hand, the prodrug reduces serum PAM activity 
just as quickly (at the first measured time point) as the free acid.  The former indicates 
that the ester persists for a longer period in the bloodstream than the free acid.  The latter 
indicates that the effective concentration of free acid is the same as that of the prodrug 




It is possible, as an example, that the prodrug is able to penetrate certain cells which 
secrete PAM into the bloodstream (possibly atrial myocytes) and inactivate newly 
synthesized PAM prior to its release (yielding the persistent inhibitory effects) while 
concurrently enough is hydrolyzed to the free acid in the circulation to inactivate PAM 
which is already circulating in the bloodstream (yielding the initial, rapid inactivation and 
decrease in serum PAM activity). 
     Since the prodrug was more effective in reducing serum PAM activity, and for a 
longer time, than the free acid (also, the methyl ester is a synthetic precursor of the free 
acid and therefore requires less work to obtain) we decided to evaluate the prodrug as an 
anti-inflammatory agent against carrageenan-induced edema.  Remarkably, at a dose of 
150 mg/kg, the methyl ester prodrug was able to reduce inflammation, relative to 
untreated controls, by nearly 100% over the six hour course of the experiment.  Lower 
doses of 50 and 100 mg/kg also exhibited a potent anti-inflammatory effect.  After one 
hour, paw volumes were 80% of untreated positive controls for animals dosed at 50, 100, 
or 150 mg/kg.  The 150 mg/kg dose increased to near 100% inhibition of inflammation 
by three hours post-dosing, and this effect persisted throughout the time frame of the 
experiment (6 hours).  After six hours, the 50 and 100 mg/kg doses yielded paws which 
were approximately 30% and 60%, respectively, less inflamed than the untreated 
controls.  The 10 mg/kg dose was 40% inhibitory after one hour, and after six hours there 
was no difference in paw volumes between treated and untreated animals. 
     It is certainly interesting that the anti-inflammatory effect of the prodrug is so much 
more pronounced than its ability to inhibit serum PAM.  Although we have no data for 




abolished, the 100 mg/kg dose was at least 80% anti-inflammatory for four hours in the 
carrageenan edema experiment, while only inhibiting serum PAM by 25% after four 
hours, and reaching a maximum of 35% inhibition of serum PAM after three hours.  
Earlier experiments by this laboratory (Ogonowski, 1997) using 500 mg/kg of PBA 
exhibited a 67% inhibition of carrageenan-related paw swelling relative to untreated 
controls, where they saw, with this same dose of PBA, nearly 100% abolition of serum 
PAM activity.  Recall that, for Methyl-N-Ac-(L)-Phe-Acrylate, the opposite was true; 
inflammation was nearly completely abolished but inhibition of serum PAM never 
exceeded 40%.  Therefore, although inhibition of serum PAM appears to be a marker for 
anti-inflammatory properties, there is apparently not a direct correlation between the two 
events.  Again, the methyl ester prodrug is lipophilic and uncharged and may be able to 
diffuse into macrophages or neutrophils (or mast cells) and inactivate PAM therein, 
whereas PBA or the free acid acrylate are not. 
     Finally, our collaborators at Mercer (Bauer, 2007) performed some further 
experiments with out acrylate inhibitors to investigate whether they could inhibit purified 
COX-1 and COX-2, or COX-2 stimulated by LPS in whole blood assays.  As discussed 
above, inhibiting peptide amidation and preventing the biosynthesis of SP prevents NK-1 
receptor activation.  SP occupation of the NK-1 receptor would be expected to induce 
COX-2 activity via downstream events (NF-κB and others) while at the same time 
stimulating PLA2 which serves to liberate the COX-2 substrate arachidonic acid from 
membrane phospholipids.  Therefore, we expected that the acrylates would NOT inhibit 
purified COX-2, but would inhibit the formation of the COX-2 product PGE2 in the 




the case as the acrylates were unable to inhibit purified COX-2, even at concentrations as 
high as 1 mM, while1 mM PBA and 0.5 mM Methyl-N-Ac-(L)-Phe-Acrylate were able 
to significantly inhibit COX-2 in the whole blood assay (82% and 63%, respectively).  To 
lend further credence to the above, COX-1 (which is constituitively expressed and not 
subject to induction by LPS) was not inhibited by either PBA or the prodrug acrylate at 
these concentrations. 
     As mentioned above, PAM had been shown to be active in small-cell lung carcinoma 
and is involved in a variety of autocrine growth loops which allow transformed cells to 
remain in an abnormally active and proliferative state.  In addition, Ras-transformed cells 
have been shown to have decreased expression of various connexin proteins which serve 
to form gap-junctions, areas of cell-to-cell contact whereby neighboring cells may pass 
“information” to each other, especially with the idea of limiting the proliferation of 
healthy cells which are directly in contact with each other.  By evaluating the levels of 
PAM in the normal (WB-Neo) and transformed (WB-Ras) cell lines, in the presence and 
absence of PBA, we attempted to correlate inhibition of PAM activity with the ability of 
the transformed cells to form gap-junctions and return to a more normal phenotype.  The 
ability of the cells to form gap junctions is thought to be governed by connexin-43 
phosphorylation (de Feijter, 1996), where lack of phosphorylation translates into a 
lessened ability to form these junctions.  This phosphorylation is thought to be governed 
downstream of the MAP-Kinase pathway, with constituitively-active MAP-Kinase 
resulting in a decrease in connexin phosphorylation.  As discussed above, MAP-Kinase 
activity, through PLC and PKC activation, is stimulated by occupation of the NK-1 




Therefore, we believed that inhibition of peptide amidation could conceivably lead to a 
decrease in MAP-Kinase activity, even though Ras itself is slightly upstream of MAP-K. 
     Indeed, treatment with PBA resulted in a decrease in PAM activity in both WB-Neo 
and WB-Ras cells.  Concurrently, immunostaining for connexin showed an increase in 
immunoreactivity at the membrane of Ras-transformed cells, indicating that gap junctions 
were forming in greater abundance in the PBA-treated cells.  Furthermore, a dye-transfer 
assay indicated that the permeability of transformed cells, through newly-formed gap 
junctions, presumably, increased upon PBA treatment.  Also, our collaborators (Dr. 
Diane Matesic, et al., Mercer University) noted that the PBA-treated WB-Ras cells 
returned to a more normal (resembling WB-Neo) morphology and phenotype.  Finally, 
the phosphorylation of connexin-43 was increased in the PBA-treated WB-Ras cells, 
which was expected to (and did) result in increased gap-junctional communication 
between the Ras-transformed cells (Sunman, 2004). 
     We have shown that our acrylate inhibitors are remarkable anti-inflammatory agents 
in both adjuvant-induced arthritis and carrageenan-induced edema, and that this effect is 
at least partially correlated to decreases in serum PAM activity.  We also predicted, on 
the basis of the second-messenger pathways stimulated by SP occupation of the NK-1 
receptor that these compounds should inhibit the induction of COX-2, and that indeed 
proved to be the case.  In addition, our studies on WB-Ras and WB-Neo cells indicated 
that inhibition of peptide amidation is able, through restoration of gap-junctional 
communication, to return Ras-transformed cells to a more normal phenotype while 
concurrently showing that these cells contained active PAM which could be inhibited by 




is able to ameliorate chronic and acute inflammation and to have positive effects on 
transformed cells.  These compounds and their descendants are certainly worthy of 
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